VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 13 (1-15 junio / 2023)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

Next pandemic, let Cuba vaccinate the world

Jun 1. Achal Prabhala is the coordinator of the AccessIBSA project, which campaigns for access to medicines in India, Brazil and South Africa. Vitor Ido is a program officer in the Health, Intellectual Property and Biodiversity Program at the South Centre in Geneva.

A nurse shows a young patient a vial of the Cuban-made Soberana 02 coronavirus vaccine in August 2021. (Ramon Espinosa/AP)

How can humanity prevent the next pandemic from being as disastrous as this one, in which as many as 15 million people have died? This past week, countries of the World Health Organization met in Geneva to begin debating a pandemic preparedness accord. A primary aim is to quickly develop new cures and vaccines — and the capacity to deliver them to everyone on the planet.

While no one yet knows what the WHO will recommend, it's possible to predict one thing it will not: easing U.S. sanctions on Cuba's homegrown biotech industry, which has the wherewithal to develop cutting-edge vaccines and treatments and share them with countries unable to afford First World pharmaceutical companies' premium prices.

This is a mistake.

During the COVID-19 crisis, the United States had the opportunity to share its vaccine technology, and its failure to do so prolonged the pandemic at home and abroad. In June 2022, a senior Biden administration official admitted that the omicron variant, which has been responsible for more than 300,000 deaths in the United States and more than 1.5 million globally, might never have emerged if the world had been sufficiently vaccinated in 2021.

What is less known is that Cuba had the same opportunity to help vaccinate the world. The story of how Cuba was systematically blocked in its quest to make its own highly effective vaccines widely available offers crucial lessons.

The most recent chapter of this story began in summer 2021. The delta variant was ravaging India and making its way around the world. New vaccines offered hope, but the most under-resourced countries could not get them for love or money. While the United States and Europe donated doses, their efforts were hardly enough to solve the global problem. Crucially, these governments could not persuade the companies they had financed to share the technologies that could have enabled other countries to make vaccines on their own. In this grim landscape, it was astonishing to learn that Cuba had made two effective coronavirus vaccines from scratch — and then vowed to share its intellectual property worldwide.

"We realized we wouldn't have the money to buy vaccines for our people, so we had to make our own, and we had to do it in a very short time," Rolando Pérez Rodríguez, the director of science and innovation at BioCubaFarma, told us recently. In August 2021, one of BioCubaFarma's laboratories also produced a

booster. Both demonstrated more than 90 percent efficacy, on par with the leading Western vaccines.

The cost of developing these shots was $50 million, according to BioCubaFarma, far less than the billions invested by the U.S. government and the hundreds of millions invested by Germany in theirs.

Remarkably, Cuba eventually exported almost as many vaccine doses as it used at home, supplying Venezuela, Mexico, Vietnam, Syria, Nicaragua, Belarus and Iran. But while many countries in Africa and South Asia also desperately needed vaccines, they did not take advantage of Cuba's offer.

To explain why they did not, we must go back to 1962, when the U.S. economic embargo against Cuba went into effect. Since then, escalating sanctions, which the United States has enforced by applying steady political and financial pressure, have isolated Cuba not just from America but also effectively from the world. Stiff penalties for violating U.S. sanctions have ensured that institutions and governments routinely over-comply with them.

Cuba could have asked the WHO to certify its vaccines to make it easier for other countries to buy them with international aid. But it couldn't afford to engage with the WHO after President Donald Trump reversed the mild sanctions reforms introduced by his predecessor and designated Cuba a state sponsor of terrorism. This has meant that, even in countries where it is legal to transact with Cuba, few banks are willing to risk hefty fines and criminal sanctions for being perceived as supporting terrorism.

Cuban-American relations are a political live wire, but new times call for new measures. The world has changed since 1962. The specter haunting it today is not communism but another global health emergency. There is little indication that the Biden administration will pressure U.S. pharmaceutical companies to share their medical inventions internationally. But President Biden could take a giant step toward global health security by rolling back the Trump administration's draconian Cuba policies. If he went further by allowing for new exceptions in the U.S. sanctions regime, then Cuba could keep developing — and sharing — innovative vaccines and treatments for the world's diseases.

More than three years on, it's obvious that the world reacted poorly to the onset of the coronavirus, that lives were unnecessarily lost. But there is time now to prepare for the next pandemic, to set a course toward a more equitable distribution of medical technologies. The United States' age-old embargo is hurting not just Cuba. It's hurting everyone.

Fuente: The Washington Post. Disponible en https://www.washingtonpost.com/opinions/2023/06/01/pandemic-vaccines-cuba-who-planning/

Avanzando hacia el objetivo "Cero Meningitis"

5 jun. En el llamado "cinturón de la meningitis" de la franja central de África, con unos 470 millones de habitantes, padecen de forma endémica infecciones meningocócicas y brotes regulares con una gran mortalidad. El meningococo del serogrupo A fue el causante usual hasta la introducción de la vacuna MenAfriVac, que ha logrado hacer desaparecer en la práctica a este agente (las extraordinarias particularidades de esta vacuna ya se comentaron en esta web en 2020).

Pese a este avance con el serogrupo A, quedan en esta región de África los serogrupos C, W y X. Con el foco puesto en estos serogrupos se ha desarrollado un ECA fase 3 con una vacuna pentavalente (MenACWYX). Los resultados son favorables, pues se ha mostrado segura e inmunógena, con datos de no inferioridad comparados con la vacuna tetravalente de MenACWY.

En otras regiones del mundo, como en la que nos encontramos, se investigan otras vacunas pentavalentes

que incluyen al MenB en vez del MenX. Dos productos en investigación han mostrado datos preliminares favorables, tal como se ha informado en la reciente reunión de la ESPID.

Estos estudios parecen acercar el objetivo de "cero meningitis" formulado por la OMS para 2030.

El editorial del *New England Journal of Medicine* del 25 de mayo de 2023 (Stephens D, N Engl J Med 2023), titulado *"Global control of meningococcal disease"*, analiza los resultados de un ensayo clínico efectuado en el denominado cinturón africano de la meningitis con una vacuna antimeningocócica pentavalente (MenACWYX), publicado en ese mismo número de la revista (Haidara F, N Engl J Med 2023).

EL CINTURÓN DE LA MENINGITIS EN ÁFRICA

En esta zona geográfica, comprendida entre Senegal y Gambia en el oeste, y Etiopía, Eritrea y norte de Kenia en el este (ver imagen de arriba), con una población estimada de unos 470 millones de personas, se registran epidemias periódicas cada 5-10 años de enfermedad meningocócica, tradicionalmente sobre todo por el serogrupo A (Parikh SR, J Infect 2020). En estos brotes, la tasa de ataque es muy elevada, de 100 a 800 casos/100·000 personas, y algunas comunidades alcanzan tasas de 1 caso/100 personas (Mbaeyi SA, MMWR Recomm Rep 2020).



La magnitud de estos brotes condujo a la creación del Meningitis Vaccine Program (al que la revista Clinical Infectious Diseases dedicó un suplemento en 2015), una acción conjunta entre PATH (Program for Appropriate Technology in Health), la OMS, la farmacéutica Serum Institute de India y la Fundación Bill y Melinda Gates. Este programa desarrolló la vacuna MenAfriVac, una vacuna monovalente frente al meningococo del serogrupo A y conjugada con toxoide tetánico (Viviani S, Vaccines (Basel) 2022). Esta vacuna, de coste inferior a 0,5 dólares por dosis, ha sido empleada desde 2010 en más de 26 países africanos y ha conseguido la eliminación virtual de la enfermedad meningocócica por serogrupo A en el África subsahariana.

A pesar de este enorme logro, la enfermedad meningocócica sigue siendo endémica en toda la zona, añadiéndose, además, brotes epidémicos especialmente durante la estación seca (de diciembre a mayo). Los serogrupos predominantes son el C (complejo clonal 10217), W (complejo clonal 11) y X (complejo clonal 181) (Haidara F, N Engl J Med 2023). Se necesita, por tanto, disponer de vacunas multivalentes para todo el cinturón africano de la meningitis y zonas adyacentes (Carr J, Clin Microbiol Infect 2022).

PRIMEROS RESULTADOS DE UNA VACUNA ANTIMENINGOCÓCICA PENTAVALENTE ACWYX EN ÁFRICA

Sobre la base del trabajo y las alianzas que condujeron al desarrollo de la vacuna MenAfriVac se ha desarrollado un ensayo clínico para analizar la inmunogenicidad y seguridad de una vacuna conjugada antimeningocócica pentavalente (ACWYX) (Haidara FC, N Engl J Med 2023) en personas de 2 a 29 años en la región del África subsahariana.

Se trata de un ensayo fase 3 aleatorizado, doble ciego, llevado a cabo en Mali y Gambia, que ha incluido 1800 participantes. Los resultados muestran no inferioridad de la respuesta inmune a la vacuna pentavalente

comparada con la tetravalente MenACWY, y no se han registrado problemas de seguridad.

Por otra parte, se está llevando a cabo otro ensayo clínico (NCT05093829) con esta misma vacuna en lactantes con el objetivo de poder incluirla en el Programa Ampliado de Inmunizaciones (PAI o EPI por sus siglas en inglés) de la OMS.

PERSPECTIVAS FUTURAS

Todos estos estudios forman parte de la estrategia de la OMS para eliminar la meningitis para 2030, con tres objetivos fundamentales: 1) eliminación de las epidemias de meningitis bacterianas; 2) reducción el número de casos de meningitis bacterianas prevenibles con vacunas en un 50 % y los fallecimientos en un 70 %; y 3) reducción de las posibles secuelas.

Esta hoja de ruta, que se ha elaborado mediante consultas multidisciplinares, allana el camino para conseguirlo tras su aprobación por la 73.ª Asamblea Mundial de la Salud en noviembre de 2020.

VACUNAS ANTIMENINGOCÓCICAS PENTAVALENTES ABCWY

Uno de los pilares de este esfuerzo es el desarrollo de nuevas vacunas. Fuera de los países africanos, los ensayos clínicos que se están desarrollando para la obtención de vacunas pentavalentes incluyen los serogrupos A, B, C, W e Y.

En el último congreso de la ESPID (European Society of Pediatric Infectious Diseases), celebrado en Lisboa en mayo de 2023, se han presentado los resultados preliminares de dos ensayos clínicos en fase 3, todavía no finalizados y no publicados:

Vacuna MenABCWY (Pfizer) (NCT04440163). Vacuna pentavalente ABCWY (MenB-fHbp + MenACWY-TT) en personas de 10-25 años (n=2412). Dos dosis con intervalo de 6 meses. La vacuna pentavalente indujo una respuesta inmune protectora frente a los 5 serogrupos con criterio de no inferioridad respecto a la tetravalente MenACWY-CRM y a la monovalente MenB-fHbp. La vacuna pentavalente fue bien tolerada, con excelente perfil de seguridad.

Vacuna MenABCWY (GSK) (NCT04502693). Vacuna pentavalente ABCWY (MenACWY-CRM + 4CMenB) en personas de 10-25 años (n=3651). Dos dosis con intervalo de 6 meses. La vacuna pentavalente indujo una respuesta inmune protectora frente a los 5 serogrupos con criterio de no inferioridad respecto a la tetravalente MenACWY-CRM y a la monovalente 4CMenB. La vacuna pentavalente fue bien tolerada, con excelente perfil de seguridad.

En resumen, aunque persisten los retos, se van materializando avances para el control de la meningitis a nivel mundial.

Fuente: Asociación Española de Pediatría. Disponible en https://vacunasaep.org/profesionales/noticias/meningitis-cero-vacuna-menacwyx-en-africa

Se afianza la biotecnología cubana

8 jun. Con la firma de tres importantes acuerdos, Cuba, Rusia y Belarús ampliaron este jueves el nivel de cooperación en el campo de la biotecnología. La rúbrica aconteció en el Parque de Ciencia y Arte «Sirius», en presencia del miembro del Buró Político y primer ministro, Manuel Marrero Cruz, quien realiza una visita oficial a esta nación euroasiática.

El primero de los instrumentos es un memorándum de entendimiento que permitirá establecer una estrategia de cooperación científico-técnica, la transferencia y la asimilación de tecnología, así como la comercialización de principios activos para la producción de medicamentos y sus patrones de referencia.

Según explicó el presidente del Grupo Empresarial de las Industrias Biotecnológicas y Farmacéuticas (Biocubafarma), Eduardo Martínez Díaz, este memorándum se firmó entre dicha entidad y JSC Componentes Activos, empresa rusa, líder en la producción de ingredientes activos. Añadió que Biocubafarma desempeña un papel importante en el mercado de América Latina y en la investigación y desarrollo de productos de origen químico.

El segundo es un contrato de suministro de sustancias farmacéuticas, es decir, la adquisición de varios principios activos de medicamentos genéricos; por ejemplo, el del antibiótico Azitromicina.

El tercer documento es una carta de intención de la Unión Económica Euroasiática para crear una alianza multinacional, que permita alcanzar la soberanía en el corto plazo, en pos del desarrollo y la producción de vacunas y medicamentos.

En este caso, refirió Martínez Díaz, proponemos un portafolio de productos en programas de tratamiento de enfermedades infecciosas y crónicas tales como la oncología, la neurología y la diabetes, que pueda comercializarse en esta zona euroasiática, pero también en la región de América Latina.

Además, pueden incluirse transferencias de tecnología entre nuestros países, de modo que tributen a la soberanía en la fabricación de medicamentos, vacunas, dispositivos y equipos médicos. Otro punto importante es el de promover intercambios científicos, académicos y empresariales para el desarrollo de nuevos productos, señaló.

«Nosotros pretendemos que la empresa FarmaCuba nos represente en América Latina. Estamos muy contentos de haber firmado estos documentos sobre la cooperación con nuestros socios, y estamos seguros que serán efectivos los resultados», dijo el representante de JSC Componentes Activos, quien valoró «de excelentes las relaciones entre Rusia, Cuba y BioCubaFarma», basadas «sobre todo en la confianza».

El Presidente de BioCubaFarma también mostró satisfacción por esta «alianza que hemos establecido en el

día de hoy, que va a brindar resultados muy positivos tanto para la Federación de Rusia como para Cuba, y también para otros países de la región euroasiática y de América Latina y el Caribe».

De unir esfuerzos por lograr un mejor impacto en los servicios médicos que recibe la población de cada uno de nuestros países se habló en la firma de los documentos. Por eso, Martínez Díaz propuso a «nuestros amigos de la JSC Componentes Activos trabajar fuerte para materializar lo que hemos acorado en el día de hoy».

Previo a la firma de los acuerdos, Marrero Cruz, junto a otros jefes de delegaciones que asisten al Consejo Intergubernamental Euroasiático, recorrieron la exposición Eurasia-nuestro hogar, en el Parque de Ciencia y Arte «Sirius», la cual está dedicada a los logros en el desarrollo de la cooperación y los lazos económicos en el espacio eurasiático, donde existen varios stands de Cuba.

Fuente: Presidencia Cuba. Disponible en https://www.presidencia.gob.cu/es/noticias/se-afianza-la-biotecnologia-cubana/

Moderna y Pfizer son demandadas por tecnología desarrollada por investigadores de San Diego que hizo posible la vacuna COVID-19

8 jun. Moderna, Pfizer y BioNTech fueron citadas el martes en demandas en las que se les acusa de robar un método patentado desarrollado por investigadores del Instituto de Investigación Scripps que hizo posible la vacuna COVID-19.

Promosome presentó ante el tribunal federal de San Diego dos demandas distintas por violación de patentes: una contra Moderna por su vacuna Spikevax y otra contra Pfizer y su socio BioNTech por su vacuna Comirnaty. La empresa, que tiene oficinas en San Diego y Nueva York, desarrolla y comercializa los descubrimientos de Gerald Edelman y Vincent Mauro, ambos galardonados con el Premio Nobel y que realizaron investigaciones en el Instituto de Investigación Scripps de La Jolla.

A última hora del martes 6 de junio, Moderna, Pfizer y BioNTech no pudieron ser localizadas para hacer comentarios sobre la demanda.

La patente objeto de las demandas es un método novedoso para modificar el ARN mensajero, o ARNm, que da instrucciones a las células para la producción de proteínas. La modificación de los investigadores acabó haciendo que las vacunas de ARNm fueran más seguras y significativamente más eficaces al ayudar al sistema inmunitario a producir suficientes proteínas para combatir el virus con pequeñas dosis de ARNm. La técnica fue desarrollada por los científicos de Scripps Edelman, Mauro, Stephen Chappell y Wei Zhou en 2009, afirma la demanda.

La demanda contra Moderna sostiene que en 2013, en virtud de un acuerdo de divulgación confidencial, el método patentado se compartió con los más altos dirigentes de la empresa biofarmacéutica, entre ellos el

consejero delegado Stéphane Bancel y el presidente Stephen Hoge. Sin embargo, Moderna no concedió la licencia de la tecnología.

La demanda presentada contra Pfizer y BioNTech alega que, en 2015, Promosome compartió la tecnología con la científica de BioNTech, la Dr. Katalin Karikó, pero ninguna de las dos empresas concedió la licencia de la tecnología.

En cada demanda Promosome busca "recibir su parte legítima de las decenas de miles de millones en ingresos", cada empresa "ya ha ganado e incontables miles de millones que ganará al infringir deliberadamente la Patente '179".

Moderna obtuvo $18 400 millones en ventas de su vacuna contra el coronavirus el año pasado, según los archivos de la SEC. Pfizer y BioNTech obtuvieron $37 800 millones por las ventas de su vacuna COVID-19, Comirnaty, el año pasado.

"La tecnología vanguardista de nuestro cliente ha contribuido a preservar a cientos de millones de personas de los efectos nocivos del COVID-19", declaró Bill Carmody, abogado principal del asunto y socio del despacho Susman Godfrey. "Por desgracia, estas grandes farmacéuticas no han dado a Promosome lo que se merece".

Las demandas por infracción de patentes no son infrecuentes en el ámbito de la biotecnología y la farmacia.

Anteriormente se han presentado múltiples demandas relacionadas con las vacunas contra el coronavirus y la tecnología que las hizo posibles.

Por ejemplo, en febrero Moderna pagó al gobierno federal $400 millones por una técnica química que empleó en su vacuna COVID-19. En agosto, Moderna demandó a Pfizer y BioNTech por infracción de patentes relacionadas con la tecnología de ARNm utilizada en su vacuna COVID-19.

Fuente: The San Diego Union-Tribune. Disponible en https://www.sandiegouniontribune.com/en-espanol/noticias/ut-espanol/articulo/2023-06-08/moderna-y-pfizer-son-demandadas-por-tecnologia-desarrollada-por-investigadores-de-san-diego-que-hizo-posible-la-vacuna-covid-19

COVID shots should target XBB variants in 2023-24 campaign, US FDA staff say

Jun 12. COVID-19 vaccines being developed and manufactured for the 2023-2024 campaign should target one of the currently dominant XBB variants, the U.S. Food and Drug Administration's (FDA) staff reviewers said on Monday.

The comments were made in documents posted ahead of Thursday's meeting of a panel of FDA's independent experts, who are expected to make recommendations on what strain an updated COVID-19 booster should target.

An advisory group to the World Health Organization (WHO) in May recommended that COVID-19 booster shots for the year should be updated to target XBB subvariants.

Last year's COVID vaccine boosters in the United States featured both the original strain of the vaccine and Omicron in a so-called bivalent shot.

About 17% of people in the United States received a COVID booster shot in the 2022-2023 vaccination season, according to CDC data that was current through early May.

COVID-related deaths in the United States spiked in January, but have mostly fallen since then. They fell 14.3% in the past week.

Regulators say vaccines need to be updated to deal with the unpredictability of the virus.

"There is no indication that SARS-CoV-2 evolution is slowing down, though immunity appears to be mitigating severe clinical outcomes," the FDA's staff said.

The COVID vaccination campaign should feature a monovalent vaccine targeting either the XBB.1.5, XBB.1.16, or XBB.2.3, the FDA's reviewers said.

XBB subvariants accounted for more than 95% of the circulating virus variants in the United States by early June 2023, they added.

COVID-19 vaccine makers like Pfizer/BioNtech (PFE.N), Moderna Inc (MRNA.O) and Novavax Inc (NVAX.O) are already developing versions of their respective vaccines targeting XBB.1.5 and other currently circulating strains.

Fuente: Reuters. Disponible en https://www.reuters.com/business/healthcare-pharmaceuticals/updated-covid-vaccines-need-target-xbb-strains-us-fda-staff-2023-06-12/

Resultados positivos de nueva vacuna contra chikungunya

14 jun. Un nuevo estudio clínico, el primero en seres humanos, revela resultados prometedores de un ensayo de fase III de la vacuna contra la chikungunya. Según explican los autores del estudio, publicado el pasado 12 de junio en la revista médica británica *The Lancet*, la vacuna tendría capacidad para proteger a millones de personas frente a esta enfermedad.



El mosquito tigre asiático se extiende cada vez más.

Descubierta por primera vez en Tanzania en la década de 1950, la llamada fiebre chikungunya es una enfermedad viral transmitida por el mosquito tigre y desde entonces se ha extendido a diversas partes de África, Asia, el Caribe y Sudamérica. Actualmente las regiones tropicales registran las tasas más elevadas del virus, siendo Paraguay, Brasil, Bolivia y Tailandia los países más afectados. Los casos a nivel mundial son relativamente bajos. Paraguay es el país con más infectados,y registró 82.240 casos y 43 muertes entre enero y marzo de 2023. Tailandia registró 259 casos y ninguna muerte durante el mismo periodo.

Los síntomas son dolor articular y muscular intenso, fiebre alta y erupciones cutáneas. Aunque estos suelen mejorar en una semana, el dolor articular (artralgia) puede persistir durante meses y, en algunos casos, derivar en una artritis reumática crónica. Actualmente no existe una terapia antivírica específica.

"El chikungunya es mortal en muy pocos casos, pero la enfermedad no es nada agradable. Puedes estar enfermo durante dos semanas. Además, en los casos graves, se produce una artritis muy dolorosa que puede durar semanas", afirma Peter Kremsner, especialista en enfermedades infecciosas y tropicales de la Universidad de Tubinga.

El cambio climático fomenta la propagación

Aunque la enfermedad provocada por el virus chikungunya sólo es común en los países de clima tropical, el cambio climático está provocando que mosquitos portadores de la enfermedad se acerquen más a los polos, lo que significa que podría aumentar el espectro de población al que se le aplica la vacuna.

"El mosquito tigre asiático, que transmite el virus, se está extendiendo cada vez más. Esta especie de mosquito ya es autóctona del sur de Europa, y cada vez es más común en Alemania", explica Kremsner.

La malaria es un excelente ejemplo de cómo el aumento de las temperaturas globales está provocando que los mosquitos transmisores de enfermedades amplíen sus territorios. Entre 1898 y 2016, las especies de mosquitos Anopheles portadores de la malaria han ampliado su área de distribución en 4,7 km por año al sur del Ecuador, lo que equivale a unos 550 km en total durante ese período.

Vacuna contra el Chikungunya, una novedad

El nuevo estudio de The Lancet presenta los resultados del primer ensayo de fase III realizado con una vacuna contra esta enfermedad.

Según el estudio, 28 días después de una única vacunación con "VLA1553", la vacuna produjo niveles de anticuerpos que neutralizaron el virus, con efectos que duraron hasta 180 días en el 98,9% de los participantes.

"Tras la vacunación, puede detectarse una respuesta inmunitaria protectora en casi todos los individuos vacunados al cabo de cuatro semanas", afirma Torsten Feldt, especialista en infecciones y enfermedades tropicales del Hospital Universitario de Düsseldorf (Alemania).

En 2018, el virus Chikungunya fue incluido en la lista de patógenos prioritarios para el desarrollo de vacunas por la Organización Mundial de la Salud (OMS).

Fuente: DW. Disponible en https://www.dw.com/es/resultados-positivos-en-ensayos-para-una-nueva-vacuna-contra-el-virus-chikungunya/a-65915246

Vacuna de última generación promete erradicar la poliomielitis de manera definitiva

16 jun. Pese a los arduos trabajos de la Organización Mundial de la Salud (OMS) y los sistemas de salud de las naciones, la poliomielitis no ha sido erradicada completamente y cada año se reportan casos y brotes puntuales. Una nueva vacuna de última generación tienen el potencial de cumplir con el objetivo de dejar atrás de manera definitiva el virus que dañó el sistema nervioso de millones de personas durante el siglo XX.

Las actuales vacunas orales contra la polio suministran el poliovirus vivo debilitado para que los cuerpos de los recién nacidos aprendan a defenderse de la enfermedad. El proceso es el mismo para prácticamente cualquier vacuna y gracias a las campañas masivas de vacunación, se ha eliminado hasta en un 99% los poliovirus que se encuentran 'silvestres' en el exterior. Pero en muy contadas excepciones, el virus suministrado como vacuna logra mutar en una forma activa, lo que detona la enfermedad y provoca brotes

en regiones de cualquier parte del mundo. La polio, por tanto, no ha podido erradicarse porque la mejor arma que tenemos contra ella, en extraordinarias ocasiones, la revive.

En el estudio titulado “Estabilización genética de vacunas orales atenuadas contra poliovirus tipos 1 y 3”, publicado en Nature, los investigadores presentaron una nueva generación de vacunas con cepas de virus más seguras incapaces de ‘despertar’, incluso aunque muten. Este avance es la primera gran actualización que obtienen las vacunas contra la poliomielitis desde su invención en la década de 1950.

La polio no ha desparecido, es endémica de tres países

La enfermedad se transmite principalmente a través de la ingesta de alimentos o agua contaminada con partículas de heces fecales. Aunque los síntomas son parecidos a los de la gripe común, en infecciones graves, el virus invade el sistema nervioso central y daña las células de la médula espinal. La debilidad muscular, la parálisis total o parcial de extremidades y la muerte son sus efectos más graves. En la actualidad, solo hay tres países donde se reporta la poliomielitis como una enfermedad endémica: Afganistán, Pakistán y Nigeria.

“Con tal variabilidad en la vacunación dentro y entre países, el virus de la polio ha persistido hasta el siglo XXI, con consecuencias a veces trágicas. Hemos diseñado estas nuevas vacunas utilizando las lecciones aprendidas durante muchos años de lucha contra la poliomielitis y creemos que ayudarán a eliminar la enfermedad de una vez por todas”, señala Raúl Andino, coautor del artículo.

El equipo de científicos probó sus nuevas cepas seguras de poliovirus en poblaciones de ratones. Los roedores fueron inmunizados contra la exposición directa contra los tres tipos de polio y la vacuna no se activó, incluso cuando sufrió mutaciones.

Aunque el equipo se muestra optimista sobre su nueva vacuna, el camino para incorporarlas a las actuales campañas de vacunación es largo. La actual investigación es la primera fase de desarrollo preclínico. El siguiente paso es la realización de ensayos clínicos con distintas etapas donde varía el número de humanos suministrados con la vacuna. Finalmente, si la vacuna sale según lo esperado, comenzará la etapa regulatoria y su consecuente aprobación.

La polio podría alcanzar su erradicación definitiva y formar parte de un muy selecto club de enfermedades que ya no existen donde solo se encuentran la viruela y la peste bovina. Para que ello ocurra, las campañas de vacunación deben persistir y las autoridades sanitarias no deben confiarse, indican los científicos.

Fuente: WIRED. Disponible en https://es.wired.com/articulos/vacuna-de-ultima-generacion-promete-erradicar-la-poliomielitis-de-manera-definitiva

Iran to produce new vaccines in cooperation with Cuba: health minister

Jun16. Bahram Einollahi made the comments on a trip to Cuba accompanying a high-ranking Iranian delegation headed by the president Raeisi on the last leg of their tour to three Latin American countries.

"We have had long-standing cooperation with Cuba since 1979 Islamic Revolution until now in the field of creating health networks in the country," the health miniter said.

Saying that Cuba is one of the advanced countries in the field of vaccine production, Einollahi added that the vaccine production technology was imported from Cuba to Iran.

Pointing out to the MoUs signed between the two countries, the Iranian official said," Based on these agreements, we plan to increase the volume and types of our vaccines so that we can produce newer vaccines."

"Drugs with high technology, especially in the treatment of cancer, will be produced in cooperation with Cuba," Einollahi added.

In the meeting between Iran and Cuba's health delegation, which was held with the participation of the two nations' ministers, it was decided to form a joint working group on health science and technology between the two countries.

According to the Iranian health minister, Cuban biotechnology experts and Iranian nanotechnology scientists will conduct a joint research program.

Fuente: MEHR News Agency. Disponible en https://en.mehrnews.com/news/202035/Iran-to-produce-new-vaccines-in-coop-with-Cuba-health-min

VACCI MONITOR

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

@finlayediciones

EBSCO Information Services · Scopus · DOAJ Directory of Open Access Journals · SciELO · redalyc.org · FreeMedical Journals · HINARI Research in Health · latindex · SeCiMed

IFV Instituto Finlay de Vacunas · SiViFinlay · VacyT

CUBA

Artículos científicos publicados en Medline

Filters activated: Publication date from 2023/06/01 to 2023/06/15. "COVID-19 vaccine" (Title/Abstract) 580 records.

COVID-19 vaccines adverse events: potential molecular mechanisms.
Lamprinou M, Sachinidis A, Stamoula E, Vavilis T, Papazisis G. Immunol Res. 2023 Jun;71(3):356-372. doi: 10.1007/s12026-023-09357-5. Epub 2023 Jan 6. PMID: 36607502

Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD.
Kim S, Seok HY. Neurol Sci. 2023 Jun;44(6):1841-1848. doi: 10.1007/s10072-023-06676-1. Epub 2023 Feb 13. PMID: 36781562

COVID-19 anti-vaccine attitude and hesitancy.
Hasanzad M, Namazi H, Larijani B. J Diabetes Metab Disord. 2022 Nov 5;22(1):1-4. doi: 10.1007/s40200-022-01018-y. eCollection 2023 Jun. PMID: 36373157

Trust and COVID-19 vaccine hesitancy.
Carrieri V, Guthmuller S, Wübker A. Sci Rep. 2023 Jun 7;13(1):9245. doi: 10.1038/s41598-023-35974-z. PMID: 37286569

COVID-19: The disease, the vaccine and the heart.
Turner CJ. J Paediatr Child Health. 2023 Jun;59(6):786-793. doi: 10.1111/jpc.16407. Epub 2023 May 9. PMID: 37158762

COVID-19 vaccine equity in Africa.
Turyasingura N, James WG, Vermund SH. Trans R Soc Trop Med Hyg. 2023 Jun 2;117(6):470-472. doi: 10.1093/trstmh/trac130. PMID: 36622662

Factors, enablers and challenges for COVID-19 vaccine development.
Excler JL, Saville M, Privor-Dumm L, Gilbert S, Hotez PJ, Thompson D, Abdool-Karim S, Kim JH. BMJ Glob Health. 2023 Jun;8(6):e011879. doi: 10.1136/bmjgh-2023-011879. PMID: 37277195

COVID-19 and splenectomy: Education matters.
Crickx E. Br J Haematol. 2023 Jun;201(6):1023-1024. doi: 10.1111/bjh.18767. Epub 2023 Mar 30. PMID: 36994879

Obesity and Viral Infections.
Jaisinghani P, Kumar R. Gastroenterol Clin North Am. 2023 Jun;52(2):393-402. doi: 10.1016/j.gtc.2023.03.012. PMID: 37197881

Assessing the robustness of COVID-19 vaccine efficacy trials: systematic review and meta-analysis, January 2023.
Hoang TNA, Quach HL, Hoang VN, Tran VT, Pham QT, Vogt F. Euro Surveill. 2023 Jun;28(22):2200706. doi: 10.2807/1560-7917.ES.2023.28.22.2200706. PMID: 37261728

Vaccination in pregnancy.
Nassar AH, Hobeika E, Chamsy D, El-Kak F, Usta IM. Int J Gynaecol Obstet. 2023 Jun 7. doi: 10.1002/ijgo.14876. Online ahead of print. PMID: 37283471

COVID-19 vaccine decision-making among pregnant and lactating women in Bangladesh.
Limaye RJ, Singh P, Paul A, Fesshaye B, Lee C, Zavala E, Wade S, Ali H, Rahman H, Akter S, Karron R, Jahan Siddiqua T. Vaccine. 2023 Jun 13;41(26):3885-3890. doi: 10.1016/j.vaccine.2023.05.024. Epub 2023 May 15. PMID: 37208208

Acute hepatitis of unknown origin in children: Behind the statistics.
Elsheikh R, Tien HT, Makram AM, Van NT, Le TTB, Vasanthakumaran T, Huy NT. Hepatology. 2023 Jun 1;77(6):2118-2127. doi: 10.1002/hep.32682. Epub 2022 Aug 9. PMID: 35862247

COVID-19 Vaccine Hesitancy and Experiences of Discrimination Among Black Adults.
Willis DE, Andersen JA, Montgomery BEE, Selig JP, Shah SK, Zaller N, Bryant-Moore K, Scott AJ, Williams M, McElfish PA. J Racial Ethn Health Disparities. 2023 Jun;10(3):1025-1034. doi: 10.1007/s40615-022-01290-x. Epub 2022 Apr 7. PMID: 35391714

Vaccine access, equity and justice: COVID-19 vaccines and vaccination.
Privor-Dumm L, Excler JL, Gilbert S, Abdool Karim SS, Hotez PJ, Thompson D, Kim JH. BMJ Glob Health. 2023 Jun;8(6):e011881. doi: 10.1136/bmjgh-2023-011881. PMID: 37290896

COVID-19 Vaccine Hesitancy, Medical Mistrust, and Mattering in Ethnically Diverse Communities.
Charura D, Hill AP, Etherson ME. J Racial Ethn Health Disparities. 2023 Jun;10(3):1518-1525. doi: 10.1007/s40615-022-01337-z. Epub 2022 May 31. PMID: 35641735

Associations between COVID-19 vaccine uptake, race/ethnicity, and political party affiliation.
Andersen JA, Gloster E, Hall S, Rowland B, Willis DE, Kraleti SS, McElfish PA. J Behav Med. 2023 Jun;46(3):525-531. doi: 10.1007/s10865-022-00379-2. Epub 2022 Nov 22. PMID: 36417011

Views and perceptions of the public toward COVID-19 vaccine in Saudi Arabia.
Thabit AK, Badr AF, Jad L, Jose J, Kaae S, Jacobsen R, Al-Saudi G. Saudi Pharm J. 2023 Jun;31(6):942-947. doi: 10.1016/j.jsps.2023.05.001. Epub 2023 May 8. PMID: 37197386

COVID-19 vaccine uptake and hesitancy in Chinese patients with asthma.
Chang C, Zhang X, Feng Y, Jin R, Sun L, Liang Y, Liu X, Ma Y, Song J, Xiang P, Zhang E, Chen L, Jiang Y, Huang K, Wang W, Chen Y, Sun Y. J Asthma. 2023 Jun 9:1-10. doi: 10.1080/02770903.2023.2220790. Online ahead of print. PMID: 37272671

Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.
Xu K, Gao B, Li J, Xiang Y, Cao L, Zhao M. Hum Vaccin Immunother. 2023 Jun 6:2220630. doi: 10.1080/21645515.2023.2220630. Online ahead of print. PMID: 37282614

COVID-19 Vaccine Perspective Among University Lecturers and Students: A Qualitative Study of Pre Implementation of Vaccination.

Rahayuwati L, Mutyara K, Nugraha RR, Khatiwada M, Dochez C, Kartasasmita C. J Multidiscip Healthc. 2023 Jun 10;16:1619-1629. doi: 10.2147/JMDH.S416123. eCollection 2023. PMID: 37325125

Are surgeons ready to get the COVID-19 vaccine?
Farid Y, Vissers G, Ortiz S, Tondu T, Thiessen F, Coppieters Y, Wauthy P. Acta Chir Belg. 2023 Jun;123(3):238-243. doi: 10.1080/00015458.2021.1975892. Epub 2021 Sep 20. PMID: 34474635

Anetoderma after mRNA COVID-19 vaccine.
Massi A, Rapparini L, Misciali C, Baraldi C, Pileri A. Ital J Dermatol Venerol. 2023 Jun;158(3):269-270. doi: 10.23736/S2784-8671.23.07305-X. PMID: 37278506

Social media use and COVID-19 vaccine status among a nationally representative population sample in Uganda.
Greenleaf AR, Croker-Benn A, Aibo D, Biraro S, Mugisha V, Kwizera MH, Kabanda R, Justman J, El-Sadr WM. Digit Health. 2023 Jun 7;9:20552076231180733. doi: 10.1177/20552076231180733. eCollection 2023 Jan-Dec. PMID: 37325068

The COVID-19 Pandemic and Adult Cardiac Transplantation: Impact, Interventions, and Implications.
Chih S, Clarke BA, Albert M, Buchan CA, Kafil TS, Kim DH, Kumar D, Smith SJ, Solera Rallo JT, Stubbs MJ, McDonald MA. Can J Cardiol. 2023 Jun;39(6):853-864. doi: 10.1016/j.cjca.2023.03.014. Epub 2023 Mar 23. PMID: 36965667

Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico.
Rodriguez DM, Major CG, Sánchez-González L, Jones E, Delorey MJ, Alonso C, Rivera-Amill V, Paz-Bailey G, Adams LE. Vaccine. 2023 Jun 1;41(24):3627-3635. doi: 10.1016/j.vaccine.2023.04.081. Epub 2023 May 5. PMID: 37173267

Characterizing Responses to COVID-19 Vaccine Promotion on TikTok.
Southwick L, Francisco A, Bradley M, Klinger E, Chandra Guntuku S. Am J Health Promot. 2023 Jun;37(5):638-645. doi: 10.1177/08901171221141974. Epub 2022 Dec 9. PMID: 36494184

COVID-19 vaccines and increased blood pressure.
Kleebayoon A, Wiwanitkit V. Eur J Intern Med. 2023 Jun;112:121. doi: 10.1016/j.ejim.2023.03.030. Epub 2023 Mar 30. PMID: 37003922

Covid-19 vaccine roll-out in England: A qualitative evaluation.
Mounier-Jack S, Paterson P, Bell S, Letley L, Kasstan B, Chantler T. PLoS One. 2023 Jun 2;18(6):e0286529. doi: 10.1371/journal.pone.0286529. eCollection 2023. PMID: 37267295

Management of COVID-19 and vaccination in Nepal: A qualitative study.
Karki A, Rijal B, Koirala B, Makai P, Kc P, Adhikary P, Joshi S, Basnet S, Bhattarai S, Karki J. Health Expect. 2023 Jun;26(3):1170-1179. doi: 10.1111/hex.13732. Epub 2023 Feb 16. PMID: 36797845

Safety and Effectiveness of Maternal COVID-19 Vaccines Among Pregnant People and Infants.
Fleming-Dutra KE, Zauche LH, Roper LE, Ellington SR, Olson CK, Sharma AJ, Woodworth KR, Tepper N, Havers F, Oliver SE, Twentyman E, Jatlaoui TC. Obstet Gynecol Clin North Am. 2023 Jun;50(2):279-297. doi: 10.1016/j.ogc.2023.02.003. Epub 2023 Feb 21. PMID: 37149310

Using Twitter to Understand COVID-19 Vaccine-Related Ageism during the Pandemic.
Bacsu JR, Andrew MK, Azizi M, Berger C, Cammer A, Chasteen AL, Fraser SA, Grewal KS, Green S, Gowda-Sookochoff R, Mah JC, McGilton KS, Middleton L, Nanson K, Spiteri RJ, Tang Y, O'Connell ME. Gerontologist. 2023 Jun 2:gnad061. doi: 10.1093/geront/gnad061. Online ahead of print. PMID: 37267449

COVID-19 vaccine acceptance and predictors among pregnant women in Ethiopia: Systematic Review and Meta-Analysis.
Worede DT, Kassahun M, Endalew B. Public Health Pract (Oxf). 2023 Jun;5:100386. doi: 10.1016/j.puhip.2023.100386. Epub 2023 Apr 23. PMID: 37122635

Coronavirus Disease-2019 in the Immunocompromised Host.
Bertini CD Jr, Khawaja F, Sheshadri A. Clin Chest Med. 2023 Jun;44(2):395-406. doi: 10.1016/j.ccm.2022.11.012. Epub 2022 Nov 22. PMID: 37085228

Predictors of COVID-19 vaccine hesitancy among Jordanian older adults.
Abu Kamel AM, Alnazly E, Shawish NS. Int J Nurs Pract. 2023 Jun;29(3):e13144. doi: 10.1111/ijn.13144. Epub 2023 Mar 6. PMID: 36879519

Adolescent autonomy for the COVID-19 vaccine.
Ting P. J Public Health Policy. 2023 Jun;44(2):325-328. doi: 10.1057/s41271-023-00398-6. Epub 2023 Feb 14. PMID: 36788273

COVID-19 Vaccine Hesitancy in an Underrepresented Minority Community.
Balhotra K, Chahal K, Silver M, Atallah F, Narayanamoorthy S, Minkoff H. J Community Health. 2023 Jun;48(3):489-495. doi: 10.1007/s10900-022-01184-3. Epub 2023 Jan 24. PMID: 36692822

Explaining the gender gap in COVID-19 vaccination attitudes.
Toshkov D. Eur J Public Health. 2023 Jun 1;33(3):490-495. doi: 10.1093/eurpub/ckad052. PMID: 37178211

How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020-2022.
Lai CC, Lee PI, Hsueh PR. J Microbiol Immunol Infect. 2023 Jun;56(3):433-441. doi: 10.1016/j.jmii.2023.04.001. Epub 2023 Apr 6. PMID: 37061349

Socioeconomic status and disparities in COVID-19 vaccine uptake in Eastern Oslo, Norway.
Lillebråten A, Todd M, Dimka J, Bakkeli NZ, Mamelund SE. Public Health Pract (Oxf). 2023 Jun;5:100391. doi: 10.1016/j.puhip.2023.100391. Epub 2023 May 28. PMID: 37293528

A COVID-19 vaccine candidate based on SARS-CoV-2 spike protein and immune-stimulating complexes.
Villarraza J, Fuselli A, Gugliotta A, Garay E, Rodríguez MC, Fontana D, Antuña S, Gastaldi V, Battagliotti JM, Tardivo MB, Alvarez D, Castro E, Cassataro J, Ceaglio N, Prieto C. Appl Microbiol Biotechnol. 2023 Jun;107(11):3429-3441. doi: 10.1007/s00253-023-12520-5. Epub 2023 Apr 24. PMID: 37093307

Acute cardiac events after COVID-19 vaccines and during spontaneous SARS-CoV-2 infection.
Marabotti C, Pingitore A. J Cardiovasc Med (Hagerstown). 2023 Jun 1;24(6):323-325. doi: 10.2459/JCM.0000000000001464. PMID: 37129927

COVID-19 Vaccine Videos: Health Literacy Considerations.
Feinberg I, Ogrodnick M, Bernhardt J. Health Lit Res Pract. 2023 Jun;7(2):e111-e118. doi: 10.3928/24748307-20230523-02. Epub 2023 Jun 1. PMID: 37306321

Das sind die neuen Ziffern für die Covid-Impfung.
Zimmermann GW. MMW Fortschr Med. 2023 Jun;165(11):30-31. doi: 10.1007/s15006-023-2575-y. PMID: 37258829

Evaluation of a Community COVID-19 Vaccine Ambassador Train-the-Trainer Program.
Corley AMS, Gomes SM, Martin KJ, Watkins S, Lindsey K, Frenck RW Jr, Mitchell MJ, Rule ARL, Crosby LE. J Immigr Minor Health. 2023 Jun 5:1-5. doi: 10.1007/s10903-023-01502-4. Online ahead of print. PMID: 37273119

Safety of COVID-19 vaccines.
Virginia R, Guido R. Eur J Intern Med. 2023 Jun;112:15-16. doi: 10.1016/j.ejim.2023.04.009. Epub 2023 Apr 10. PMID: 37045709

Female reproduction and abnormal uterine bleeding after COVID-19 vaccination.
Paik H, Kim SK. Clin Exp Reprod Med. 2023 Jun;50(2):69-77. doi: 10.5653/cerm.2023.05925. Epub 2023 May 16. PMID: 37258099

Determinants of COVID-19 vaccine Hesitancy: 2020 California Health Interview Survey.
Moon I, Han J, Kim K. Prev Med Rep. 2023 Jun;33:102200. doi: 10.1016/j.pmedr.2023.102200. Epub 2023 Apr 5. PMID: 37034299

COVID-19 vaccination and changes in preventive behaviours: findings from the 2021 vaccine roll-out in Switzerland.
Hitchman SC, Geber S, Tribelhorn L, Friemel TN. Eur J Public Health. 2023 Jun 1;33(3):482-489. doi: 10.1093/eurpub/ckad050. PMID: 37015103

COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats.
Hotez PJ, Gilbert S, Saville M, Privor-Dumm L, Abdool-Karim S, Thompson D, Excler JL, Kim JH. BMJ Glob Health. 2023 Jun;8(6):e011883. doi: 10.1136/bmjgh-2023-011883. PMID: 37277196

Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 years.
Yogurtcu ON, Funk PR, Forshee RA, Anderson SA, Marks PW, Yang H. Vaccine X. 2023 Aug;14:100325. doi: 10.1016/j.jvacx.2023.100325. Epub 2023 Jun 2. PMID: 37324525

Broadly neutralizing antibodies against COVID-19.
Zhou D, Ren J, Fry EE, Stuart DI. Curr Opin Virol. 2023 Jun 5;61:101332. doi: 10.1016/j.coviro.2023.101332. Online ahead of print. PMID: 37285620

Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.
Ciapponi A, Berrueta M, P K Parker E, Bardach A, Mazzoni A, Anderson SA, Argento FJ, Ballivian J, Bok K, Comandé D, Goucher E, Kampmann B, Munoz FM, Rodriguez Cairoli F, Santa María V, Stergachis AS, Voss G, Xiong X, Zamora N, Zaraa S, Buekens PM. Vaccine. 2023 Jun 7;41(25):3688-3700. doi: 10.1016/j.vaccine.2023.03.038. Epub 2023 Mar 27. PMID: 37012114

A COVID-19 perspective of Vogt-Koyanagi-Harada disease.
Dutta Majumder P, Sadhu S, González-López JJ, Mochizuki M. Indian J Ophthalmol. 2023 Jun;71(6):2587-2591. doi: 10.4103/IJO.IJO_172_23. PMID: 37322685

Burden of COVID-19 disease and vaccine coverages in Apulian splenectomized patients: A retrospective observational study.
Bianchi FP, Stefanizzi P, Rizzi D, Signorile N, Cuscianna E, Daleno A, Migliore G, Tafuri S. Br J Haematol. 2023 Jun;201(6):1072-1080. doi: 10.1111/bjh.18731. Epub 2023 Mar 21. PMID: 36942786

Social-political and vaccine related determinants of COVID-19 vaccine hesitancy in Tanzania: A qualitative inquiry.
Mtenga S, Mhalu G, Osetinsky B, Ramaiya K, Kassim T, Hooley B, Tediosi F. PLOS Glob Public Health. 2023 Jun 14;3(6):e0002010. doi: 10.1371/journal.pgph.0002010. eCollection 2023. PMID: 37315101

COVID-19 vaccine hesitancy and attitudes in Pakistan: a cross-sectional phone survey of major urban cities.
Khan AA, Abdullah M, Aliani R, Mohiuddin AF, Sultan F. BMC Public Health. 2023 Jun 9;23(1):1112. doi: 10.1186/s12889-023-15905-3. PMID: 37296386

Lipid nanoparticle-mediated drug delivery to the brain.
Khare P, Edgecomb SX, Hamadani CM, Tanner EEL, S Manickam D. Adv Drug Deliv Rev. 2023 Jun;197:114861. doi: 10.1016/j.addr.2023.114861. Epub 2023 May 6. PMID: 37150326

Overview of the cardio-metabolic impact of the COVID-19 pandemic.
Barkhordarian M, Behbood A, Ranjbar M, Rahimian Z, Prasad A. Endocrine. 2023 Jun;80(3):477-490. doi: 10.1007/s12020-023-03337-3. Epub 2023 Apr 27. PMID: 37103684

COVID-19 vaccination and governance in the case of low, middle and high-income countries.
Lupu D, Tiganasu R. BMC Public Health. 2023 Jun 5;23(1):1073. doi: 10.1186/s12889-023-15975-3. PMID: 37277743

Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review.
Ansari B, Najafi MA, Kheradmand M, Najafi F, Najafi MR. Rev Neurol (Paris). 2023 Jun;179(6):630-635. doi: 10.1016/j.neurol.2022.11.009. Epub 2023 Feb 1. PMID: 36754672

Upper extremity deep vein thrombosis following BBIBP-CorV COVID-19 vaccine (Sinopharm vaccine): A case report.
Riazi A, Faghih Dinevari M, Abbasian S, Jabbaripour Sarmadian A. Clin Case Rep. 2023 Jun 13;11(6):e7535. doi: 10.1002/ccr3.7535. eCollection 2023 Jun. PMID: 37323251

COVID-19 vaccination and household savings: An economic recovery channel.
Ren H, Zheng Y. Financ Res Lett. 2023 Jun;54:103711. doi: 10.1016/j.frl.2023.103711. Epub 2023 Feb 23. PMID: 36852174

COVID-19 vaccination decisions among Gypsy, Roma, and Traveller communities: A qualitative study moving beyond "vaccine hesitancy".

Kühlbrandt C, McGowan CR, Stuart R, Grenfell P, Miles S, Renedo A, Marston C. Vaccine. 2023 Jun 13;41(26):3891-3897. doi: 10.1016/j.vaccine.2023.04.080. Epub 2023 May 1. PMID: 37202271

Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
Smith K, Hegazy K, Cai MR, McKnight I, Rousculp MD, Alves K. Vaccine. 2023 Jun 13;41(26):3930-3936. doi: 10.1016/j.vaccine.2023.05.016. Epub 2023 May 10. PMID: 37211453

COVID-19 vaccination-related myocarditis: a Korean nationwide study.
Cho JY, Kim KH, Lee N, Cho SH, Kim SY, Kim EK, Park JH, Choi EY, Choi JO, Park H, Kim HY, Yoon HJ, Ahn Y, Jeong MH, Cho JG. Eur Heart J. 2023 Jun 2:ehad339. doi: 10.1093/eurheartj/ehad339. Online ahead of print. PMID: 37264895

COVID-19 Vaccine and Health Care Visits for Menstrual Changes.
Harris E. JAMA. 2023 Jun 6;329(21):1817. doi: 10.1001/jama.2023.8658. PMID: 37195725

Estimating the impact of COVID-19 vaccine inequities: a modeling study.
Gozzi N, Chinazzi M, Dean NE, Longini IM Jr, Halloran ME, Perra N, Vespignani A. Nat Commun. 2023 Jun 6;14(1):3272. doi: 10.1038/s41467-023-39098-w. PMID: 37277329

Threat of resurgence or hope for global eradication of poliovirus?
Kim CY, Piamonte B, Allen R, Thakur KT. Curr Opin Neurol. 2023 Jun 1;36(3):229-237. doi: 10.1097/WCO.0000000000001156. Epub 2023 Apr 18. PMID: 37078665

Social media and COVID-19 vaccination hesitancy during pregnancy: a mixed methods analysis.
Golder S, McRobbie-Johnson ACE, Klein A, Polite FG, Gonzalez Hernandez G. BJOG. 2023 Jun;130(7):750-758. doi: 10.1111/1471-0528.17481. Epub 2023 Apr 20. PMID: 37078279

Experiences from COVID-19 vaccination in patients with epilepsy.
Yang L, He J, Song Z, Zhen W, Chen R, Zhang C, Yang H, Liu D. Epilepsia Open. 2023 Jun;8(2):307-312. doi: 10.1002/epi4.12667. Epub 2023 Mar 25. PMID: 36305698

Does covid-19 affect pregnancies?
Marshall M. New Sci. 2023 Jun 3;258(3441):14-15. doi: 10.1016/S0262-4079(23)00987-9. Epub 2023 Jun 2. PMID: 37292183

Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19.
Taboe HB, Asare-Baah M, Iboi EA, Ngonghala CN. Math Biosci. 2023 Jun;360:108981. doi: 10.1016/j.mbs.2023.108981. Epub 2023 Feb 16. PMID: 36803672

Motivators and Barriers to COVID-19 Vaccination in Young Adults Living in the USA.
Lee YM, Simonovich SD, Li S, Amer L, Wagner L, Hill J, Spulark R, Aquino E. Clin Nurs Res. 2023 Jul;32(6):971-982. doi: 10.1177/10547738231177331. Epub 2023 Jun 2. PMID: 37264835

Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.
Filippini F, Giacomelli M, Bazzani C, Fredi M, Semeraro P, Tomasi C, Franceschini F, Caruso A, Cavazzana I, Giagulli C. BMC Med. 2023 Jun 14;21(1):210. doi: 10.1186/s12916-023-02868-w. PMID: 37316832

Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: A multilevel study of 2021-2022 data.
Boing AF, Boing AC, Barberia L, Borges ME, Subramanian SV. Vaccine. 2023 Jun 13;41(26):3937-3945. doi: 10.1016/j.vaccine.2023.05.030. Epub 2023 May 17. PMID: 37221119

Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.
Al-Hatamleh MAI, Abusalah MA, Hatmal MM, Alshaer W, Ahmad S, Mohd-Zahid MH, Rahman ENSEA, Yean CY, Alias IZ, Uskoković V, Mohamud R. J Taibah Univ Med Sci. 2023 Jun;18(3):600-638. doi: 10.1016/j.jtumed.2022.11.007. Epub 2022 Dec 17. PMID: 36570799

Limb Lymphedema After COVID-19 Vaccine Booster: Reply.
Tang CYL, Chua WM. Clin Nucl Med. 2023 Jun 6. doi: 10.1097/RLU.0000000000004741. Online ahead of print. PMID: 37276502

Political network composition predicts vaccination attitudes.
Facciani M, Lazić A, Viggiano G, McKay T. Soc Sci Med. 2023 Jul;328:116004. doi: 10.1016/j.socscimed.2023.116004. Epub 2023 Jun 2. PMID: 37295206

COVID-19-related adrenal haemorrhage: Multicentre UK experience and systematic review of the literature.
Elhassan YS, Iqbal F, Arlt W, Baldeweg SE, Levy M, Stewart PM, Wass J, Pavord S, Aled Rees D, Ronchi CL. Clin Endocrinol (Oxf). 2023 Jun;98(6):766-778. doi: 10.1111/cen.14881. Epub 2023 Feb 5. PMID: 36710422

Vaccine hesitancy in cancer patients: A rapid review.
Butow P, Shaw J, Bartley N, Milch V, Sathiaraj R, Turnbull S, Der Vartanian C. Patient Educ Couns. 2023 Jun;111:107680. doi: 10.1016/j.pec.2023.107680. Epub 2023 Feb 24. PMID: 36842287

Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities.
Zhang W, Kedzierski L, Chua BY, Mayo M, Lonzi C, Rigas V, Middleton BF, McQuilten HA, Rowntree LC, Allen LF, Purcell RA, Tan HX, Petersen J, Chaurasia P, Mordant F, Pogorelyy MV, Minervina AA, Crawford JC, Perkins GB, Zhang E, Gras S, Clemens EB, Juno JA, Audsley J, Khoury DS, Holmes NE, Thevarajan I, Subbarao K, Krammer F, Cheng AC, Davenport MP, Grubor-Bauk B, Coates PT, Christensen B, Thomas PG, Wheatley AK, Kent SJ, Rossjohn J, Chung AW, Boffa J, Miller A, Lynar S, Nelson J, Nguyen THO, Davies J, Kedzierska K. Nat Immunol. 2023 Jun;24(6):966-978. doi: 10.1038/s41590-023-01508-y. Epub 2023 May 29. PMID: 37248417

Seesaw Effect Between COVID-19 and Influenza From 2020 to 2023 in World Health Organization Regions: Correlation Analysis.
Wang Q, Jia M, Jiang M, Liu W, Yang J, Dai P, Sun Y, Qian J, Yang W, Feng L. JMIR Public Health Surveill. 2023 Jun 12;9:e44970. doi: 10.2196/44970. PMID: 37191650

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19.
Dogan M, Yilmaz B. Acta Pharm. 2023 Jun 12;73(2):257-268. doi: 10.2478/acph-2023-0020. Print 2023 Jun 1. PMID: 37307370

Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance.
Bozio CH, Butterfield KA, Briggs Hagen M, Grannis S, Drawz P, Hartmann E, Ong TC, Fireman B, Natarajan K, Dascomb K, Gaglani M, DeSilva MB, Yang DH, Midgley CM, Dixon BE, Naleway AL, Grisel N, Liao IC, Reese SE, Fadel WF, Irving SA, Lewis N, Arndorfer J, Murthy K, Riddles J, Valvi NR, Mamawala M, Embi PJ, Thompson MG, Stenehjem E. J Infect Dis. 2023 Jun 15;227(12):1348-1363. doi: 10.1093/infdis/jiad040. PMID: 36806690

COVID-19 Vaccination and Community Management: A Qualitative Study.
Fernández-Basanta S, López-Villasenín S, Freijomil-Vázquez C, Movilla-Fernández MJ, Coronado C. J Nurs Educ. 2023 Jun;62(6):343-350. doi: 10.3928/01484834-20230404-02. Epub 2023 Jun 1. PMID: 37279977

Multidimensional futuristic approaches to address the pandemics beyond COVID-19.
Kotwal SB, Orekondey N, Saradadevi GP, Priyadarshini N, Puppala NV, Bhushan M, Motamarry S, Kumar R, Mohannath G, Dey RJ. Heliyon. 2023 Jun;9(6):e17148. doi: 10.1016/j.heliyon.2023.e17148. Epub 2023 Jun 11. PMID: 37325452

The effect of COVID-19 vaccine literacy on attitudes towards COVID-19 vaccine among university students.
Durmus Iskender M, Eren H, Durmuş A. Health Info Libr J. 2023 Jun 1. doi: 10.1111/hir.12489. Online ahead of print. PMID: 37264270

SARS-CoV-2 infection (COVID-19) and male fertility: Something we should be worried about?
Zeginiadou T, Symeonidis EN, Symeonidis A, Vakalopoulos I. Urologia. 2023 Jun 5:3915603231175941. doi: 10.1177/03915603231175941. Online ahead of print. PMID: 37278004

COVID-19 vaccine side effects on menstrual disturbances among Iranian women.
Rastegar T, Feryduni L, Fakhraei M. New Microbes New Infect. 2023 Jun;53:101114. doi: 10.1016/j.nmni.2023.101114. Epub 2023 Apr 11. PMID: 37065964

Conspiracy beliefs, COVID-19 vaccine uptake and adherence to public health interventions during the pandemic in Europe.
Regazzi L, Lontano A, Cadeddu C, Di Padova P, Rosano A. Eur J Public Health. 2023 Jun 8:ckad089. doi: 10.1093/eurpub/ckad089. Online ahead of print. PMID: 37290405

Imaging for Cardiovascular Complications of COVID-19: Cardiac Manifestations in Context.
Crosier R, Kafil TS, Paterson DI. Can J Cardiol. 2023 Jun;39(6):779-792. doi: 10.1016/j.cjca.2023.01.022. Epub 2023 Jan 31. PMID: 36731604

Supply chain planning of vaccine and pharmaceutical clusters under uncertainty: The case of COVID-19.
Kochakkashani F, Kayvanfar V, Haji A. Socioecon Plann Sci. 2023 Jun;87:101602. doi: 10.1016/j.seps.2023.101602. Epub 2023 Apr 18. PMID: 37255585

Strategies That Promote Equity in COVID-19 Vaccine Uptake for Latinx Communities: a Review.

Demeke J, Ramos SR, McFadden SM, Dada D, Nguemo Djiometio J, Vlahov D, Wilton L, Wang M, Nelson LE. J Racial Ethn Health Disparities. 2023 Jun;10(3):1349-1357. doi: 10.1007/s40615-022-01320-8. Epub 2022 May 6. PMID: 35524004

Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity.
Provine NM, Klenerman P. Eur J Immunol. 2023 Jun;53(6):e2250022. doi: 10.1002/eji.202250022. Epub 2022 Nov 20. PMID: 36330560

The lockdown and vaccination distribution in Thailand's COVID-19 epidemic: A model study.
Polwiang S. Infect Dis Model. 2023 Jun;8(2):551-561. doi: 10.1016/j.idm.2023.05.002. Epub 2023 May 28. PMID: 37275749

Cowpox to COVID: History of vaccination in the immunocompromised host.
Schaenman J, Avery R. Transpl Infect Dis. 2023 Jun;25(3):e14051. doi: 10.1111/tid.14051. Epub 2023 Apr 7. PMID: 37029494

Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial.
Dulfer EA, Geckin B, Taks EJM, GeurtsvanKessel CH, Dijkstra H, van Emst L, van der Gaast-de Jongh CE, van Mourik D, Koopmans PC, Domínguez-Andrés J, van Crevel R, van de Maat JS, de Jonge MI, Netea MG. Lancet Reg Health Eur. 2023 Apr 12;29:100628. doi: 10.1016/j.lanepe.2023.100628. eCollection 2023 Jun. PMID: 37261212

Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.
Joudeh AI, Lutf AQ, Mahdi S, Tran G. Vaccine. 2023 Jun 13;41(26):3801-3812. doi: 10.1016/j.vaccine.2023.05.048. Epub 2023 May 22. PMID: 37244811

Behavioral and Social Drivers of COVID-19 Vaccination in the United States, August-November 2021.
Bonner KE, Vashist K, Abad NS, Kriss JL, Meng L, Lee JT, Wilhelm E, Lu PJ, Carter RJ, Boone K, Baack B, Masters NB, Weiss D, Black C, Huang Q, Vangala S, Albertin C, Szilagyi PG, Brewer NT, Singleton JA. Am J Prev Med. 2023 Jun;64(6):865-876. doi: 10.1016/j.amepre.2023.01.014. Epub 2023 Jan 25. PMID: 36775756

COVID-19 Vaccine Acceptance, Attitude, Hesitancy, and Its Associated Factors among Wolaita Sodo University Students: A Mixed-Method Study.
Lombebo AA, Wolde GD, Shomoro BT, Efa AG, Bscho MT, Suleiman EH, Temesgen AS, Arega MZ, Obsa MS. J Environ Public Health. 2023 Jun 1;2023:2082695. doi: 10.1155/2023/2082695. eCollection 2023. PMID: 37305076

COVID-19 immunotherapy: a mathematical model.
Tavares JN, Gomes E. Math Med Biol. 2023 Jun 14;40(2):199-221. doi: 10.1093/imammb/dqad003. PMID: 37038322

Understanding Stakeholders' Perspectives to Increase COVID-19 Vaccine and Booster Uptake among Black Individuals with Rheumatic Conditions.

Ezeh N, Sirek G, Ulysse SN, Williams JN, Chandler MT, Ojikutu BO, York M, Crespo-Bosque M, Jean-Jacques M, Roberson T, Mancera-Cuevas K, Milaeger H, Losina E, Dhand A, Son MB, Ramsey-Goldman R, Feldman CH. Arthritis Care Res (Hoboken). 2023 Jun 13. doi: 10.1002/acr.25172. Online ahead of print. PMID: 37309724

Does COVID-19 Vaccination Disturb Menstrual Cycling?
Weinberg CR. Am J Epidemiol. 2023 Jun 2;192(6):849-850. doi: 10.1093/aje/kwad039. PMID: 36799647

Mitigating COVID-19 Risk and Vaccine Hesitancy Among Underserved African American and Latinx Individuals with Mental Illness Through Mental Health Therapist-Facilitated Discussions.
Venegas-Murillo AL, Bazargan M, Grace S, Cobb S, Vargas R, Givens S, Li-Sarain S, Delgado C, Villatoro J, Goodall A, Tesimale R, Ramirez S, Brown M, Uyanne J, Assari S. J Racial Ethn Health Disparities. 2023 Jun;10(3):1358-1370. doi: 10.1007/s40615-022-01321-7. Epub 2022 May 9. PMID: 35534682

Health care workers' self-perceived infection risk and COVID-19 vaccine uptake: A mixed methods study.
Nyamuryekung'e KK, Amour M, Mboya I, Ndumwa H, Kengia J, Njiro BJ, Mhamilawa L, Shayo E, Ngalesoni F, Kapologwe N, Kalolo A, Metta E, Msuya S. PLOS Glob Public Health. 2023 Jun 7;3(6):e0001223. doi: 10.1371/journal.pgph.0001223. eCollection 2023. PMID: 37285332

Attitudes towards COVID-19 vaccination and intention to get vaccinated in Western Balkans: cross-sectional survey.
Jeremic Stojkovic V, Cvjetkovic S, Jankovic J, Mandic-Rajcevic S, Matovic Miljanovic S, Stevanovic A, Jovic Vranes A, Stamenkovic Z. Eur J Public Health. 2023 Jun 1;33(3):496-501. doi: 10.1093/eurpub/ckad066. PMID: 37119531

Vaccine Attitudes Mediate Relationships Between Caregiver Political Ideology and Likelihood of Child Vaccination for COVID-19.
Durkin LK, Flynn EM, Johnson ML, Davies WH, Greenley RN. Matern Child Health J. 2023 Jun;27(6):984-990. doi: 10.1007/s10995-023-03642-3. Epub 2023 Mar 30. PMID: 36995648

Increasing the COVID-19 immunization rate through allergy testing.
Bent RK, Weinbrenner J, Faihs V, Steffens S, Nau T, Vitus M, Mathes S, Darsow U, Biedermann T, Brockow K. J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1228-1235. doi: 10.1111/jdv.18979. Epub 2023 Mar 4. PMID: 36808753

Systemic lupus erythematosus myocarditis and COVID-19 vaccination: Comment.
Kleebayoon A, Wiwanitkit V. Reumatol Clin (Engl Ed). 2023 Jun-Jul;19(6):349. doi: 10.1016/j.reumae.2023.02.008. Epub 2023 May 24. PMID: 37258399

Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
Kana BD, Arbuthnot P, Botwe BK, Choonara YE, Hassan F, Louzir H, Matsoso P, Moore PL, Muhairwe A, Naidoo K, Ndomondo-Sigonda M, Madhi SA. Lancet Infect Dis. 2023 Jun 5:S1473-3099(22)00878-7. doi: 10.1016/S1473-3099(22)00878-7. Online ahead of print. PMID: 37290473

In vitro high-content tissue models to address precision medicine challenges.
Afewerki S, Stocco TD, Rosa da Silva AD, Aguiar Furtado AS, Fernandes de Sousa G, Ruiz-Esparza GU, Webster TJ, Marciano FR, Strømme M, Zhang YS, Lobo AO. Mol Aspects Med. 2023 Jun;91:101108. doi: 10.1016/j.mam.2022.101108. Epub 2022 Aug 17. PMID: 35987701

A single dose of COVID-19 vaccine induces a strong T cell and B cell response in healthcare professionals recovered from SARS-CoV-2 infection.
Laranjeira P, Rodrigues T, Silva A, Barbosa P, Reis T, Lopes C, Pinho A, Silva S, Silva I, Carvalho A, Pacheco V, Rodrigues F, Araújo L, Antunes I, Paiva A. Clin Exp Med. 2023 Jun;23(2):529-537. doi: 10.1007/s10238-022-00801-8. Epub 2022 Feb 21. PMID: 35190936

COVID-19, post-acute COVID-19 syndrome (PACS, "long COVID") and post-COVID-19 vaccination syndrome (PCVS, "post-COVIDvac-syndrome"): Similarities and differences.
Scholkmann F, May CA. Pathol Res Pract. 2023 Jun;246:154497. doi: 10.1016/j.prp.2023.154497. Epub 2023 May 3. PMID: 37192595

Resident Factors Associated With Breakthrough SARS-CoV-2 Infections.
Montoya A, Wen K, Travers JL, Rivera-Hernandez M, White E, Mor V, Berry SD. J Am Med Dir Assoc. 2023 Jun;24(6):901-905. doi: 10.1016/j.jamda.2023.02.102. Epub 2023 Mar 2. PMID: 36965506

Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events.
Noh Y, Ko HY, Kim JH, Yoon D, Choe YJ, Choe SA, Jung J, Shin JY. Epidemiol Health. 2023 Jun 7:e2023054. doi: 10.4178/epih.e2023054. Online ahead of print. PMID: 37309115

Impact of the COVID-19 pandemic on uveitis patient care.
Vu AF, Kodati S, Lin P, Bodaghi B, Emami-Naeini P; COVID-19 Practice Patterns Study Group. Br J Ophthalmol. 2023 Jun;107(6):790-794. doi: 10.1136/bjophthalmol-2021-320368. Epub 2022 Jan 24. PMID: 35074784

Biological rhythms in COVID-19 vaccine effectiveness in an observational cohort study of 1.5 million patients.
Hazan G, Duek OA, Alapi H, Mok H, Ganninger A, Ostendorf E, Gierasch C, Chodick G, Greenberg D, Haspel JA. J Clin Invest. 2023 Jun 1;133(11):e167339. doi: 10.1172/JCI167339. PMID: 37053011

Redirected vaccine imprinting by co-administration of COVID-19 and influenza vaccines.
Boyton RJ, Altmann DM. Lancet Reg Health Eur. 2023 May 10;29:100644. doi: 10.1016/j.lanepe.2023.100644. eCollection 2023 Jun. PMID: 37261213

COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.
Jiang M, Väisänen E, Kolehmainen P, Huttunen M, Ylä-Herttuala S, Meri S, Österlund P, Julkunen I. Vaccine. 2023 Jun 13;41(26):3813-3823. doi: 10.1016/j.vaccine.2023.04.049. Epub 2023 Apr 25. PMID: 37142461

Imagine distant-future outcome: Mental simulation of COVID-19 vaccinations.
Motoki K, Saito T, Takano Y. J Exp Psychol Appl. 2023 Jun;29(2):207-220. doi: 10.1037/xap0000472. Epub 2023 Apr 13. PMID: 37053430

Safety Monitoring of COVID-19 Vaccines: Perspective from the European Medicines Agency.
Durand J, Dogné JM, Cohet C, Browne K, Gordillo-Marañón M, Piccolo L, Zaccaria C, Genov G. Clin Pharmacol Ther. 2023 Jun;113(6):1223-1234. doi: 10.1002/cpt.2828. Epub 2023 Feb 6. PMID: 36524423

Adhesive Capsulitis After COVID-19 Vaccination: A Case Series.
Ghosh S, Pandey SK, Biswas A, Pandey J. Am J Phys Med Rehabil. 2023 Jun 1;102(6):e79-e82. doi: 10.1097/PHM.0000000000002194. Epub 2023 Jan 23. PMID: 36722847

Interaction of Biochemical Processes between Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension (PAH), and Coronavirus Disease 2019 (COVID-19).
Tian Z, Cen L. Pol J Microbiol. 2023 Jun 14;72(2):143-154. doi: 10.33073/pjm-2023-015. eCollection 2023 Jun 1. PMID: 37216361

Attitudes and beliefs towards COVID-19 and COVID-19 vaccination among rheumatology patients in a Los Angeles County safety net clinic.
Ward NKZ, Pal S, Ruddy K, Savvas S. BMC Rheumatol. 2023 Jun 1;7(1):13. doi: 10.1186/s41927-023-00338-7. PMID: 37259135

Respiratory syncytial virus infection in the modern era.
Ludlow M. Curr Opin Infect Dis. 2023 Jun 1;36(3):155-163. doi: 10.1097/QCO.0000000000000917. Epub 2023 Mar 20. PMID: 36939556

Delirium after COVID-19 vaccination in older adults.
Armstrong K. Nursing. 2023 Jun 1;53(6):42-45. doi: 10.1097/01.NURSE.0000927432.51378.e7. PMID: 37212818

Inequalities in COVID-19 vaccination coverage in Peru: An ecological study.
Al-Kassab-Córdova A, Mendez-Guerra C, Silva-Perez C, Herrera-Añazco P, Benites-Zapata VA. Public Health Pract (Oxf). 2023 Jun;5:100384. doi: 10.1016/j.puhip.2023.100384. Epub 2023 Apr 6. PMID: 37038538

COVID-19 vaccination willingness in peri-urban Tanzanian communities: Towards contextualising and moving beyond the individual perspective.
Van Espen M, Dewachter S, Holvoet N. SSM Popul Health. 2023 Jun;22:101381. doi: 10.1016/j.ssmph.2023.101381. Epub 2023 Mar 15. PMID: 36936725

Coronavirus disease 2019 vaccine in pediatric post-kidney transplantation.
Ajlan AA, Aleid H, Ali T, DeVol E, Marquez KAH, Aldhaferi R, Karar EM, Mohammed AEI, Tiba M, Fajji L, Aldakhil H, Al-Awwami M, Almslam MS, Assiri A, Algoufi T, Broering DC. Clin Transplant. 2023 Jun;37(6):e14983. doi: 10.1111/ctr.14983. Epub 2023 Apr 7. PMID: 37026809

Mitigating the impacts of the COVID-19 pandemic on vulnerable populations: Lessons for improving health and social equity.
Tan SY, Foo C, Verma M, Hanvoravongchai P, Cheh PLJ, Pholpark A, Marthias T, Hafidz F, Prawidya Putri L, Mahendradhata Y, Giang KB, Nachuk S, Wang H, Lim J, Legido-Quigley H. Soc Sci Med. 2023 Jul;328:116007. doi: 10.1016/j.socscimed.2023.116007. Epub 2023 Jun 2. PMID: 37279639

Fast-tracking development and regulatory approval of COVID-19 vaccines in the EU: A review of ethical implications.
Beretta G, Marelli L. Bioethics. 2023 Jun;37(5):498-507. doi: 10.1111/bioe.13151. Epub 2023 Mar 11. PMID: 36905651

Evaluation of the Community Health Worker Model for COVID-19 Response and Recovery.
Nawaz S, Moon KJ, Vazquez R, Navarrete JR, Trinh A, Escobedo L, Montiel GI. J Community Health. 2023 Jun;48(3):430-445. doi: 10.1007/s10900-022-01183-4. Epub 2023 Jan 6. PMID: 36604393

Severe rhabdomyolysis secondary to COVID-19 mRNA vaccine in a teenager.
Pucchio A, Akiva MH, Evangeliou H, Papenburg J, Salvadori MI. Pediatr Nephrol. 2023 Jun;38(6):1979-1983. doi: 10.1007/s00467-022-05808-7. Epub 2022 Nov 21. PMID: 36409362

Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine.
Shrestha NK, Burke PC, Nowacki AS, Simon JF, Hagen A, Gordon SM. Open Forum Infect Dis. 2023 Apr 19;10(6):ofad209. doi: 10.1093/ofid/ofad209. eCollection 2023 Jun. PMID: 37274183

Sensorineural Hearing Loss Among COVID-19 Patients and BNT162b2 Vaccine Recipients: Comment.
Mungmunpuntipatip R, Wiwanitkit V. Otol Neurotol. 2023 Jun 1;44(5):e358. doi: 10.1097/MAO.0000000000003871. Epub 2023 Apr 6. PMID: 37026804

Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination.
Katoto PDMC, Byamungu LN, Brand AS, Tamuzi JL, Kakubu MAM, Wiysonge CS, Gray G. NPJ Vaccines. 2023 Jun 9;8(1):89. doi: 10.1038/s41541-023-00681-3. PMID: 37296167

Cutaneous Adverse Events After COVID-19 Vaccination.
Weschawalit S, Pongcharoen P, Suthiwartnarueput W, Srivilaithon W, Daorattanachai K, Jongrak P, Chakkavittumrong P. Clin Cosmet Investig Dermatol. 2023 Jun 8;16:1473-1484. doi: 10.2147/CCID.S410690. eCollection 2023. PMID: 37313511

Risk of Adverse Events and Delirium after COVID-19 Vaccination in Patients Living with Dementia.
Cheung ECL, Leung MTY, Chen K, Wan EYF, Li X, Lai FTT, Wong CKH, Qin XS, Chan EW, Lau KK, Luo H, Lin CC, Wong ICK, Chui CSL. J Am Med Dir Assoc. 2023 Jun;24(6):892-900.e12. doi: 10.1016/j.jamda.2023.04.003. Epub 2023 Apr 21. PMID: 37156470

Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana.
Shava E, Izu A, Gaolathe T, Walker A, Carty L, Georgiou P, Kuate L, Kgathi C, Sekoto T, Seonyatseng N, Mogashoa T, Maphorisa C, Mohammed T, Ntalabgwe T, Frank TT, Matlhaku B, Diphoko A, Phindela T, Kaunda A, Kgari P, Kanyakula T, Palalani G, Phakedi I; (Botswana AZD1222 study team); Taylor S, Mmalane M, Moyo S, Makhema J. J Infect. 2023 Jun;86(6):603-606. doi: 10.1016/j.jinf.2023.02.037. Epub 2023 Mar 1. PMID: 36863535

Vertigo and Dizziness After Coronavirus Disease-2019 Vaccination: A Nationwide Analysis.
Kim SH, Yon DK, Choi YS, Lee J, Park KH, Lee YJ, Park DC, Kim SS, Rim HS, Yeo SG. J Int Adv Otol. 2023 Jun;19(3):228-233. doi: 10.5152/iao.2023.22937. PMID: 37272641

Upscaling vaccine manufacturing capacity - Kkey bottlenecks and lessons learned.
Feddema JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM. Vaccine. 2023 Jun 3:S0264-410X(23)00554-6. doi: 10.1016/j.vaccine.2023.05.027. Online ahead of print. PMID: 37277250

Projection of healthcare demand in Germany and Switzerland urged by Omicron wave (January-March 2022).
Gorji H, Stauffer N, Lunati I, Caduff A, Bühler M, Engel D, Chung HR, Loukas O, Feig S, Renz H. Epidemics. 2023 Jun;43:100680. doi: 10.1016/j.epidem.2023.100680. Epub 2023 Mar 14. PMID: 36963246

Wuhan 3 years after the outbreak of the pandemic-cardiological insights and perspectives.
Chen C, He W, Wang DW. Herz. 2023 Jun;48(3):173-179. doi: 10.1007/s00059-023-05176-4. Epub 2023 Apr 27. PMID: 37106075

The effectiveness of nonfinancial interventions and monetary incentives on COVID-19 vaccination: A meta-analysis.
Huang Y, Huang X, Yu R. Health Psychol. 2023 Jun;42(6):411-424. doi: 10.1037/hea0001288. Epub 2023 May 1. PMID: 37126030

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.
Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ, Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. Clin Lymphoma Myeloma Leuk. 2023 Jun;23(6):456-462. doi: 10.1016/j.clml.2023.03.002. Epub 2023 Mar 7. PMID: 37003846

Power, place, and access: Why history is at the center of black D.C. residents of wards 7 and 8 decisions to receive the COVID-19 vaccine.
Cho A, Mendenhall E, Griffith DM. SSM Qual Res Health. 2023 Jun;3:100270. doi: 10.1016/j.ssmqr.2023.100270. Epub 2023 Apr 13. PMID: 37073370

Cardiac inflammation associated with COVID-19 mRNA vaccination in patients with and without previous myocarditis.
Kaufmann CC, Villatore A, Heugl M, Kvakan H, Zweiker D, Sala S, Mazzone P, Huber K, Peretto G. Minerva Cardiol Angiol. 2023 Jun;71(3):242-248. doi: 10.23736/S2724-5683.22.06204-4. Epub 2023 Mar 10. PMID: 36897270

Breastfeeding provides a protective hug and the benefits have outweighed the risks during the COVID-19 pandemic.
Briana DD, Malamitsi-Puchner A. Acta Paediatr. 2023 Jun;112(6):1177-1181. doi: 10.1111/apa.16769. Epub 2023 Mar 29. PMID: 36945791

BNT162b2 mRNA Vaccine-Induced Immune Response in Oral Fluids and Serum.
Seneviratne CJ, Balan P, de Alwis R, Udawatte NS, Herath T, Toh JZN, Tin GB, Ooi EE, Hong JLG, Ying JSX. Int Dent J. 2023 Jun;73(3):435-442. doi: 10.1016/j.identj.2022.09.005. Epub 2022 Nov 17. PMID: 36402577

Susac syndrome following COVID-19 vaccination: a case-based review.
Fisher L, David P, Sobeh T, Liberman RB, Amital H. Clin Rheumatol. 2023 Jun;42(6):1713-1717. doi: 10.1007/s10067-023-06564-1. Epub 2023 Mar 6. PMID: 36877303

Vaccine attributes and vaccine uptake in Hungary: evidence from a conjoint experiment.
Thompson J, Stöckli S, Spälti AK, Phillips J, Stoeckel F, Barnfield M, Lyons B, Mérola V, Szewach P, Reifler J. Eur J Public Health. 2023 Jun 1;33(3):476-481. doi: 10.1093/eurpub/ckad043. PMID: 37004246

Analysis of COVID-19 vaccine uptake among people with underlying chronic conditions in 2022: A cross-sectional study.
Bulusu A, Segarra C, Khayat L. SSM Popul Health. 2023 Jun;22:101422. doi: 10.1016/j.ssmph.2023.101422. Epub 2023 May 2. PMID: 37151914

Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection.
Zhang A, Stacey HD, D'Agostino MR, Tugg Y, Marzok A, Miller MS. Nat Rev Immunol. 2023 Jun;23(6):381-396. doi: 10.1038/s41577-022-00813-1. Epub 2022 Dec 19. PMID: 36536068

COVID-19 infection in people living with HIV.
Brolly J, Chadwick DR. Br Med Bull. 2023 Jun 13:ldac031. doi: 10.1093/bmb/ldac031. Online ahead of print. PMID: 37312594

COVID-19 infection- and vaccination-related exacerbation of Darier's disease in a single patient.
Fukaura R, Takeichi T, Ebata A, Muro Y, Akiyama M. J Dermatol. 2023 Jun;50(6):833-836. doi: 10.1111/1346-8138.16725. Epub 2023 Jan 18. PMID: 36651040

Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities.
Fan S, Wang H, Wu D, Liu L. Acta Pharm. 2023 Jun 12;73(2):157-173. doi: 10.2478/acph-2023-0014. Print 2023 Jun 1. PMID: 37307372

Adolescents Who Have Undergone Human Papillomavirus Vaccination Are More Likely to Get a COVID-19 Vaccine.
Coronado GD, Petrik AF, Slaughter M, Kepka D, Naleway AL. J Adolesc Health. 2023 Jun;72(6):985-988. doi: 10.1016/j.jadohealth.2022.12.022. Epub 2023 Feb 11. PMID: 36781325

Association between distance to community health care facilities and COVID-19-related mortality across U.S. counties in the COVID-19-vaccine era.
Huang W, Hernandez I, Tang S, Dickson S, Berenbrok LA, Guo J. BMC Res Notes. 2023 Jun 5;16(1):96. doi: 10.1186/s13104-023-06366-3. PMID: 37277859

BA.1 Bivalent COVID-19 Vaccine Use and Stroke in England.
Andrews N, Stowe J, Miller E, Ramsay M. JAMA. 2023 Jun 15. doi: 10.1001/jama.2023.10123. Online ahead of print. PMID: 37318811

[Headache associated with COVID-19 vaccination: how to classify?].
Straube A, Ruscheweyh R, Klonowski T. Schmerz. 2023 Jun;37(3):185-194. doi: 10.1007/s00482-022-00687-1. Epub 2023 Jan 16. PMID: 36645522

Safety of mRNA COVID-19 vaccinations in patients with allergic diseases.
Rosada T, Napiórkowska-Baran K, Cała Ł, Alska E, Paulina K, Czarnowska M, Bartuzi Z. Public Health Pract (Oxf). 2023 Jun;5:100354. doi: 10.1016/j.puhip.2022.100354. Epub 2022 Dec 24. PMID: 36590876

Necrotizing pancreatitis, microangiopathic hemolytic anemia and thrombocytopenia following the second dose of Pfizer/BioNTech COVID-19 mRNA vaccine.
Stöllberger C, Kastrati K, Dejaco C, Scharitzer M, Finsterer J, Bugingo P, Melichart-Kotik M, Wilfing A. Wien Klin Wochenschr. 2023 Jun 6:1-5. doi: 10.1007/s00508-023-02225-0. Online ahead of print. PMID: 37280395

Identifying gaps in vaccination perception after mandating the COVID-19 vaccine in Saudi Arabia.
Alsuhebany N, Alowais SA, Aldairem A, Almohareb SN, Bin Saleh K, Kahtani KM, Alnashwan LI, Alay SM, Alamri MG, Alhathlol GK, Asiri I. Vaccine. 2023 Jun 1;41(24):3611-3616. doi: 10.1016/j.vaccine.2023.04.057. Epub 2023 Apr 26. PMID: 37164821

A rapid increase in coverage of COVID-19 vaccination, Central African Republic.
Amani A, Atuhebwe P, Mboussou FF, Ngoy N, M'boufoungou NE, Osei-Sarpong F, Traore C, Mihigo R, Chaiban T. Bull World Health Organ. 2023 Jun 1;101(6):431-436. doi: 10.2471/BLT.22.289155. Epub 2023 Mar 31. PMID: 37265680

Alpha-1-antitrypsin antagonizes COVID-19: a review of the epidemiology, molecular mechanisms, and clinical evidence.
Bai X, Schountz T, Buckle AM, Talbert JL, Sandhaus RA, Chan ED. Biochem Soc Trans. 2023 Jun 9:BST20230078. doi: 10.1042/BST20230078. Online ahead of print. PMID: 37294003

The effect of mixed vaccination rollout strategy: A modelling study.
Stollenwerk N, Estadilla CDS, Mar J, Bidaurrazaga Van-Dierdonck J, Ibarrondo O, Blasco-Aguado R, Aguiar M. Infect Dis Model. 2023 Jun;8(2):318-340. doi: 10.1016/j.idm.2023.03.002. Epub 2023 Mar 10. PMID: 36945695

A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines.
Singh RS, Singh A, Masih GD, Batra G, Sharma AR, Joshi R, Prakash A, Suroy B, Sarma P, Prajapat M, Kaur H, Bhattacharyya A, Upadhyay S, Medhi B. Heliyon. 2023 Jun;9(6):e16813. doi: 10.1016/j.heliyon.2023.e16813. Epub 2023 Jun 7. PMID: 37303517

COVID-19 vaccine safety profile in Republic of Korea, February 26, 2021 through April 30, 2022.
Lee YK, Kwon Y, Lim D, Seo SY, Kim EK, Kim SY, Heo Y, Cho E. Clin Exp Pediatr. 2023 Jun 13. doi: 10.3345/cep.2022.00815. Online ahead of print. PMID: 37309116

COVID-19 vaccine effectiveness in people with substance use disorder.
Huang Y. Lancet Psychiatry. 2023 Jun;10(6):372-373. doi: 10.1016/S2215-0366(23)00149-9. Epub 2023 May 1. PMID: 37141908

Experiences, coping strategies and perspectives of people in Malaysia during the COVID-19 pandemic.
Cheah PK, Jalloh MB, Cheah PK, Ongkili D, Schneiders ML, Osterrieder A, Peerawaranun P, Waithira N, Davies A, Mukaka M, Cheah PY. BMC Public Health. 2023 Jun 6;23(1):1085. doi: 10.1186/s12889-023-15892-5. PMID: 37280573

Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis.
Singh RB, Parmar UPS, Ichhpujani P, Jeng BH, Jhanji V. Cornea. 2023 Jun 1;42(6):731-738. doi: 10.1097/ICO.0000000000003246. Epub 2023 Jan 25. PMID: 36706232

The role of trained immunity in COVID-19: Lessons for the next pandemic.
Netea MG, Ziogas A, Benn CS, Giamarellos-Bourboulis EJ, Joosten LAB, Arditi M, Chumakov K, van Crevel R, Gallo R, Aaby P, van der Meer JWM. Cell Host Microbe. 2023 Jun 14;31(6):890-901. doi: 10.1016/j.chom.2023.05.004. PMID: 37321172

CATCH-UP vaccines: protocol for a randomized controlled trial using the multiphase optimization strategy (MOST) framework to evaluate education interventions to increase COVID-19 vaccine uptake in Oklahoma.
Janitz AE, Neil JM, Bray LA, Jervis LL, Ross L, Campbell JE, Doescher MP, Spicer PG, Williams ML, Lopez AK, Uribe-Frias CA, Chen S, James JA, VanWagoner TM. BMC Public Health. 2023 Jun 14;23(1):1146. doi: 10.1186/s12889-023-16077-w. PMID: 37316843

Determination of factors influencing young adults' intention to have COVID-19 vaccine in the Philippines: An integration of Health Belief Model and the Theory of Planned Behavior.
Ong AKS, Prasetyo YT, Lagura FC, Ramos RN, Salazar JML, Sigua KM, Villas JA, Nadlifatin R, Persada SF. Public Health Pract (Oxf). 2023 Jun;5:100359. doi: 10.1016/j.puhip.2023.100359. Epub 2023 Feb 10. PMID: 36818574

COVID-19 vaccine hesitancy among women planning for pregnancy, pregnant or breastfeeding mothers in Jordan: A cross-sectional study.
Masa'deh R, Momani A, Rayan A, Hamaideh SH, Masadeh OM, Al-Yateem N. PLoS One. 2023 Jun 1;18(6):e0286289. doi: 10.1371/journal.pone.0286289. eCollection 2023. PMID: 37262063

Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2.
Lin G, Yan H, Sun J, Zhao J, Zhang Y. Mol Ther Nucleic Acids. 2023 Jun 13;32:650-666. doi: 10.1016/j.omtn.2023.04.021. Epub 2023 Apr 23. PMID: 37151990

Clinicopathological Characteristics of Autoimmune-Like Hepatitis Induced by COVID-19 mRNA Vaccine (Pfizer-BioNTech, BNT162b2): A Case Report and Literature Review.
Kim JH, Chae HB, Woo S, Song MS, Kim HJ, Woo CG. Int J Surg Pathol. 2023 Jun 4:10668969231177877. doi: 10.1177/10668969231177877. Online ahead of print. PMID: 37272061

Graves' disease after exposure to the SARS-CoV-2 vaccine: a case report and review of the literature.
Takedani K, Notsu M, Ishiai N, Asami Y, Uchida K, Kanasaki K. BMC Endocr Disord. 2023 Jun 15;23(1):132. doi: 10.1186/s12902-023-01387-2. PMID: 37316819

Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.

Ishio T, Tsukamoto S, Yokoyama E, Izumiyama K, Saito M, Muraki H, Kobayashi M, Mori A, Morioka M, Kondo T. Ann Hematol. 2023 Jun;102(6):1421-1431. doi: 10.1007/s00277-023-05204-7. Epub 2023 Apr 12. PMID: 37041299

COVID-19 vaccination status and related process of care outcomes among U.S. adults with active epilepsy-National Health Interview Survey, United States, 2021.
Kobau R, Luncheon C, Pastula DM, Greenlund KJ. Epilepsy Behav. 2023 Jun;143:109223. doi: 10.1016/j.yebeh.2023.109223. Epub 2023 Apr 14. PMID: 37119577

Empowering Youth Vaccine Ambassadors to Promote COVID-19 Vaccination in Local Communities: A 7-Step Approach.
Minkah PA, Borg A, Ryan GW, Goulding M, Perrone D, Castiel M, Rosal MC, Lemon SC. Health Promot Pract. 2023 Jun 11:15248399231178542. doi: 10.1177/15248399231178542. Online ahead of print. PMID: 37303187

Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.
Geraci G, Bernat J, Rodier C, Acha V, Acquah J, Beakes-Read G. Ther Innov Regul Sci. 2023 Jun 2:1-12. doi: 10.1007/s43441-023-00536-y. Online ahead of print. PMID: 37266868

Bivalent COVID-19 vaccine antibody responses to Omicron variants suggest that responses to divergent variants would be improved with matched vaccine antigens.
Wang W, Goguet E, Paz Padilla S, Vassell R, Pollett S, Mitre E, Weiss CD. J Infect Dis. 2023 Jun 6:jiad111. doi: 10.1093/infdis/jiad111. Online ahead of print. PMID: 37279924

Optic Neuritis After COVID-19 Vaccination: An Analysis of the Vaccine Adverse Event Reporting System.
Jaffry M, Aftab OM, Mostafa FB, Faiz I, Jaffry K, Mandava K, Rosario S, Jedidi K, Khan H, Souayah N. J Neuroophthalmol. 2023 Jun 14. doi: 10.1097/WNO.0000000000001900. Online ahead of print. PMID: 37314860

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.
Xue Y, Mei H, Chen Y, Griffin JD, Liu Q, Weisberg E, Yang J. MedComm (2020). 2023 May 14;4(3):e254. doi: 10.1002/mco2.254. eCollection 2023 Jun. PMID: 37193304

A Nationwide Survey of mRNA COVID-19 Vaccinee's Experiences on Adverse Events and Its Associated Factors.
Yoon D, Jeon HL, Noh Y, Choe YJ, Choe SA, Jung J, Shin JY. J Korean Med Sci. 2023 Jun 5;38(22):e170. doi: 10.3346/jkms.2023.38.e170. PMID: 37272559

Investigating preferences of the covid-19 vaccine among individuals in Iran: Discrete choice experiment analysis.
Parvizi S, Mehrara M, Taiebnia A. Health Sci Rep. 2023 Jun 12;6(6):e1332. doi: 10.1002/hsr2.1332. eCollection 2023 Jun. PMID: 37313535

Examining the Relationship Between Rurality, Risk Perception, and COVID-19 Vaccine Willingness Among Rural Latinos in Arizona and California.

Straus A, Sharma N, Mattie H, Pine KH, Lopez G. J Community Health. 2023 Jun 15. doi: 10.1007/s10900-023-01217-5. Online ahead of print. PMID: 37316613

Self-reported symptoms after COVID-19 vaccination. Distinct sex, age, and geographical outcomes in Lebanese and Italian cohorts.
Khalil M, Bonfrate L, Di Ciaula A, Portincasa P; LEITvax Group^. Intern Emerg Med. 2023 Jun 15. doi: 10.1007/s11739-023-03321-9. Online ahead of print. PMID: 37322183

Forecasting recovery from COVID-19 using financial data: An application to Vietnam.
Lastunen J, Richiardi M. World Dev Perspect. 2023 Jun;30:100503. doi: 10.1016/j.wdp.2023.100503. Epub 2023 Mar 22. PMID: 36987404

Is the COVID-19 bad news game good news? Testing whether creating and disseminating fake news about vaccines in a computer game reduces people's belief in anti-vaccine arguments.
Rędzio AM, Izydorczak K, Muniak P, Kulesza W, Doliński D. Acta Psychol (Amst). 2023 Jun;236:103930. doi: 10.1016/j.actpsy.2023.103930. Epub 2023 May 1. PMID: 37146384

Inactivated COVID-19 vaccine booster dose shortened the viral shedding time of patients infected with the Omicron variant BA.2.
Wu J, Shi X, Tao B, Zhan Y, Lu X, Wang J. Int J Infect Dis. 2023 Jun;131:26-31. doi: 10.1016/j.ijid.2023.03.028. Epub 2023 Mar 21. PMID: 36948448

Do different platforms of coronavirus vaccines have different impacts on psoriasis flares?
Chularojanamontri L, Likittanasombat S, Chaiyabutr C, Silpa-Archa N, Wongpraparut C. Exp Dermatol. 2023 Jun;32(6):922-929. doi: 10.1111/exd.14793. Epub 2023 Mar 20. PMID: 36940925

Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials.
Ahmadizar F, Luxi N, Raethke M, Schmikli S, Riefolo F, Saraswati PW, Bucsa C, Osman A, Liddiard M, Maques FB, Petrelli G, Sonderlichová S, Thurin NH, Villalobos F, Trifirò G, Sturkenboom M; ilmiovaccinoCOVID19 collaborating group. Drug Saf. 2023 Jun;46(6):575-585. doi: 10.1007/s40264-023-01304-5. Epub 2023 Apr 27. PMID: 37103643

The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19.
Borralleras C, Castrodeza Sanz J, Arrazola P, Cámara Hijón C, Eiros JM, Castrodeza Sanz J, Arrazola P, Cámara Hijón C, Fernández-Prada M, Gil de Miguel A, Mirada Masip G, Moraga-Llop F, Ocaña Rodríguez D, Puig-Barberà J, Vázquez J, Vergara-Alert J, de Cambra S. Rev Esp Quimioter. 2023 Jun 12:cambra12jun2023. doi: 10.37201/req/046.2023. Online ahead of print. PMID: 37303137

Endemic, epidemic and pandemic infections: the roles of natural and acquired herd immunity.
Stevens DL, Bryant AE. Curr Opin Infect Dis. 2023 Jun 1;36(3):171-176. doi: 10.1097/QCO.0000000000000916. Epub 2023 Mar 20. PMID: 36939580

Healthcare workers' (HCWs) attitudes and related factors towards COVID-19 vaccination: a rapid systematic review.
Li M, Luo Y, Watson R, Zheng Y, Ren J, Tang J, Chen Y. Postgrad Med J. 2023 Jun 15;99(1172):520-528. doi: 10.1136/postgradmedj-2021-140195. PMID: 37319159

SARS-CoV-2 infection in technology-dependent children: a multicenter case series.
Robinson J, Dewan T, Morris SK, Bitnun A, Gill P, Tal TE, Laxer RM, Yeh EA, Yea C, Ulloa-Gutierrez R, Brenes-Chacon H, Yock-Corrales A, Ivankovich-Escoto G, Soriano-Fallas A, Mezerville MH, Papenburg J, Lefebvre MA, Nateghian A, Aski BH, Manafi A, Dwilow R, Bullard J, Cooke S, Restivo L, Lopez A, Sadarangani M, Roberts A, Le Saux N, Bowes J, Purewal R, Lautermilch J, Wong JK, Piche D, Top KA, Foo C, Panetta L, Merckx J, Barton M. Infection. 2023 Jun;51(3):737-741. doi: 10.1007/s15010-022-01910-y. Epub 2022 Aug 29. PMID: 36038707

The role of blood groups, vaccine type and gender in predicting the severity of side effects among university students receiving COVID-19 vaccines.
Almalki OS, Santali EY, Alhothali AA, Ewis AA, Shady A, Fathelrahman AI, Abdelwahab SF. BMC Infect Dis. 2023 Jun 6;23(1):378. doi: 10.1186/s12879-023-08363-0. PMID: 37280542

Role of available COVID-19 vaccines in reducing deaths and perspective for next generation vaccines and therapies to counter emerging viral variants: an update.
Wahid M, Jawed A, Mandal RK, Areeshi MY, El-Shall NA, Mohapatra RK, Tuli HS, Dhama K, Pellicano R, Fagoonee S, Haque S. Minerva Med. 2023 Jun 9. doi: 10.23736/S0026-4806.23.08509-9. Online ahead of print. PMID: 37293890

Keeping you posted: analysis of fertility-related social media posts after introduction of the COVID-19 vaccine.
Pecoriello J, Yoder N, Smith MB, Blakemore JK. Eur J Contracept Reprod Health Care. 2023 Jun;28(3):168-172. doi: 10.1080/13625187.2023.2189501. Epub 2023 Mar 30. PMID: 36995737

The impacts of the COVID-19 pandemic on patients with viral hepatitis B infection: follow-up, compliance with antiviral treatment, and vaccine preferences.
Ozdemir B, Altunsoy A, Akinci E, Guner R. Eur Rev Med Pharmacol Sci. 2023 Jun;27(11):5310-5317. doi: 10.26355/eurrev_202306_32650. PMID: 37318505

Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis.
Piechotta V, Siemens W, Thielemann I, Toews M, Koch J, Vygen-Bonnet S, Kothari K, Grummich K, Braun C, Kapp P, Labonté V, Wichmann O, Meerpohl JJ, Harder T. Lancet Child Adolesc Health. 2023 Jun;7(6):379-391. doi: 10.1016/S2352-4642(23)00078-0. Epub 2023 Apr 18. PMID: 37084750

Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
Kuriyama K, Murakami K, Masuda T, Sugiura K, Sakui S, Schuring RP, Mori M. Vaccine. 2023 Jun 7;41(25):3763-3771. doi: 10.1016/j.vaccine.2023.05.001. Epub 2023 May 8. PMID: 37198021

Dementia, infections and vaccines: 30 years of controversy.
Ecarnot F, Boccardi V, Calcagno A, Franceschi C, Fülop T, Itzhaki RF, Michel JP, Panza F, Rainero I, Solfrizzi V, Ticinesi A, Veronese N, Maggi S. Aging Clin Exp Res. 2023 Jun;35(6):1145-1160. doi: 10.1007/s40520-023-02409-8. Epub 2023 May 9. PMID: 37160649

Dataset on safety and protective efficacy studies of COVID-19 vaccine candidates based on structurally modified plant virus in female hamsters.
Kovalenko AO, Ryabchevskaya EM, Evtushenko EA, Kondakova OA, Ivanov PA, Arkhipenko MV, Nikitin NA, Karpova OV. Data Brief. 2023 Jun;48:109158. doi: 10.1016/j.dib.2023.109158. Epub 2023 Apr 19. PMID: 37095758

Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
Stowe J, Miller E, Andrews N, Whitaker HJ. PLoS Med. 2023 Jun 7;20(6):e1004245. doi: 10.1371/journal.pmed.1004245. Online ahead of print. PMID: 37285378

Safety Monitoring of mRNA COVID-19 Vaccine Third Doses Among Children Aged 6 Months-5 Years - United States, June 17, 2022-May 7, 2023.
Hause AM, Marquez P, Zhang B, Moro PL, Myers TR, Bradley C, Bazel S, Panchanathan SS, Shimabukuro TT, Shay DK. MMWR Morb Mortal Wkly Rep. 2023 Jun 9;72(23):621-626. doi: 10.15585/mmwr.mm7223a2. PMID: 37289661

Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark.
Rasmussen LD, Lebech AM, Øvrehus A, Poulsen BK, Christensen HR, Nielsen H, Johansen IS, Omland LH, Wiese L, Helleberg M, Storgaard M, Dalager-Pedersen M, Rasmussen TA, Benfield T, Petersen TS, Andersen ÅB, Gram MA, Stegger M, Edslev SM, Obel N. Br J Clin Pharmacol. 2023 Jun;89(6):1820-1833. doi: 10.1111/bcp.15644. Epub 2023 Jan 13. PMID: 36519217

COVID-19 vaccination exacerbates ex vivo IL-6 release from isolated PBMCs.
Langgartner D, Winkler R, Brunner-Weisser J, Rohleder N, Jarczok MN, Gündel H, Weimer K, Reber SO. Sci Rep. 2023 Jun 12;13(1):9496. doi: 10.1038/s41598-023-35731-2. PMID: 37308487

Why should I vaccinate? The role of mindfulness and health-protective behaviours during the COVID-19 pandemic.
Rufai OH, Chu J, Sayibu M, Shahani R, Amosun TS, Lugu BK, Gonlepa MK, Cherisol MP. Health Policy Technol. 2023 Jun;12(2):100749. doi: 10.1016/j.hlpt.2023.100749. Epub 2023 Apr 23. PMID: 37287500

COVID-19 vaccination rates among adolescents (12-17 years) by immigrant background and sociodemographic factors: A nationwide registry study in Norway.
Hussaini L, Labberton AS, Winje BA, Kraft KB, Kjøllesdal MKR, Gleditsch RN, Godøy AA. Vaccine. 2023 Jun 1;41(24):3673-3680. doi: 10.1016/j.vaccine.2023.04.079. Epub 2023 May 1. PMID: 37179165

The Effect of Combining the COVID-19 Vaccine with the Seasonal Influenza Vaccine on Reducing COVID-19 Vaccine Rejection Among Libyans.
Ghazy RM, Sallam M, Abdullah FSA, Hussein M, Hussein MF. J Epidemiol Glob Health. 2023 Jun;13(2):292-302. doi: 10.1007/s44197-023-00107-2. Epub 2023 May 12. PMID: 37171545

Implementation During a Pandemic: Findings, Successes, and Lessons Learned from Community Grantees.
Mathias W, Nichols KA, Golden-Wright J, Fairman CM, Felder TM, Workman L, Wickersham KE, Flicker KJ, Sheng J, Noblet SB, Adams SA, Eberth JM, Heiney SP, Wilcox S, Hébert JR, Friedman DB. J Cancer Educ. 2023 Jun;38(3):957-962. doi: 10.1007/s13187-022-02213-4. Epub 2022 Sep 3. PMID: 36056185

Subacute cutaneous lupus erythematosus induced by Pfizer COVID-19 vaccine.
Magnaterra E, Magliulo M, Mariotti EB, Ruffo DI Calabria V, Quintarelli L, Corrà A, Aimo C, Verdelli A, Caproni M. Ital J Dermatol Venerol. 2023 Jun;158(3):266-267. doi: 10.23736/S2784-8671.23.07373-5. Epub 2023 Mar 7. PMID: 36881332

Companies hoard COVID-19 vaccines, stalling future research.
Cohen J. Science. 2023 Jun 9;380(6649):1001-1002. doi: 10.1126/science.adj1033. Epub 2023 Jun 8. PMID: 37289896

Understanding the concept of trust and other factors related to COVID-19 vaccine intentions among Black/African American older adults prior to vaccine development.
Harris OO, Perry TE, Johnson JK, Lichtenberg P, Washington T, Kitt B, Shaw M, Keiser S, Tran T, Vest L, Maloof M, Portacolone E. SSM Qual Res Health. 2023 Jun;3:100230. doi: 10.1016/j.ssmqr.2023.100230. Epub 2023 Feb 4. PMID: 36785539

Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
Huang C, Wei Y, Yan VKC, Ye X, Kang W, Yiu HHE, Shami JJP, Cowling BJ, Tse ML, Castle DJ, Chui CSL, Lai FTT, Li X, Wan EYF, Wong CKH, Hayes JF, Chang WC, Chung AKK, Lau CS, Wong ICK, Chan EW. Lancet Psychiatry. 2023 Jun;10(6):403-413. doi: 10.1016/S2215-0366(23)00111-6. Epub 2023 May 1. PMID: 37141907

A Review on Artificial Intelligence Approaches and Rational Approaches in Drug Discovery.
Srivathsa AV, Sadashivappa NM, Hegde AK, Radha S, Mahesh AR, Ammunje DN, Sen D, Theivendren P, Govindaraj S, Kunjiappan S, Pavadai P. Curr Pharm Des. 2023 Jun 6;29(15):1180-1192. doi: 10.2174/1381612829666230428110542. PMID: 37132148

COVID-19 vaccination in pregnancy: How discrepant public health discourses shape responsibility for fetal health.
Manca TA, Top KA, Graham JE. SSM Qual Res Health. 2023 Jun;3:100265. doi: 10.1016/j.ssmqr.2023.100265. Epub 2023 Apr 10. PMID: 37069999

Broad-spectrum pan-genus and pan-family virus vaccines.
Tan CW, Valkenburg SA, Poon LLM, Wang LF. Cell Host Microbe. 2023 Jun 14;31(6):902-916. doi: 10.1016/j.chom.2023.05.017. PMID: 37321173

"Solidarity:" A failed call to action during the COVID-19 pandemic.
Bulled N. Public Health Pract (Oxf). 2023 Jun;5:100379. doi: 10.1016/j.puhip.2023.100379. Epub 2023 Mar 16. PMID: 36987526

Menstrual abnormalities post-COVID vaccination: a cross-sectional study on adult Lebanese women.
Dabbousi AA, El Masri J, El Ayoubi LM, Ismail O, Zreika B, Salameh P. Ir J Med Sci. 2023 Jun;192(3):1163-1170. doi: 10.1007/s11845-022-03089-5. Epub 2022 Jul 26. PMID: 35881229

Post-acute COVID-19 in three doses vaccinated autoimmune rheumatic diseases patients: frequency and pattern of this condition.

Silva CA, de Vinci Kanda Kupa L, Medeiros-Ribeiro AC, Pasoto SG, Saad CGS, Yuki EFN, Landim JIVD, Léda VHFE, de Camargo Correia LS, Sartori AF, Martins CCMF, Ribeiro CT, Waridel F, de Oliveira Martins VA, Shinjo SK, Andrade DCO, Barros PDS, Neto EFB, Aikawa NE, Bonfa E. Adv Rheumatol. 2023 Jun 8;63(1):26. doi: 10.1186/s42358-023-00309-z. PMID: 37291679

Dendrobium officinale aqueous extract influences the immune response following vaccination against SARS-CoV-2.
Gao X, Ye T, Lei Y, Zhang Q, Luo Y, Yang H, Zeng X, Zhou W, Wen Q, Liu J, Xiong H, Wan R. Biomed Pharmacother. 2023 Jun;162:114702. doi: 10.1016/j.biopha.2023.114702. Epub 2023 Apr 13. PMID: 37062221

Potentiating the Cross-Reactive IFN-γ T Cell and Polyfunctional T Cell Responses by Heterologous GX-19N DNA Booster in Mice Primed with Either a COVID-19 mRNA Vaccine or Inactivated Vaccine.
Seo YB, Ko A, Shin D, Kim J, Suh YS, Na J, Ryu JI, Lee S, Oh MJ, Sung YC. Int J Mol Sci. 2023 Jun 5;24(11):9753. doi: 10.3390/ijms24119753. PMID: 37298704

How do psychobehavioural variables shed light on heterogeneity in COVID-19 vaccine acceptance? Evidence from United States general population surveys on a probability panel and social media.
Charles GK, Braunstein SP, Barker JL, Fung H, Coome L, Kumar R, Huang VS, Kemp H, Grant E, Bernard D, Barefoot D, Sgaier SK. BMJ Open. 2023 Jun 6;13(6):e066897. doi: 10.1136/bmjopen-2022-066897. PMID: 37280023

Updated Guidance Regarding The Risk ofAllergic Reactions to COVID-19 Vaccines and Recommended Evaluation and Management: A GRADE Assessment, and International Consensus Approach.
Greenhawt M, Dribin TE, Abrams EM, Shaker M, Chu DK, Golden DB, Akin C, Anagnostou A, ALMuhizi F, Alqurashi W, Arkwright P, Baldwin JL, Banerji A, Bégin P, Ben-Shoshan M, Bernstein J, Bingeman TA, Bindslev-Jensen C, Blumenthal K, Byrne A, Cahil J, Cameron S, Campbell D, Campbell R, Cavender M, Chan ES, Chinthrajah S, Comberiatti P, Eastman JJ, Ellis AK, Fleischer DM, Fox A, Frischmeyer-Guerrerio PA, Gagnon R, Garvey LH, Grayson MH, Clarisse Isabwe GA, Hartog N, Hendron D, Horner CC, O'B Hourihane J, Iglesia E, Kan M, Kaplan B, Katelaris CH, Kim H, Kelso JM, Kahn DA, Lang D, Ledford D, Levin M, Lieberman JA, Loh R, Mack DP, Mazer B, Mody K, Mosnaim G, Munblit D, Mustafa SS, Nanda A, Nathan R, Oppenheimer J, Otani IM, Park M, Pawankar R, Perrett KP, Peter J, Phillips EJ, Picard M, Pitlick M, Ramsey A, Rasmussen TH, Rathkopf MM, Reddy H, Robertson K, Rodriguez Del Rio P, Sample S, Sheshradi A, Shiek J, Sindher SB, Spergel JM, Stone CA, Stukus D, Tang ML, Tracy JM, Turner PJ, Vander Leek TK, Wallace DV, Wang J, Wasserman S, Weldon D, Wolfson AR, Worm M, Yacoub MR. J Allergy Clin Immunol. 2023 Jun 7:S0091-6749(23)00746-7. doi: 10.1016/j.jaci.2023.05.019. Online ahead of print. PMID: 37295474

Guillain-Barré Syndrome due to COVID-19 Vero Cell Vaccination Associated with Concomitant COVID-19 Infection-induced ARDS and Treated Successfully by Therapeutic Plasma Exchange: A First Case Report from Vietnam.
Duong-Quy S, Huynh-Truong-Anh D, Nguyen-Quang T, Nguyen-Thi-Kim T, Tran-Ngoc-Anh T, Nguyen-Van-Hoai N, Do-Thi-Thu M, Nguyen-Van T, Tang-Thi-Thao T, Nguyen-Tuan A, Nguyen-Van T, Tran-Xuan Q, Vu-Tran-Thien Q, Trinh-Du T, Tran-Thai T, Nguyen-Duy T, Tran-Van H, Vo-Thi-Kim A. Pulm Ther. 2023 Jun;9(2):271-280. doi: 10.1007/s41030-023-00219-x. Epub 2023 Mar 29. PMID: 36991236

An overview on in vitro and in vivo antiviral activity of lactoferrin: its efficacy against SARS-CoV-2 infection.
Rosa L, Cutone A, Conte MP, Campione E, Bianchi L, Valenti P. Biometals. 2023 Jun;36(3):417-436. doi: 10.1007/s10534-022-00427-z. Epub 2022 Aug 3. PMID: 35920949

Antibody response dynamics to CoronaVac vaccine and booster immunization in adults and the elderly: A long-term, longitudinal prospective study.
Volpe GJ, Vessoni SCS, Soares LB, Leite Dos Santos Almeida MAA, Braga PE, de Moraes GR, Ferreira NN, Garibaldi PMM, Kashima S, Fonseca BAL, Calado RT, García HAB, de França JID, de Lima MA, Pacheco PHM, Borges MC, Covas DT. IJID Reg. 2023 Jun;7:222-229. doi: 10.1016/j.ijregi.2023.04.003. Epub 2023 Apr 6. PMID: 37102137

Parents' COVID-19, HPV, and Monkeypox vaccination intention: A multilevel structural equation model of risk, benefit, barrier, and efficacy perceptions and individual characteristics.
Liu S, Chu H. Patient Educ Couns. 2023 Jun 7;114:107842. doi: 10.1016/j.pec.2023.107842. Online ahead of print. PMID: 37301013

A deep learning predictive model for public health concerns and hesitancy toward the COVID-19 vaccines.
Farghaly HM, Gomaa MM, Elgeldawi E, Askr H, Elshaier YAMM, Ella HA, Darwish A, Hassanien AE. Sci Rep. 2023 Jun 6;13(1):9171. doi: 10.1038/s41598-023-36319-6. PMID: 37280253

Correction of vaccine effectiveness derived from test-negative case-control studies.
Habibzadeh F. BMC Med Res Methodol. 2023 Jun 10;23(1):137. doi: 10.1186/s12874-023-01962-0. PMID: 37301843

Intention to receive COVID-19 vaccine and its health belief model (HBM)-based predictors: Comment.
Kleebayoon A, Wiwanitkit V. Hum Vaccin Immunother. 2023 Jun 4:2219181. doi: 10.1080/21645515.2023.2219181. Online ahead of print. PMID: 37271581

Drug-induced radiation recall reactions and non-anticancer drugs: A descriptive analysis from VigiBase®.
Aubin-Beale E, Giorgi L, Beurrier M, Granel-Brocard F, Gillet P, Fresse A. Fundam Clin Pharmacol. 2023 Jun;37(3):673-679. doi: 10.1111/fcp.12866. Epub 2023 Jan 11. PMID: 36607138

SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
Kim E, Khan MS, Ferrari A, Huang S, Sammartino JC, Percivalle E, Kenniston TW, Cassaniti I, Baldanti F, Gambotto A. Microbiol Spectr. 2023 Jun 15;11(3):e0436322. doi: 10.1128/spectrum.04363-22. Epub 2023 May 10. PMID: 37162333

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Alves K, Plested JS, Galbiati S, Chau G, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Smith K, Marcheschi A, Pfeiffer S, McFall H, Smith G, Glenn GM, Dubovsky F, Mallory RM; Novavax 2019nCoV-101 Study Group. Vaccine. 2023 Jun 2:S0264-410X(23)00612-6. doi: 10.1016/j.vaccine.2023.05.051. Online ahead of print. PMID: 37271706

Getting Human Papillomavirus Vaccination Back on Track: A National Survey.
Kahn BZ, Huang Q, Thompson P, Gilkey MB, Alton Dailey S, Brewer NT. J Adolesc Health. 2023 Jun;72(6):950-957. doi: 10.1016/j.jadohealth.2023.01.004. Epub 2023 Mar 13. PMID: 36922312

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Kaplonek P, Cizmeci D, Kwatra G, Izu A, Lee JS, Bertera HL, Fischinger S, Mann C, Amanat F, Wang W, Koen AL, Fairlie L, Cutland CL, Ahmed K, Dheda K, Barnabas SL, Bhorat QE, Briner C, Krammer F, Saphire EO, Gilbert SC, Lambe T, Pollard AJ, Nunes M, Wuhrer M, Lauffenburger DA, Madhi SA, Alter G. Nat Immunol. 2023 Jun 15. doi: 10.1038/s41590-023-01513-1. Online ahead of print. PMID: 37322179

Analysis of Socio-demographic, Economic and Individual Reasons for COVID-19 Vaccination Hesitancy in Ecuador: A Nationwide Longitudinal Study.
Lapo-Talledo GJ, Talledo-Delgado JA, Portalanza D, Ballaz S, Siteneski A. J Community Health. 2023 Jun;48(3):467-479. doi: 10.1007/s10900-023-01188-7. Epub 2023 Jan 18. PMID: 36652158

Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study.
Ku JH, Sy LS, Qian L, Ackerson BK, Luo Y, Tubert JE, Lee GS, Florea A, Bruxvoort KJ, Talarico CA, Qiu S, Tian Y, Tseng HF. Vaccine. 2023 Jun 1;41(24):3636-3646. doi: 10.1016/j.vaccine.2023.04.075. Epub 2023 May 3. PMID: 37173268

COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
Yeo T, Siew RWE, Gulam MY, Tye JSN, Aw AYY, Sivalingam T, Peng X, Yong KP, Saffari SE, Chao Y, Tan K. J Neurol. 2023 Jun;270(6):2817-2825. doi: 10.1007/s00415-023-11692-4. Epub 2023 Apr 7. PMID: 37027019

Attitudes towards COVID-19 vaccination among incarcerated persons in the Federal Bureau of Prisons, June-July 2021.
Fukunaga R, Kaplan ZE, Rodriguez T, Hagan L, Aarvig K, Dusseau C, Crockett M, Long M. Vaccine. 2023 Jun 1;41(24):3604-3610. doi: 10.1016/j.vaccine.2023.04.077. Epub 2023 May 2. PMID: 37164822

mRNA COVID-19 vaccination early in pregnancy and the risk of spontaneous abortion in an international pregnancy registry.
Mansour O, Hernandez-Diaz S, Wyszynski DF. Pharmacoepidemiol Drug Saf. 2023 Jun;32(6):685-693. doi: 10.1002/pds.5600. Epub 2023 Feb 15. PMID: 36750979

Trust Associated with South Korean Sojourners' Chinese COVID-19 Vaccination Intent and Concerns: A Qualitative Study.
Lin Y, Liu X. J Epidemiol Glob Health. 2023 Jun 1:1-9. doi: 10.1007/s44197-023-00123-2. Online ahead of print. PMID: 37261712

Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort.
Huang CF, Jang TY, Wu PH, Kuo MC, Yeh ML, Wang CW, Liang PC, Wei YJ, Hsu PY, Huang CI, Hsieh MY, Lin YH, Hsiao HH, Hsu CM, Huang CT, Lee CY, Chen YH, Chen TC, Lin KD, Wang SH, Wang SF, Huang JF, Dai CY, Chuang WL, Yu ML. Virol J. 2023 Jun 2;20(1):112. doi: 10.1186/s12985-023-02056-5. PMID: 37268999

Seroprevalence of SARS-CoV-2 IgG and associated factors among people living with HIV over the first 12 months following the outbreak of COVID-19 in Burkina Faso, a sub-Saharan African country.

Kaboré OD, Poda A, Ouattara CA, Michodigni FN, Belem AA, Sawadogo Y, Zoungrana J, Galal L, Meda CZ, Godreuil S, Ouédraogo AS. PLoS One. 2023 Jun 14;18(6):e0286665. doi: 10.1371/journal.pone.0286665. eCollection 2023. PMID: 37315090

A call to action: securing an uninterrupted supply of Africa's medical products and technologies post COVID-19.
Ejekam CS, Emeje M, Lukulay P, Uche CR, Odibeli O, Sanusi O, Anyakora C. J Public Health Policy. 2023 Jun;44(2):276-284. doi: 10.1057/s41271-023-00405-w. Epub 2023 Mar 30. PMID: 36997622

Vulvar Aphthous Ulcers in Perimenarchal Adolescents after COVID-19 Vaccination: A Multicenter Case Series.
Sartor RA, Lawson A, Moncada-Madrazo M, Altchek C, Vash-Margita A, Cron J. J Pediatr Adolesc Gynecol. 2023 Jun;36(3):268-272. doi: 10.1016/j.jpag.2023.01.003. Epub 2023 Jan 25. PMID: 36708984

Public trust is earned: Historical discrimination, carceral violence, and the COVID-19 pandemic.
Anderson A, Lewis DF 4th, Shafer P, Anderson J, LaVeist TA. Health Serv Res. 2023 Jun 6. doi: 10.1111/1475-6773.14187. Online ahead of print. PMID: 37279782

The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists.
Visser C, Yousefi A, Nierman MC, Huisman MV, Gulpen AJW, van Ommen CH, Kruip MJHA; Dutch COVID and Thrombosis Coalition. Thromb Res. 2023 Jun 12;228:121-127. doi: 10.1016/j.thromres.2023.06.005. Online ahead of print. PMID: 37321159

Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.
Cohen M, Thomel-Rocchi O, Siva A, Okuda DT, Karabudak R, Efendi H, Terzi M, Carra-Dalliere C, Durand-Dubief F, Thouvenot E, Ciron J, Zephir H, Bourre B, Casez O, De Seze J, Moreau T, Neau JP, Pelletier D, Kantarci O, Tutuncu M, Derache N, Bensa C, Louapre C, Benoit J, Landes-Chateau C, Lebrun-Frenay C. Mult Scler. 2023 Jun 15:13524585231179669. doi: 10.1177/13524585231179669. Online ahead of print. PMID: 37322880

Predictors of a weak antibody response to COVID-19 mRNA vaccine in systemic lupus erythematosus.
Parsons C, Rubio J, Boulougoura A, Krishfield S, Kyttaris V. Rheumatol Int. 2023 Jun 13. doi: 10.1007/s00296-023-05347-w. Online ahead of print. PMID: 37310438

Metabolic Adaptations Correlated with Antibody Response after Immunization with Inactivated SARS-CoV-2 in Brazilian Subjects.
de Souza Nogueira J, Santos-Rebouças CB, Piergiorge RM, Valente AP, Gama-Almeida MC, El-Bacha T, Lopes Moreira ML, Baptista Marques BS, de Siqueira JR, de Carvalho EM, da Costa Ferreira O Jr, Porto LC, Kelly da Silva Fidalgo T, Costa Dos Santos G Jr. J Proteome Res. 2023 Jun 2;22(6):1908-1922. doi: 10.1021/acs.jproteome.3c00014. Epub 2023 May 11. PMID: 37167433

Polyarteritis nodosa diagnosed in a young male after COVID-19 vaccine: A case report.
Makiyama A, Abe Y, Furusawa H, Kogami M, Ando T, Tada K, Onimaru M, Ishizu A, Yamaji K, Tamura N. Mod Rheumatol Case Rep. 2023 Jun 15:rxad037. doi: 10.1093/mrcr/rxad037. Online ahead of print. PMID: 37319013

Understanding Factors Impacting Coronavirus Disease 2019 Vaccine Hesitancy in a Rural Surgical Clinic.
Thakur S, Cervantes JD, Thakur A. Surg Infect (Larchmt). 2023 Jun;24(5):456-461. doi: 10.1089/sur.2022.378. Epub 2023 Apr 20. PMID: 37083508

The effectiveness of COVID-19 vaccination against all-cause mortality in patients with type 2 diabetes mellitus: The observation during the initial period of the cancellation of the "Dynamic Zero Policy" in mainland China.
Liu S, Jiang C, Liu Y, Zhang Y, Qiu X, Luo J, Xu Y, Wang J. Diabetes Res Clin Pract. 2023 Jun;200:110694. doi: 10.1016/j.diabres.2023.110694. Epub 2023 May 8. PMID: 37164159

Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study.
Moreno-Torres V, Soriano V, Calderón-Parra J, Martínez-Urbistondo M, Treviño A, de San Vicente Z, de Mendoza C, Ruiz-Irastorza G. Autoimmun Rev. 2023 Jun;22(6):103341. doi: 10.1016/j.autrev.2023.103341. Epub 2023 Apr 14. PMID: 37062441

Letter to the Editor Response: Exploring COVID-19 Vaccine Hesitancy Among Stakeholders in African American and Latinx Communities in the Deep South Through the Lens of the Health Belief Model.
Bateman LB, Hall AG, Anderson WA, Cherrington AL, Helova A, Judd S, Kimberly R, Oates GR, Osborne T, Ott C, Ryan M, Strong C, Fouad MN. Am J Health Promot. 2023 Jun;37(5):720-721. doi: 10.1177/08901171221146436. Epub 2023 Jan 11. PMID: 36630288

Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2.
Bannick MS, Gao F, Brown ER, Janes HE. Am J Epidemiol. 2023 Jun 2;192(6):1016-1028. doi: 10.1093/aje/kwad046. PMID: 36883907

Postvaccination Immunogenicity of COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease: Comment.
Kleebayoon A, Wiwanitkit V. J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):e89-e90. doi: 10.1097/MPG.0000000000003761. Epub 2023 Mar 12. PMID: 36913710

Self-reported long COVID-19 symptoms are rare among vaccinated healthcare workers.
AlBahrani S, AlBarrak A, AlGubaisi N, Alkurdi H, Alburaiki D, AlGhamdi A, AlOthaiqy M, Tayeb S, Tayeb N, Abdraboh S, Khairi A, Alshareef L, AlHarbi A, AlRabeeah S, Alqahtani AS, Alqahtani JS, Hakami FH, Al-Maqati TN, Alkhrashi SA, Almershad MM, AlAbbadi A, Hakami MH, Faqihi O, Altawfiq KJA, Jebakumar AZ, Al-Tawfiq JA. J Infect Public Health. 2023 Jun 5;16(8):1276-1280. doi: 10.1016/j.jiph.2023.05.037. Online ahead of print. PMID: 37315430

Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan.
Nadeem I, Ul Munamm SA, Ur Rasool M, Fatimah M, Abu Bakar M, Rana ZK, Khatana UF, Jordon L, Saqlain M, Mahdi N, McLoughlin H. Postgrad Med J. 2023 Jun 8;99(1171):463-469. doi: 10.1136/postgradmedj-2022-141649. PMID: 37294716

Rural-Urban Differences in Vaccination and Hesitancy Rates and Trust: US COVID-19 Trends and Impact Survey on a Social Media Platform, May 2021-April 2022.

Soorapanth S, Cheung R, Zhang X, Mokdad AH, Mensah GA. Am J Public Health. 2023 Jun;113(6):680-688. doi: 10.2105/AJPH.2023.307274. Epub 2023 Apr 13. PMID: 37053528

Immunogenicity of COVID-19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: A systematic review and meta-analysis.
Al-Haideri M, Mohammad TAM, Darvishzadehdeldari S, Karbasi Z, Alimohammadi M, Faramarzi F, Khorasani S, Rasouli A, Tahmasebi S, Darvishi M, Akhavan-Sigari R. Int J Rheum Dis. 2023 Jun 12. doi: 10.1111/1756-185X.14713. Online ahead of print. PMID: 37309305

A new look on politicized reticence to vaccination: populism and COVID-19 vaccine refusal.
Roccato M, Russo S. Psychol Med. 2023 Jun;53(8):3769-3770. doi: 10.1017/S0033291721004736. Epub 2021 Nov 4. PMID: 34734558

Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future.
Black SB, Chandler RE, Edwards KM, Sturkenboom MCJM. Vaccine. 2023 Jun 7;41(25):3790-3795. doi: 10.1016/j.vaccine.2023.04.055. Epub 2023 May 15. PMID: 37198019

Audiometry-Confirmed Sudden Sensorineural Hearing Loss Incidence Among COVID-19 Patients and BNT162b2 Vaccine Recipients.
Cohen Michael O, Tamir SO, O'Rourke N, Marom T. Otol Neurotol. 2023 Jun 1;44(5):e358-e359. doi: 10.1097/MAO.0000000000003872. Epub 2023 Apr 6. PMID: 37026821

Declining trends in vaccine confidence across sub-Saharan Africa: A large-scale cross-sectional modeling study.
de Figueiredo A, Temfack E, Tajudeen R, Larson HJ. Hum Vaccin Immunother. 2023 Jun 8:2213117. doi: 10.1080/21645515.2023.2213117. Online ahead of print. PMID: 37290478

HLA-DR4 and DRB4: Potential risk alleles for COVID-19 vaccination-related ANCA-associated vasculitis.
Loo HT, Hsu CH, Chen LF. Ther Apher Dial. 2023 Jun;27(3):593-594. doi: 10.1111/1744-9987.13925. Epub 2022 Sep 16. PMID: 36074724

Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach.
George TK, Nair NP, Singh AK, Dilesh Kumar A, Roy AD, Mohan VN, Kang G. Vaccine. 2023 Jun 7;41(25):3755-3762. doi: 10.1016/j.vaccine.2023.04.062. Epub 2023 May 12. PMID: 37183072

Inter-hospital transfer and clinical outcomes for people with COVID-19 admitted to intensive care units in Australia: an observational cohort study.
Cini C, Neto AS, Burrell A, Udy A; SPRINT-SARI Australia investigators. Med J Aust. 2023 Jun 5;218(10):474-481. doi: 10.5694/mja2.51917. Epub 2023 Apr 10. PMID: 37037671

Detection of SARS-CoV-2 IgA and IgG in human milk and breastfeeding infant stool 6 months after maternal COVID-19 vaccination.
Stafford LS, Valcarce V, Henry M, Neu J, Parker L, Mueller M, Vicuna V, Gowen T, Cato E, Kosik I, Yewdell JW, Atkinson M, Cacho N, Li N, Larkin J 3rd. J Perinatol. 2023 Jun;43(6):775-781. doi: 10.1038/s41372-022-01581-5. Epub 2023 Jan 12. PMID: 36631564

Humoral immune response and live-virus neutralization of the SARS-CoV-2 omicron (BA.1) variant after COVID-19 mRNA vaccination in children and young adults with chronic kidney disease.
Stich M, Di Cristanziano V, Tönshoff B, Weber LT, Dötsch J, Rammer MT, Rieger S, Heger E, Garbade SF, Burgmaier K, Benning L, Speer C, Habbig S, Haumann S. Pediatr Nephrol. 2023 Jun;38(6):1935-1948. doi: 10.1007/s00467-022-05806-9. Epub 2022 Nov 21. PMID: 36409368

Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G, Jäger M, Dichtl S, Bauer A, Lass-Flörl C, Reindl M, Wilflingseder D, Posch W. Microbiol Spectr. 2023 Jun 15;11(3):e0516322. doi: 10.1128/spectrum.05163-22. Epub 2023 Apr 26. PMID: 37098903

Impact of pandemics and disruptions to vaccination on infectious diseases epidemiology past and present.
Hamson E, Forbes C, Wittkopf P, Pandey A, Mendes D, Kowalik J, Czudek C, Mugwagwa T. Hum Vaccin Immunother. 2023 Jun 8:2219577. doi: 10.1080/21645515.2023.2219577. Online ahead of print. PMID: 37291691

Supporting One Health for Pandemic Prevention: The Need for Ethical Innovation.
Diller ER, Williamson L. J Bioeth Inq. 2023 Jun 2:1-8. doi: 10.1007/s11673-023-10264-5. Online ahead of print. PMID: 37266851

VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe.
Salmanton-García J, Wipfler P, Valle-Simón P, Merakou C, Kopsidas I, Bethe U, Steinbach A, Spivak O, Součková L, Mendonça MA, Koniordou M, Hellemans M, Frías-Iniesta J, Davis RJ, Barta I, Azzini AM, Askling HH, Argyropoulos CD, Álvarez-Barco E, Akova M, Bonten MMJ, Cohen-Kandli M, Cox RJ, Flisiak R, Husa P, Jancoriene L, Koscalova A, Launay O, Lundgren J, Mallon P, Marques L, Nauclér P, Ochando J, Pana ZD, Tacconelli E, Tóth K, Trelle S, van Damme P, Zaoutis TE, Zeitlinger M, Albus K, Stewart FA, Hofstraat SHI, Bruijning-Verhagen P, Cornely OA; VACCELERATE Consortium. Electronic address: trialsites@vaccelerate.eu. Vaccine. 2023 Jun 13;41(26):3915-3922. doi: 10.1016/j.vaccine.2023.05.006. Epub 2023 May 18. PMID: 37210309

TNFepitope: A webserver for the prediction of TNF-α inducing epitopes.
Dhall A, Patiyal S, Choudhury S, Jain S, Narang K, Raghava GPS. Comput Biol Med. 2023 Jun;160:106929. doi: 10.1016/j.compbiomed.2023.106929. Epub 2023 Apr 20. PMID: 37126926

Well Child Wednesdays: An interprofessional pilot-program to increase pediatric immunizations Post-COVID.
Stewart-Lynch A, Lombardo S, Ceriani D, Mastrangelo S. J Interprof Educ Pract. 2023 Jun;31:100606. doi: 10.1016/j.xjep.2023.100606. Epub 2023 Jan 18. PMID: 36688206

Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study.
Su WJ, Liu YL, Chang CH, Lin YC, Huang WI, Wu LC, Chen SF, Lin YS, Hsieh YL, Yang CA, Lin CH, Chan KA, Lee PI, Chuang JH, Yang CH. J Microbiol Immunol Infect. 2023 Jun;56(3):558-565. doi: 10.1016/j.jmii.2023.01.016. Epub 2023 Feb 8. PMID: 36804307

Self-Destructive Structural Color Liquids for Time-Temperature Indicating.
Huang C, Shang Y, Hua J, Yin Y, Du X. ACS Nano. 2023 Jun 13;17(11):10269-10279. doi: 10.1021/acsnano.3c00467. Epub 2023 May 31. PMID: 37255215

"Effect of COVID-19 Vaccination on Menstrual Cycle Patterns of Reproductive-Age Women: A Multi-centric Observational Study.".
Kumar N, Gangane N, Mohapatra I, Rukadikar C, Sharmila V, Pushpalatha K, Eerike M, Santhoshi G, Samantaray SR, Seth S, Trigunait P, Reddy NJ, Patel S, Rani S, Mishra R, Negi K. Curr Drug Res Rev. 2023 Jun 8. doi: 10.2174/2589977515666230608140606. Online ahead of print. PMID: 37291775

Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study.
Visos-Varela I, Zapata-Cachafeiro M, Piñeiro-Lamas M, Carracedo-Martínez E, Saez M, Herdeiro MT, Figueiras A, Salgado-Barreira Á. Eur Neuropsychopharmacol. 2023 Jun;71:96-108. doi: 10.1016/j.euroneuro.2023.03.011. Epub 2023 Apr 4. PMID: 37094487

Short-term adverse effects of COVID-19 vaccines after the first, second, and booster doses: a cross-sectional survey from Punjab, Pakistan, and the implications.
Mustafa ZU, Maqbool F, Wahid M, Salman M, Haroon S, Khan YH, Mallhi TH, Godman B. Rev Soc Bras Med Trop. 2023 Jun 2;56:e0044. doi: 10.1590/0037-8682-0044-2023. eCollection 2023. PMID: 37283345

Jerne's "immune network theory", of interacting anti-idiotypic antibodies applied to immune responses during COVID-19 infection and after COVID-19 vaccination.
Kurbel S. Bioessays. 2023 Jun 9:e2300071. doi: 10.1002/bies.202300071. Online ahead of print. PMID: 37300287

Role of vaccination and anti-SARS-CoV-2 antibodies in the clinical outcome of hospitalized COVID-19 patients.
Bernal E, García-Villalba E, Pons E, Vicente MR, Tomás C, Minguela A; GERS. Med Clin (Barc). 2023 Jun 9;160(11):476-483. doi: 10.1016/j.medcli.2022.12.018. Epub 2023 Jan 23. PMID: 36813683

Strategic planning for the optimal distribution of COVID-19 vaccines.
Ochoa-Barragán R, Munguía-López ADC, Ponce-Ortega JM. Socioecon Plann Sci. 2023 Jun;87:101559. doi: 10.1016/j.seps.2023.101559. Epub 2023 Mar 14. PMID: 37255586

Guillain-Barré syndrome following COVID-19 vaccination: An updated systematic review of cases.
Shaheen N, Ramadan A, Nashwan AJ, Shaheen A, Ahmad S, Motawea KR, Mohamed S, Mohamed RS, Swed S, Aiash H. Clin Case Rep. 2023 Jun 7;11(6):e7456. doi: 10.1002/ccr3.7456. eCollection 2023 Jun. PMID: 37305891

Translatability scoring in prospective and retrospective COVID drug development cases.
Wendler A, Wehling M. Eur J Clin Pharmacol. 2023 Jun 6:1-21. doi: 10.1007/s00228-023-03517-0. Online ahead of print. PMID: 37278822

Antibody Response to the BA.5 Bivalent Vaccine Shot: a Two-Year Follow-Up Study following Initial COVID-19 mRNA Vaccination.
Hirotsu Y, Sugiura H, Takatori M, Mochizuki H, Omata M. Microbiol Spectr. 2023 Jun 15;11(3):e0131623. doi: 10.1128/spectrum.01316-23. Epub 2023 May 16. PMID: 37191496

Multisystem inflammatory syndrome in children associated with COVID-19: from pathophysiology to clinical management and outcomes.
Lee S, Erdem G, Yasuhara J. Minerva Pediatr (Torino). 2023 Jun 7. doi: 10.23736/S2724-5276.23.07205-1. Online ahead of print. PMID: 37284807

Multiple evanescent white dot syndrome following COVID-19 vaccines.
Bouhout S, Hébert M, Vadboncoeur J, Aubin MJ. Can J Ophthalmol. 2023 Jun;58(3):e122-e124. doi: 10.1016/j.jcjo.2022.10.002. Epub 2022 Oct 23. PMID: 36288774

Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022.
Langlete P, Tesli M, Veneti L, Starrfelt J, Elstrøm P, Meijerink H. Vaccine. 2023 Jun 13;41(26):3923-3929. doi: 10.1016/j.vaccine.2023.05.022. Epub 2023 May 10. PMID: 37211454

The identification and phylogenetic analysis of SARS-CoV-2 delta variants in Taiwan.
Liu LT, Tsai JJ, Chu JJH, Chen CH, Chen LJ, Lin PC, Tsai CY, Hsu MC, Chuang WL, Hwang SJ, Chong IW. Kaohsiung J Med Sci. 2023 Jun;39(6):624-636. doi: 10.1002/kjm2.12665. Epub 2023 Mar 23. PMID: 36951529

Cytokine levels in maternal and infant blood after COVID-19 vaccination during pregnancy: Correspondence.
Kleebayoon A, Wiwanitkit V. J Reprod Immunol. 2023 Jun;157:103947. doi: 10.1016/j.jri.2023.103947. Epub 2023 Apr 6. PMID: 37087817

Serologic response to COVID-19 infection or vaccination in pediatric kidney transplant recipients compared to healthy children.
Ziv N, Gimelraikh Y, Ashkenazi-Hoffnung L, Alfandary H, Borovitz Y, Dagan A, Levi S, Hamdani G, Levy-Erez D, Landau D, Koren G, Talgam-Horshi E, Haskin O. Transpl Immunol. 2023 Jun;78:101839. doi: 10.1016/j.trim.2023.101839. Epub 2023 Apr 17. PMID: 37076050

Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
Verburgh ML, van Pul L, Grobben M, Boyd A, Wit FWNM, van Nuenen AC, van Dort KA, Tejjani K, van Rijswijk J, Bakker M, van der Hoek L, Schim van der Loeff MF, van der Valk M, van Gils MJ, Kootstra NA, Reiss P. Microbiol Spectr. 2023 Jun 15;11(3):e0115523. doi: 10.1128/spectrum.01155-23. Epub 2023 May 11. PMID: 37166335

Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using isotope dilution mass spectrometry.
Sutton WJH, Branham PJ, Williamson YM, Cooper HC, Najjar FN, Pierce-Ruiz CL, Barr JR, Williams TL. Vaccine. 2023 Jun 13;41(26):3872-3884. doi: 10.1016/j.vaccine.2023.04.044. Epub 2023 May 8. PMID: 37202272

Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics.
Uzun S, Zinner C, Beenen AC, Alborelli I, Bartoszek EM, Yeung J, Calgua B, Reinscheid M, Bonsert P, Stalder AK, Haslbauer J, Vosbeck J, Mazzucchelli L, Hoffmann T, Terracciano LM, Hutter G, Manz M,

Panne I, Böttler T, Hofmann M, Bengsch B, Heim MH, Bernsmeier C, Jiang S, Tzankov A, Beretta-Piccoli BT, Matter MS. J Hepatol. 2023 Jun 6:S0168-8278(23)00348-3. doi: 10.1016/j.jhep.2023.05.020. Online ahead of print. PMID: 37290592

COVID-19 vaccine safety during the antenatal period in women with idiopathic inflammatory myopathies.
Andreoli L, Sen P, Lini D, Vincze MN, Schreiber K, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. Rheumatology (Oxford). 2023 Jun 1;62(6):e175-e179. doi: 10.1093/rheumatology/keac644. PMID: 36370070

Relationship between anthropometric and body composition parameters and anti-SARS-CoV-2 specific IgG titers in females vaccinated against COVID-19 according to the heterologous vaccination course: A cohort study.
Golec M, Zembala-John J, Fronczek M, Konka A, Bochenek A, Wystyrk K, Botor H, Zalewska M, Chrapiec M, Kasperczyk S, Brzoza Z, Bułdak RJ. PLoS One. 2023 Jun 13;18(6):e0287128. doi: 10.1371/journal.pone.0287128. eCollection 2023. PMID: 37310975

Evaluation of Correctional Facility COVID-19 Outbreaks With Layered Mitigation Strategies Including Vaccination: Colorado, 2020-2021.
Martinez HE, Marshall KE, Showell VW 4th, Tate JE, Kirking HL, Broudy M, Matzinger SR, Burakoff A, Deng L, Payne DC, Fleming-Dutra K, Jervis RH. J Correct Health Care. 2023 Jun;29(3):198-205. doi: 10.1089/jchc.21.12.0146. Epub 2023 Mar 29. PMID: 36989514

Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK.
Lam ICH, Wong CKH, Zhang R, Chui CSL, Lai FTT, Li X, Chan EWY, Luo H, Zhang Q, Man KKC, Cheung BMY, Tang SCW, Lau CS, Wan EYF, Wong ICK. EClinicalMedicine. 2023 Jun;60:102000. doi: 10.1016/j.eclinm.2023.102000. Epub 2023 May 11. PMID: 37197226

Paediatric healthcare and hospital worker SARS-CoV-2 IgG antibody: A longitudinal cohort study.
Cappetto KD, Brown JC, Englund JA, Zerr DM, Dickerson JA, Wang X, Strelitz B, Klein EJ. IJID Reg. 2023 Jun;7:281-286. doi: 10.1016/j.ijregi.2023.05.001. Epub 2023 May 12. PMID: 37234562

Harnessing immunoinformatics for developing a multiple-epitope peptide-based vaccination approach against SARS-CoV-2 spike protein.
Moustafa RI, Faraag AHI, El-Shenawy R, Agwa MM, Elsayed H. Saudi J Biol Sci. 2023 Jun;30(6):103661. doi: 10.1016/j.sjbs.2023.103661. Epub 2023 Apr 28. PMID: 37163156

Decisions about adopting novel COVID-19 vaccines among White adults in a rural state, USA: A qualitative study.
Kohut M, Scharnetzki L, Pajka J, Jacobs EA, Fairfield KM. Health Expect. 2023 Jun;26(3):1052-1064. doi: 10.1111/hex.13714. Epub 2023 Mar 2. PMID: 36864735

Burgeoning therapeutic strategies to curb the contemporary surging viral infections.
Akram F, Waheed HM, Shah FI, Haq IU, Nasir N, Akhtar MT, Farooq Gohar U. Microb Pathog. 2023 Jun;179:106088. doi: 10.1016/j.micpath.2023.106088. Epub 2023 Mar 31. PMID: 37004965

Chronic and delayed neurological manifestations of persistent infections.
Pandya D, Johnson TP. Curr Opin Neurol. 2023 Jun 1;36(3):198-206. doi: 10.1097/WCO.0000000000001154. Epub 2023 Apr 19. PMID: 37078647

Assessing the Role of Trust in Public Health Agencies and COVID-19 Vaccination Status Among a Community Sample of African Americans in North Carolina.
Lloyd SL, Foy CG, Caban-Holt A, Gwathmey T, Williams KL, Starks TD, Mathews A, Vines AI, Richmond A, Byrd GS. J Racial Ethn Health Disparities. 2023 Jun 5:1-11. doi: 10.1007/s40615-023-01646-x. Online ahead of print. PMID: 37273163

Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses - fall 2021, Wisconsin.
DeJonge PM, Lambrou AS, Segaloff HE, Bateman A, Sterkel A, Griggs C, Baggott J, Kelly P, Thornburg N, Epperson M, Desamu-Thorpe R, Abedi G, Hsu CH, Nakayama JY, Ruffin J, Turner-Harper D, Matanock A, Almendares O, Whaley M, Chakrabarti A, DeGruy K, Daly M, Westergaard R, Tate JE, Kirking HL. BMC Infect Dis. 2023 Jun 5;23(1):374. doi: 10.1186/s12879-023-08332-7. PMID: 37277736

Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022.
van Iersel SCJL, McDonald SA, de Gier B, Knol MJ, de Melker HE, Henri van Werkhoven CH, Hahné SJM; RIVM COVID-19 epidemiology and surveillance team. Vaccine. 2023 Jun 13;41(26):3847-3854. doi: 10.1016/j.vaccine.2023.05.018. Epub 2023 May 10. PMID: 37202273

[Evaluation of the Dunning Kruger effect in relation to vaccination: a study of messages on the social network LinkedIn.].
Sánchez Ordóñez M, Bermejo Velasco PE, Rubio Moraga ÁL. Rev Esp Salud Publica. 2023 Jun 15;97:e202306051. PMID: 37325904

Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias.
Andrejko KL, Pry JM, Myers JF, Mehrotra M, Lamba K, Lim E, Fukui N, DeGuzman JL, Openshaw J, Watt J, Jain S, Lewnard JA, Covid-Case-Control Study Team OBOTC. Am J Epidemiol. 2023 Jun 2;192(6):895-907. doi: 10.1093/aje/kwad017. PMID: 36702469

Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.
Kehagia E, Papakyriakopoulou P, Valsami G. Vaccine. 2023 Jun 1;41(24):3589-3603. doi: 10.1016/j.vaccine.2023.05.011. Epub 2023 May 11. PMID: 37179163

From iatrogenesis to vaccine skepticism: US mothers' negative vaccine perceptions and non-vaccination practices as reverberations of medical harm.
Richlin JB. Med Anthropol Q. 2023 Jun;37(2):118-133. doi: 10.1111/maq.12764. Epub 2023 May 10. PMID: 37161842

Comparison of the first and sixth waves of the SARS-COV-2 coronavirus pandemic in patients with immune-mediated disease.

Lobo Rodríguez C, López-Calleja AM, Morales de Los Ríos Luna P, Sánchez Vázquez S, Molinero Sampedro Á, López-Esteban A. Reumatol Clin (Engl Ed). 2023 Jun 1:S2173-5743(23)00110-7. doi: 10.1016/j.reumae.2023.02.011. Online ahead of print. PMID: 37286470

SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022.
Bloomfield LE, Ngeh S, Cadby G, Hutcheon K, Effler PV. Emerg Infect Dis. 2023 Jun;29(6):1162-1172. doi: 10.3201/eid2906.230130. Epub 2023 May 4. PMID: 37141626

Estimating global and regional between-country inequality in routine childhood vaccine coverage in 195 countries and territories from 2019 to 2021: a longitudinal study.
Lai X, Zhang H, Pouwels KB, Patenaude B, Jit M, Fang H. EClinicalMedicine. 2023 Jun;60:102042. doi: 10.1016/j.eclinm.2023.102042. Epub 2023 Jun 8. PMID: 37304497

Rate of COVID-19 vaccination among patients with cancer who tested positive for severe acute respiratory syndrome-coronavirus 2: Analysis of the American Society of Clinical Oncology Registry.
Kurbegov D, Bruinooge SS, Lei XJ, Kirkwood MK, Dickson N, Hattiangadi T, Mileham KF, Patrick A, Williams JH, Kaltenbaugh M, Gralow JR, Garrett-Mayer E. Cancer. 2023 Jun 1;129(11):1752-1762. doi: 10.1002/cncr.34726. Epub 2023 Mar 15. PMID: 36920457

Predominantly defective $CD8^+$ T cell immunity to SARS-CoV-2 mRNA vaccination in lung transplant recipients.
Taus E, Shino MY, Ibarrondo FJ, Hausner MA, Hofmann C, Yang OO. J Transl Med. 2023 Jun 8;21(1):374. doi: 10.1186/s12967-023-04234-z. PMID: 37291575

Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases.
Benny L, Mehta P, Ahmed S, Paul A, Sukumaran A, Mohanan M, Vijayan A, Kaveri K, Padmaja R, Shenoy P. Rheumatol Int. 2023 Jun;43(6):1033-1039. doi: 10.1007/s00296-023-05314-5. Epub 2023 Apr 8. PMID: 37029793

The location of unilateral axillary lymphadenopathy after COVID-19 vaccination compared with that of metastasis from breast cancer without vaccination.
Mukai K, Tsunoda H, Imai R, Numata A, Kida K, Oba K, Yagishita K, Yamauchi H, Kanomata N, Kurihara Y. Jpn J Radiol. 2023 Jun;41(6):617-624. doi: 10.1007/s11604-023-01387-1. Epub 2023 Jan 10. PMID: 36626076

Severity of the Omicron SARS-CoV-2 variant compared with the previous lineages: A systematic review.
Arabi M, Al-Najjar Y, Mhaimeed N, Salameh MA, Paul P, AlAnni J, Abdelati AA, Laswi I, Khanjar B, Al-Ali D, Elshafeey A, Mhaimeed O, Burney Z, D'Souza A, Sinha P, Bhatti M, Pillai KV, Homssi M, Bshesh K, Yagan L, Zakaria D. J Cell Mol Med. 2023 Jun;27(11):1443-1464. doi: 10.1111/jcmm.17747. Epub 2023 May 18. PMID: 37203288

Patients with Post-COVID-19 Vaccination Myocarditis Have More Favorable Strain in Cardiac Magnetic Resonance Than Those With Viral Myocarditis.
Vaiyani D, Elias MD, Biko DM, Whitehead KK, Harris MA, Partington SL, Fogel MA. Pediatr Cardiol. 2023 Jun;44(5):1108-1117. doi: 10.1007/s00246-023-03150-9. Epub 2023 Apr 1. PMID: 37004523

Distinct platelet crosstalk with adaptive and innate immune cells after adenoviral and mRNA vaccination against SARS-CoV-2.
Lombardi L, Maiorca F, Marrapodi R, Sabetta A, Scafa N, Pallucci D, Miglionico M, Romiti GF, Corica B, Piconese S, Polimeni A, Pulcinelli F, Cangemi R, Visentini M, Basili S, Stefanini L. J Thromb Haemost. 2023 Jun;21(6):1636-1649. doi: 10.1016/j.jtha.2023.03.003. Epub 2023 Mar 12. PMID: 36918114

Human inherited complete STAT2 deficiency underlies inflammatory viral diseases.
Bucciol G, Moens L, Ogishi M, Rinchai D, Matuozzo D, Momenilandi M, Kerrouche N, Cale CM, Treffeisen ER, Al Salamah M, Al-Saud BK, Lachaux A, Duclaux-Loras R, Meignien M, Bousfiha A, Benhsaien I, Shcherbina A, Roppelt A; COVID Human Genetic Effort; Gothe F, Houhou-Fidouh N, Hackett SJ, Bartnikas LM, Maciag MC, Alosaimi MF, Chou J, Mohammed RW, Freij BJ, Jouanguy E, Zhang SY, Boisson-Dupuis S, Béziat V, Zhang Q, Duncan CJ, Hambleton S, Casanova JL, Meyts I. J Clin Invest. 2023 Jun 15;133(12):e168321. doi: 10.1172/JCI168321. PMID: 36976641

Recurring nodular scleritis following inactivated vaccination for COVID-19.
Peyman A, Pourazizi M, Dehghani S, Ghorbani S. Clin Case Rep. 2023 Jun 13;11(6):e7420. doi: 10.1002/ccr3.7420. eCollection 2023 Jun. PMID: 37323271

Therapeutic Management with Repurposing Approaches: A Mystery During COVID-19 Outbreak.
Chaudhury S, Kaur P, Gupta D, Anand P, Chaudhary M, Tiwari S, Mittal A, Gupta J, Kaur S, Singh VD, Dhawan D, Singh P, Sahu SK. Curr Mol Med. 2023 Jun 13. doi: 10.2174/1566524023666230613141746. Online ahead of print. PMID: 37312440

Projected Health Outcomes Associated With 3 US Supreme Court Decisions in 2022 on COVID-19 Workplace Protections, Handgun-Carry Restrictions, and Abortion Rights.
Gaffney A, Himmelstein DU, Dickman S, Myers C, Hemenway D, McCormick D, Woolhandler S. JAMA Netw Open. 2023 Jun 1;6(6):e2315578. doi: 10.1001/jamanetworkopen.2023.15578. PMID: 37289459

Indiana Parental Perceptions of the Acceptability of General and HPV-Specific State Vaccine Requirements.
Walker KK, Kasting ML, Head KJ, Sturm L, Zimet GD. J Community Health. 2023 Jun;48(3):528-538. doi: 10.1007/s10900-023-01198-5. Epub 2023 Feb 6. PMID: 36745356

Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
Ergun T, Hosgoren Tekin S, Apti Sengun O, Akin Cakici O, Seckin D, Adiay C, Enul H, Yilmaz S, Ay P, Haklar G, Sili U. Vaccine. 2023 Jun 3:S0264-410X(23)00615-1. doi: 10.1016/j.vaccine.2023.05.052. Online ahead of print. PMID: 37277251

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.
van Doesum JA, Salmanton-García J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A, Farina F, Besson C, Weinbergerová B, Van Praet J, Schönlein M, López-García A, Lamure S, Guidetti A, De Ramón-Sánchez C, Batinić J, Gavriilaki E, Tragiannidis A, Tisi MC, Plantefeve G, Petzer V, Ormazabal-Vélez I, Marques de Almeida J, Marchetti M, Maertens J, Machado M, Kulasekararaj A, Hernández-Rivas JÁ, Gomes da Silva M, Fernández N, Espigado I, Drgoňa Ľ, Dragonetti G, Metafuni E, Calbacho M, Blennow O, Wolf D, van Anrooij B, Nunes Rodrigues R, Nordlander A, Martín-González JA, Liévin R,

Jiménez M, Gräfe SK, García-Sanz R, Córdoba R, Rahimli L, van Meerten T, Cornely OA, Pagano L. Blood Adv. 2023 Jun 13;7(11):2645-2655. doi: 10.1182/bloodadvances.2022009578. PMID: 37058479

One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.
Ishikawa K, Nascimento MC, Asano M, Hirata H, Itoh Y, Kelly EJ, Matsui A, Olsson U, Shoemaker K, Green J. Vaccine. 2023 Jun 2:S0264-410X(23)00542-X. doi: 10.1016/j.vaccine.2023.05.015. Online ahead of print. PMID: 37271703

Threshold conditions for curbing COVID-19 with a dynamic zero-case policy derived from 101 outbreaks in China.
Tang S, Wang X, Tang B, He S, Yan D, Huang C, Shao Y, Xiao Y, Cheke RA. BMC Public Health. 2023 Jun 6;23(1):1084. doi: 10.1186/s12889-023-16009-8. PMID: 37280554

A Saliva-Based Serological and Behavioral Analysis of SARS-CoV-2 Antibody Prevalence in Howard County, Maryland.
Brown AC, Koshute PT, Cowley HP, Robinette MS, Gravelyn SR, Patel SV, Ju EY, Frommer CT, Zambidis AE, Schneider EJ, Zhao MY, Mugo BK, Clarke W, Kruczynski K, Pisanic N, Heaney C, Colella TA. Microbiol Spectr. 2023 Jun 8:e0276522. doi: 10.1128/spectrum.02765-22. Online ahead of print. PMID: 37289070

Impact of coronavirus disease 2019 (COVID-19) vaccination on menstrual bleeding quantity: An observational cohort study.
Darney BG, Boniface ER, Van Lamsweerde A, Han L, Matteson KA, Cameron S, Male V, Acuna J, Benhar E, Pearson JT, Edelman A. BJOG. 2023 Jun;130(7):803-812. doi: 10.1111/1471-0528.17471. Epub 2023 Apr 10. PMID: 37035899

Assessment of immunoglobin G (spike and nucleocapsid protein) response to COVID-19 vaccination in Palestine.
Asmar I, Almahmoud O, Yaseen K, Jamal J, Omar A, Naseef H, Hasan S. Clin Epidemiol Glob Health. 2023 Jul-Aug;22:101330. doi: 10.1016/j.cegh.2023.101330. Epub 2023 Jun 3. PMID: 37293133

Facial Dermal Filler Injection and Vaccination: A 12-Year Review of Adverse Event Reporting and Literature Review.
Sun AH, Tiongco RFP, Manahan MA. Aesthet Surg J. 2023 Jun 14;43(7):NP544-NP557. doi: 10.1093/asj/sjad031. PMID: 36788718

Aortic thrombosis and acute limb ischemia after ChAdOx1 nCov-19 (Oxford-AstraZeneca) vaccination: a case of vaccine-induced thrombocytopenia and thrombosis (VITT).
Vierstraete M, Sabbe T. Acta Chir Belg. 2023 Jun;123(3):329-332. doi: 10.1080/00015458.2021.2017600. Epub 2021 Dec 27. PMID: 34890294

Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events?
Haji A, Alkattan A, Mahmoud N, Elkagam E, Hassanein M, Alfaifi A, Al-Tawfiq JA, Alabdulkareem K, Jokhdar H, Radwan N. IJID Reg. 2023 Jun;7:159-163. doi: 10.1016/j.ijregi.2023.03.003. Epub 2023 Mar 11. PMID: 37025346

Assessment of vaccine perception and vaccination intention of Mpox infection among the adult males in Bangladesh: A cross-sectional study findings.
Islam MR, Haque MA, Ahamed B, Tanbir M, Khan MR, Eqbal S, Rahman MA, Shahriar M, Bhuiyan MA. PLoS One. 2023 Jun 8;18(6):e0286322. doi: 10.1371/journal.pone.0286322. eCollection 2023. PMID: 37289746

Future perspectives of emerging novel drug targets and immunotherapies to control drug addiction.
Malik JA, Agrewala JN. Int Immunopharmacol. 2023 Jun;119:110210. doi: 10.1016/j.intimp.2023.110210. Epub 2023 Apr 24. PMID: 37099943

Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis.
Breu M, Lechner C, Schneider L, Tobudic S, Winkler S, Siegert S, Baumann M, Seidl R, Berger T, Kornek B. Pediatr Neurol. 2023 Jun;143:19-25. doi: 10.1016/j.pediatrneurol.2023.02.017. Epub 2023 Mar 2. PMID: 36966598

Cerebral Venous Sinus Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia in Middle-Income Countries.
van de Munckhof A, Borhani-Haghighi A, Aaron S, Krzywicka K, Sanchez van Kammen M, Cordonnier C, Kleinig T, Field TS, Poli S, Lemmens R, Scutelnic A, Lindgren E, Duan J, Arslan Y, van Gorp ECM, Hovinga JAK, Guenther A, Jood K, Tatlisumak T, Putaala J, Heldner MR, Arnold M, Aguiar de Sousa D, Wasay M, Arauz-Góngora A, Conforto A, Ferro JM, Coutinho JM. Int J Stroke. 2023 Jun 5:17474930231182901. doi: 10.1177/17474930231182901. Online ahead of print. PMID: 37277922

Antibody and T-cell responses to coronavirus disease 2019 vaccination in common variable immunodeficiency and specific antibody deficiency.
Rosenthal JA, Papa MP, Sanz M, Nicholes S, Holmberg CS, Bosque A, Keswani A, Amdur R, Lynch RM, Soriano-Sarabia N, Ein D. Ann Allergy Asthma Immunol. 2023 Jun;130(6):743-751.e3. doi: 10.1016/j.anai.2023.01.025. Epub 2023 Feb 2. PMID: 36736722

Translocator protein (TSPO)-PET as diagnostic and monitoring tool in COVID-19 related MRI-negative brainstem encephalitis: a case report.
Wischmann J, Bartos LM, Brendel M, Albert NL, Forbrig R, Straube A, Masouris I. J Neurol. 2023 Jun;270(6):2853-2856. doi: 10.1007/s00415-023-11691-5. Epub 2023 Apr 3. PMID: 37012466

Cogan's sign in a patient with suspected post-COVID-19 vaccine-associated myasthenia gravis.
Tavares-Júnior JWL, Sobreira-Neto MA, Braga-Neto P. Rev Soc Bras Med Trop. 2023 Jun 2;56:e0007. doi: 10.1590/0037-8682-0007-2023. eCollection 2023. PMID: 37283341

The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity.
DeGrasse DC, Black SD. Cureus. 2023 Jun 8;15(6):e40148. doi: 10.7759/cureus.40148. eCollection 2023 Jun. PMID: 37313287

Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
Woo EJ, Gee J, Marquez P, Baggs J, Abara WE, McNeil MM, Dimova RB, Su JR. Vaccine. 2023 Jun 13:S0264-410X(23)00687-4. doi: 10.1016/j.vaccine.2023.06.023. Online ahead of print. PMID: 37321898

Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase.
Macías Saint-Gerons D, Ibarz MT, Castro JL, Forés-Martos J, Tabarés-Seisdedos R. Drugs Real World Outcomes. 2023 Jun;10(2):263-270. doi: 10.1007/s40801-023-00355-5. Epub 2023 Feb 14. PMID: 36788170

Impact of the COVID-19 pandemic on antimicrobial stewardship support for general practices in England: a qualitative interview study.
Campbell A, Borek AJ, McLeod M, Tonkin-Crine S, Pouwels KB, Roope L, Hayhoe BW, Majeed A, Walker AS, Holmes A; STEP-UP team. BJGP Open. 2023 Jun 8:BJGPO.2022.0193. doi: 10.3399/BJGPO.2022.0193. Online ahead of print. PMID: 37290780

Impact of maternal SARS-CoV-2 booster vaccination on blood and breastmilk antibodies.
Rick AM, Lentscher A, Xu L, Wilkins MS, Nasser A, Tuttle DJ, Megli C, Marques ETA, McElroy AK, Williams JV, Martin JM. PLoS One. 2023 Jun 13;18(6):e0287103. doi: 10.1371/journal.pone.0287103. eCollection 2023. PMID: 37310982

Public Libraries for Public Health: COVID-19 Response Efforts in Prince George's County, Maryland.
Acosta D, Brown NA, Zukowski R, Mann E, Dawson-Hahn E. Am J Public Health. 2023 Jun;113(6):623-626. doi: 10.2105/AJPH.2023.307246. Epub 2023 Mar 9. PMID: 36893364

Incidence of ventricular arrhythmias related to COVID infection and vaccination in patients with Brugada syndrome: Insights from a large Italian multicenter registry based on continuous rhythm monitoring.
Casella M, Conti S, Compagnucci P, Ribatti V, Narducci ML, Marcon L, Massara F, Valeri Y, De Francesco L, Martino AM, Ghiglieno C, Schiavone M, Balla C, Dell'Era G, Pelargonio G, Forleo GB, Iacopino S, Sgarito G, Calò L, Tondo C, Russo AD, Patti G. J Cardiovasc Electrophysiol. 2023 Jun;34(6):1386-1394. doi: 10.1111/jce.15929. Epub 2023 May 17. PMID: 37194742

Safety of COVID-19 mRNA Vaccination Among Young Children in the Vaccine Safety Datalink.
Goddard K, Donahue JG, Lewis N, Hanson KE, Weintraub ES, Fireman B, Klein NP. Pediatrics. 2023 Jun 6:e2023061894. doi: 10.1542/peds.2023-061894. Online ahead of print. PMID: 37278199

"We're kind of on the back burner": Psychological distress and coping among medical social workers during the COVID-19 pandemic.
Lewinson TD, Washington TR, Allen SE, Murphey JM, Onsando WM. Soc Work Health Care. 2023 Jun 12:1-20. doi: 10.1080/00981389.2023.2221718. Online ahead of print. PMID: 37303230

Rare cases of Guillain-Barré syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021.
Lehmann HC, Oberle D, Keller-Stanislawski B, Rieck T, Streit R. Euro Surveill. 2023 Jun;28(24). doi: 10.2807/1560-7917.ES.2023.28.24.2200744. PMID: 37318764

COVID-19 BNT162b2 mRNA vaccine induced myocarditis with left ventricular thrombus in a young male.
Yeni M. Acta Cardiol. 2023 Jun;78(4):483-485. doi: 10.1080/00015385.2023.2165271. Epub 2023 Jan 23. PMID: 36688840

Autoimmunity-related neutrophilic dermatosis after coronavirus disease 2019 vaccination: A case report and literature review.
Kishibe M, Koike K, Kanno K, Ishida-Yamamoto A. J Dermatol. 2023 Jun;50(6):820-823. doi: 10.1111/1346-8138.16718. Epub 2023 Jan 5. PMID: 36606292

Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey.
Tang Q, Li F, Tian J, Kang J, He J. Clin Exp Med. 2023 Jun;23(2):457-463. doi: 10.1007/s10238-022-00832-1. Epub 2022 May 25. PMID: 35612692

Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
Makanut S, Wangteeraprasert A, Jitpewngam W, Ngoenkam J, Pongcharoen S. Vaccine. 2023 Jun 5:S0264-410X(23)00666-7. doi: 10.1016/j.vaccine.2023.06.017. Online ahead of print. PMID: 37301707

A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients.
Naveed Z, Li J, Naus M, Velásquez García HA, Wilton J, Janjua NZ; Canadian Immunization Research Network Provincial Collaborative Network investigators. Int J Infect Dis. 2023 Jun;131:75-78. doi: 10.1016/j.ijid.2023.03.027. Epub 2023 Mar 24. PMID: 36967038

Cases of acquired hemophilia A following COVID-19 vaccines: Cogent safety signal or possible reporting/detection bias? Preliminary evidence from Tuscany, Italy.
Roberto G, Paoletti O, Ferraro S, Hyeraci G, Franchini M, Gini R, Focosi D, Tuccori M. Pharmacoepidemiol Drug Saf. 2023 Jun;32(6):694-699. doi: 10.1002/pds.5615. Epub 2023 Mar 27. PMID: 36930740

COVID-19 Vaccine Tolerability in a Patient With a Delayed Allergic Reaction to Polyethylene Glycol: A Case Report.
Loli-Ausejo D, Gómez-Armayones S, Sáez-Peñataro J, González-Matamala MF, Mascaró B, Muñoz-Cano R, Bartra J. J Investig Allergol Clin Immunol. 2023 Jun 15;33(3):232-233. doi: 10.18176/jiaci.0843. Epub 2022 Jul 14. PMID: 35833860

Genomic surveillance of severe acute respiratory syndrome coronavirus 2 in Burundi, from May 2021 to January 2022.
Nduwimana C, Nzoyikorera N, Ndihokubwayo A, Ihorimbere T, Nibogora C, Ndoreraho A, Hajayandi O, Bizimana JC, Diawara I, Niyonizigiye D, Nyandwi J. BMC Genomics. 2023 Jun 10;24(1):312. doi: 10.1186/s12864-023-09420-3. PMID: 37301830

Intertwined Dysregulation of Ribosomal Proteins and Immune Response Delineates SARS-CoV-2 Vaccination Breakthroughs.
Maurya R, Shamim U, Mishra P, Swaminathan A, Raina A, Tarai B, Budhiraja S, Pandey R. Microbiol Spectr. 2023 Jun 15;11(3):e0429222. doi: 10.1128/spectrum.04292-22. Epub 2023 Apr 6. PMID: 37022180

"It kinda has like a mind": Children's and parents' beliefs concerning viral disease transmission for COVID-19 and the common cold.
Labotka D, Gelman SA. Cognition. 2023 Jun;235:105413. doi: 10.1016/j.cognition.2023.105413. Epub 2023 Feb 21. PMID: 36842249

Broad and Durable Humoral Responses Following Single Hydrogel Immunization of SARS-CoV-2 Subunit Vaccine.
Ou BS, Saouaf OM, Yan J, Bruun TUJ, Baillet J, Zhou X, King NP, Appel EA. Adv Healthc Mater. 2023 Jun 6:e2301495. doi: 10.1002/adhm.202301495. Online ahead of print. PMID: 37278391

Severe Hepatitis-associated Aplastic Anemia Following COVID-19 mRNA Vaccination.
Yamamoto M, Keino D, Sumii S, Yokosuka T, Goto H, Inui A, Sogo T, Kawakami M, Tanaka M, Yanagimachi M. Intern Med. 2023 Jun 15;62(12):1813-1816. doi: 10.2169/internalmedicine.1308-22. Epub 2023 Mar 22. PMID: 36948624

Public sector's misinformation debunking during the public health campaign: a case of Hong Kong.
Zhu R, Zhang X. Health Promot Int. 2023 Jun 1;38(3):daad053. doi: 10.1093/heapro/daad053. PMID: 37279470

RE: "RISK AND BENEFIT OF mRNA COVID-19 VACCINES FOR THE OMICRON VARIANT BY AGE, SEX, AND PRESENCE OF COMORBIDITY: A QUALITY-ADJUSTED LIFE YEARS ANALYSIS".
Kleebayoon A, Wiwanitkit V. Am J Epidemiol. 2023 Jun 2;192(6):1031. doi: 10.1093/aje/kwad069. PMID: 36958820

Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
Bordalo Ferreira F, Rafael MA, Coimbra L, Boavida N, Arrobas F, Pereira Correia F, Martins Figueiredo L, Carvalho E Branco J, Carvalho Lourenço L, Santos L, Oliveira AM. Vaccine. 2023 Jun 13;41(26):3862-3871. doi: 10.1016/j.vaccine.2023.05.012. Epub 2023 May 8. PMID: 37202269

Risk factors for reduction in adherence to protective measures following coronavirus disease 2019 (COVID-19) vaccination and vaccine perceptions among healthcare workers, in São Paulo, Brazil.
Mello López A, Borges IC, Luna-Muschi A, Mesquita Peres CH, Carreño PG, de Oliveira AM, de Almeida HBS, de Castro Marques VH, Corchs F, Levin AS, Costa SF, Sartori AMC. Infect Control Hosp Epidemiol. 2023 Jun;44(6):1019-1021. doi: 10.1017/ice.2022.142. Epub 2022 May 26. PMID: 35615951

Myositis unrelated to the inoculation site after COVID-19 vaccination: a case report.
Han JW, Oh JM, Lee DH, Jeon YD. Clin Shoulder Elb. 2023 Jun;26(2):208-211. doi: 10.5397/cise.2022.00983. Epub 2022 Nov 11. PMID: 37088882

Hypocomplementemic urticarial vasculitis case with hemophagocytic lymphohistiocytosis following SARS-CoV-2 mRNA vaccination.
Iwamura N, Eguchi K, Koga T, Tsutsumi K, Araki T, Aramaki T, Takatani A, Terada K, Ueki Y. Immunol Med. 2023 Jun;46(2):97-107. doi: 10.1080/25785826.2023.2193286. Epub 2023 Mar 23. PMID: 36950829

Heterologous versus homologous primary and booster COVID-19 vaccination do not increase flare rate in patients with psoriasis and/or psoriatic arthritis: Insights from a real-life, multicenter, case-control study.

Mercuri SR, Pacifico A, Malagoli P, Bianchi VG, Pregliasco FE, Del Fabbro M, Damiani G. J Eur Acad Dermatol Venereol. 2023 Jun;37(6):e693-e694. doi: 10.1111/jdv.18943. Epub 2023 Feb 15. PMID: 36734591

Risk factors associated with mortality in hospitalized patients with laboratory confirmed SARS-CoV-2 infection during the period of omicron (B.1.1.529) variant predominance.
O'Leary AL, Wattengel BA, Carter MT, Drye AF, Mergenhagen KA. Am J Infect Control. 2023 Jun;51(6):603-606. doi: 10.1016/j.ajic.2022.08.033. Epub 2022 Sep 6. PMID: 36075298

Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults.
Dedroogh S, Schmiedl S, Thürmann PA, Graf K, Appelbaum S, Koß R, Theis C, Zia Z, Tebbenjohanns J, Thal SC, Dedroogh M. Sci Rep. 2023 Jun 3;13(1):9036. doi: 10.1038/s41598-023-34961-8. PMID: 37270632

Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster.
Lloren KKS, Jawalagatti V, Hewawaduge C, Chandran S, Park JY, Lee JH. Microbes Infect. 2023 Jun;25(5):105101. doi: 10.1016/j.micinf.2023.105101. Epub 2023 Jan 16. PMID: 36657635

High-Throughput SARS-CoV-2 Antiviral Testing Method Using the Celigo Image Cytometer.
St Clair LA, Chan LL, Boretsky A, Lin B, Spedding M, Perera R. J Fluoresc. 2023 Jun 13. doi: 10.1007/s10895-023-03289-x. Online ahead of print. PMID: 37310590

Testing persuasive messages about booster doses of COVID-19 vaccines on intention to vaccinate in Australian adults: A randomised controlled trial.
Steffens MS, Bullivant B, Kaufman J, King C, Danchin M, Hoq M, Marques MD. PLoS One. 2023 Jun 2;18(6):e0286799. doi: 10.1371/journal.pone.0286799. eCollection 2023. PMID: 37267399

Real time monitoring of COVID-19 intervention effectiveness through contact tracing data.
Gibson GC, Woody S, James E, Weldon M, Fox SJ, Meyers LA, Bhavnani D. Sci Rep. 2023 Jun 9;13(1):9371. doi: 10.1038/s41598-023-35892-0. PMID: 37296143

The readiness of the spontaneous reporting system for COVID-19 vaccines safety monitoring in Croatia.
Kovačić B, Pavičić M, Skvrce NM, Tomić S. Acta Pharm. 2023 Jun 12;73(2):293-310. doi: 10.2478/acph-2023-0029. Print 2023 Jun 1. PMID: 37307371

Impact of vaccination against the novel coronavirus infection (COVID-19) with Sputnik V on mortality during the delta variant surge.
Dmitrieva K, Maslennikov R, Vasilieva E, Aliev S, Bakhitov V, Marcinkevich V, Levshina A, Kozlov E, Ivashkin V, Poluektova E. J Infect Public Health. 2023 Jun;16(6):922-927. doi: 10.1016/j.jiph.2023.04.008. Epub 2023 Apr 13. PMID: 37086551

Willingness of Older Adults From Culturally Diverse Populations to Participate in COVID-19 Related Treatment Trials and Associated Factors.
Brown EL, Paul-Ward A, Felber Neff D, Webb FJ, Vieira ER, Gaillard T. Gerontol Geriatr Med. 2023 Jun 9;9:23337214231179826. doi: 10.1177/23337214231179826. eCollection 2023 Jan-Dec. PMID: 37324645

Late onset granulomatous interstitial nephritis after booster dose of COVID-19 vaccination: Case report and review of literature.
Ghanekar K, Ghanekar H, Saxena R. Clin Nephrol. 2023 Jun;99(6):299-306. doi: 10.5414/CN110965. PMID: 36999525

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration.
Zhang C, Berg A, Joe CCD, Dalby PA, Douglas AD. NPJ Vaccines. 2023 Jun 5;8(1):85. doi: 10.1038/s41541-023-00674-2. PMID: 37277337

Molecular dynamic and bioinformatic studies of metformin-induced ACE2 phosphorylation in the presence of different SARS-CoV-2 S protein mutations.
Ahmed El-Arabey A, Abdalla M, Rashad Abd-Allah A, Marenga HS, Modafer Y, Aloufi AS. Saudi J Biol Sci. 2023 Jul;30(7):103699. doi: 10.1016/j.sjbs.2023.103699. Epub 2023 Jun 3. PMID: 37292255

Development of Dermatomyositis after Pfizer BioNTeh COVID-19 Vaccine: A Case Report.
Aouintia I, Daly W, Lakhoua G, Kaabi W, Charfi O, Debbeche S, Kastalli S, Zaiem A, El Aidli S. Curr Drug Saf. 2023 Jun 14. doi: 10.2174/1574886318666230614164607. Online ahead of print. PMID: 37317919

Challenges in Conducting Therapeutic Trials in Pregnancy: Emphasizing Recent Lessons Learned.
Bank TC, Stika CS, Venkataramanan R, Field C, Costantine MM. J Clin Pharmacol. 2023 Jun;63 Suppl 1:S117-S125. doi: 10.1002/jcph.2226. PMID: 37317490

Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.
Kaur U, Fatima Z, Maheshwari K, Sahni V, Dehade A, Kl A, Yadav AK, Kansal S, Jaisawal V, Chakrabarti SS. Drug Saf. 2023 Jun;46(6):553-563. doi: 10.1007/s40264-023-01301-8. Epub 2023 May 3. PMID: 37133805

Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response.
Wang X, Yuen TT, Dou Y, Hu J, Li R, Zeng Z, Lin X, Gong H, Chan CH, Yoon C, Shuai H, Ho DT, Hung IF, Zhang BZ, Chu H, Huang JD. Nat Commun. 2023 Jun 10;14(1):3440. doi: 10.1038/s41467-023-39096-y. PMID: 37301910

The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
Brzuska G, Zimna M, Baranska K, Szewczyk B, Strakova P, Ruzek D, Krol E. Microbiol Spectr. 2023 Jun 15;11(3):e0256422. doi: 10.1128/spectrum.02564-22. Epub 2023 May 18. PMID: 37199661

A sting in the tail-are antibodies against the C-terminus of Plasmodium falciparum circumsporozoite protein protective?
Murdoch J, Baum J. EMBO Mol Med. 2023 Jun 7;15(6):e17556. doi: 10.15252/emmm.202317556. Epub 2023 Apr 21. PMID: 37082835

A randomized controlled trial of an information intervention to bolster COVID-19 vaccination intention among people with purity concerns.

Chen C, Cui Z, Chen Y. Health Psychol. 2023 Jun 1. doi: 10.1037/hea0001295. Online ahead of print. PMID: 37261752

New-onset acute psychosis as a manifestation of lupus cerebritis following concomitant COVID-19 infection and vaccination: a rare case report.
Fekih-Romdhane F, Ghrissi F, Hallit S, Cheour M. BMC Psychiatry. 2023 Jun 12;23(1):419. doi: 10.1186/s12888-023-04924-4. PMID: 37308940

Immunization with Recombinant Accessory Protein-Deficient SARS-CoV-2 Protects against Lethal Challenge and Viral Transmission.
Ye C, Park JG, Chiem K, Dravid P, Allué-Guardia A, Garcia-Vilanova A, Pino Tamayo P, Shivanna V, Kapoor A, Walter MR, Kobie JJ, Plemper RK, Torrelles JB, Martinez-Sobrido L. Microbiol Spectr. 2023 Jun 15;11(3):e0065323. doi: 10.1128/spectrum.00653-23. Epub 2023 May 16. PMID: 37191507

Long-term real-world protection afforded by third mRNA doses against symptomatic SARS-COV-2 infections, COVID-19-related emergency attendances and hospitalizations amongst older Singaporeans during an Omicron XBB wave.
Wee LE, Pang D, Chiew C, Tan J, Lee V, Ong B, Lye DC, Tan KB. Clin Infect Dis. 2023 Jun 6:ciad345. doi: 10.1093/cid/ciad345. Online ahead of print. PMID: 37280047

Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment.
Böger S, van Bergen I, Beaudart C, Cheung KL, Hiligsmann M. Expert Rev Pharmacoecon Outcomes Res. 2023 Jun 14:1-11. doi: 10.1080/14737167.2023.2223983. Online ahead of print. PMID: 37294709

Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study.
Andreica I, Roman I, Redeker I, Baraliakos X, Braun J, Kiltz U. RMD Open. 2023 Jun;9(2):e002875. doi: 10.1136/rmdopen-2022-002875. PMID: 37295840

The health impact of long COVID during the 2021-2022 Omicron wave in Australia: a quantitative burden of disease study.
Howe S, Szanyi J, Blakely T. Int J Epidemiol. 2023 Jun 6;52(3):677-689. doi: 10.1093/ije/dyad033. PMID: 37011639

Microbiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: A multicenter observational study.
Aydin MA, Janapatla RP, Chen CL, Li HC, Su LH, Chiu CH. J Microbiol Immunol Infect. 2023 Jun;56(3):598-604. doi: 10.1016/j.jmii.2023.01.013. Epub 2023 Feb 2. PMID: 36774315

Correspondence on "Effect of female COVID-19 vaccination on assisted reproductive outcomes: a systematic review and meta-analysis".
Kleebayoon A, Wiwanitkit V. Fertil Steril. 2023 Jun;119(6):1087. doi: 10.1016/j.fertnstert.2023.02.017. Epub 2023 Feb 17. PMID: 36805043

Predictors of low spike antibody response in patients with systemic rheumatic disease after an initial course of COVID-19 vaccination.

Whelan MG, Santacroce L, Masto L, Qian G, Kowalski E, Vanni K, Kanjilal S, Weinblatt ME, Sparks JA, Tedeschi SK. Clin Rheumatol. 2023 Jun;42(6):1695-1700. doi: 10.1007/s10067-023-06512-z. Epub 2023 Jan 19. PMID: 36656454

Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients.
Kashiwado Y, Kimoto Y, Ohshima S, Sawabe T, Irino K, Nakano S, Hiura J, Yonekawa A, Wang Q, Doi G, Ayano M, Mitoma H, Ono N, Arinobu Y, Niiro H, Hotta T, Kang D, Shimono N, Akashi K, Takeuchi T, Horiuchi T. Rheumatology (Oxford). 2023 Jun 8:kead275. doi: 10.1093/rheumatology/kead275. Online ahead of print. PMID: 37289506

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Shaw RH, Greenland M, Stuart ASV, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, Darton T, Dinesh T, Duncan CJA, Faust SN, Ferreira DM, Finn A, Goodman AL, Green CA, Hallis B, Heath PT, Hill H, Lambe T, Libri V, Lillie PJ, Morey E, Mujadidi YF, Payne R, Plested EL, Provstgaard-Morys S, Ramasamy MN, Ramsay M, Read RC, Robinson H, Screaton GR, Singh N, Turner DPJ, Turner PJ, White R, Nguyen-Van-Tam JS, Liu X, Snape MD; Com-COV2 Study Group. J Infect. 2023 Jun;86(6):574-583. doi: 10.1016/j.jinf.2023.03.027. Epub 2023 Apr 6. PMID: 37028454

Clinical trial facilitators: A novel approach to support the execution of clinical research at the study site level.
McClure J, Asghar A, Krajec A, Johnson MR, Subramanian S, Caroff K, McBurney C, Perusich S, Garcia A, Beck DJ, Huang GD. Contemp Clin Trials Commun. 2023 Jun;33:101106. doi: 10.1016/j.conctc.2023.101106. Epub 2023 Mar 21. PMID: 37063166

IgA antibody dynamics in healthcare workers after CoronaVac® vaccination and heterologous Comirnaty® booster dose.
Bochnia-Bueno L, Ferreira LH, Genelhoud G, Nogueira MB, Raboni SM. Braz J Microbiol. 2023 Jun;54(2):921-927. doi: 10.1007/s42770-023-00935-1. Epub 2023 Mar 2. PMID: 36862369

Seroprevalence of SARS-CoV-2 in hospital workers in the southern region of Minas Gerais state in Brazil: An analysis of the pre-vaccine period.
Caixeta DA, do Carmo MAV, da Fonseca FG, Nogueira DA, Coelho LFL, Malaquias LCC. Braz J Microbiol. 2023 Jun;54(2):859-871. doi: 10.1007/s42770-023-00966-8. Epub 2023 Apr 13. PMID: 37052752

Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines.
Milevoj Kopcinovic L, Unic A, Nikolac Gabaj N, Miler M, Vrtaric A, Bozovic M, Stefanovic M. Lab Med. 2023 Jun 9:lmad044. doi: 10.1093/labmed/lmad044. Online ahead of print. PMID: 37294928

From high hopes to disenchantment: A qualitative analysis of editorial cartoons on COVID-19 vaccines in Canadian newspapers.
Pelletier C, Labbé F, Bettinger JA, Curran J, Graham JE, Greyson D, MacDonald NE, Meyer SB, Steenbeek A, Xu W, Dubé È. Vaccine. 2023 Jun 6:S0264-410X(23)00658-8. doi: 10.1016/j.vaccine.2023.06.002. Online ahead of print. PMID: 37302965

Time of day for COVID vaccine administration linked to clinical effectiveness.
Rasmussen-Torvik LJ. J Clin Invest. 2023 Jun 1;133(11):e168233. doi: 10.1172/JCI168233. PMID: 37259919

Perceived high risk of COVID-19 vaccination: The revealing power of placebo.
Beyens M, Toscano A, Van Damme P, Dogné JM, Ebo DG, Sabato V. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1954-1956. doi: 10.1016/j.jaip.2023.03.031. Epub 2023 Mar 24. PMID: 36965707

Humoral and cellular responses to SARS-CoV-2 vaccination in patients with autoantibody-mediated neuroimmunology.
Kihara K, Kinoshita M, Sugimoto T, Okazaki S, Murata H, Beppu S, Shiraishi N, Sugiyama Y, Koda T, Okuno T, Mochizuki H. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):495-497. doi: 10.1136/jnnp-2022-330478. Epub 2023 Jan 3. PMID: 36596701

High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022.
Groenheit R, Bacchus P, Galanis I, Sondén K, Bujila I, Efimova T, Garli F, Lindsjö OK, Mansjö M, Movert E, Pettke A, Rapp M, Sperk M, Söderholm S, Asin KV, Zanetti S, Karlberg ML, Bråve A, Blom K, Klingström J. Emerg Infect Dis. 2023 Jun;29(6):1240-1243. doi: 10.3201/eid2906.221862. Epub 2023 May 4. PMID: 37141616

Pre-existing humoral immunity and CD4$^+$ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination.
Shen CF, Fu YC, Ho TS, Chen PL, Lee NY, Tsai BY, Tsai PJ, Ko WC, Liu CC, Cheng CM, Shieh CC. Clin Immunol. 2023 Jun;251:109342. doi: 10.1016/j.clim.2023.109342. Epub 2023 Apr 24. PMID: 37100338

In response to Detection of SARS-CoV-2 IgA and IgG in human milk and breastfeeding infant stool 6 months after maternal COVID-19 vaccination.
Cosentino M, Marino F. J Perinatol. 2023 Jun;43(6):827. doi: 10.1038/s41372-023-01669-6. Epub 2023 Apr 25. PMID: 37185365

Blaming the unvaccinated during the COVID-19 pandemic: the roles of political ideology and risk perceptions in the USA.
Graso M, Aquino K, Chen FX, Bardosh K. J Med Ethics. 2023 Jun 9:jme-2022-108825. doi: 10.1136/jme-2022-108825. Online ahead of print. PMID: 37295936

Risk of admission to hospital with arterial or venous thromboembolism among patients diagnosed in the ambulatory setting with covid-19 compared with influenza: retrospective cohort study.
Lo Re V 3rd, Dutcher SK, Connolly JG, Perez-Vilar S, Carbonari DM, DeFor TA, Djibo DA, Harrington LB, Hou L, Hennessy S, Hubbard RA, Kempner ME, Kuntz JL, McMahill-Walraven CN, Mosley J, Pawloski PA, Petrone AB, Pishko AM, Rogers Driscoll M, Steiner CA, Zhou Y, Cocoros NM. BMJ Med. 2023 Jun 6;2(1):e000421. doi: 10.1136/bmjmed-2022-000421. eCollection 2023. PMID: 37303490

Recombinant Bacillus Calmette-Guérin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge.
Mambelli F, Marinho FV, Andrade JM, de Araujo ACVSC, Abuna RPF, Fabri VMR, Santos BPO, da Silva JS, de Magalhães MTQ, Homan EJ, Leite LCC, Dias GBM, Heck N, Mendes DAGB, Mansur DS, Báfica A,

Oliveira SC. J Immunol. 2023 Jun 15;210(12):1925-1937. doi: 10.4049/jimmunol.2200731. PMID: 37098890

Estimation of Intangible Costs for Factors Associated with Oral Antiviral Drugs for COVID-19 Treatment: A Conjoint Analysis in Japan.
Hosogaya N, Takazono T, Kurazono K, Hiroi S, Iwasaki K, Takeshima T, Ha C, Mukae H. Adv Ther. 2023 Jun 12. doi: 10.1007/s12325-023-02564-4. Online ahead of print. PMID: 37303032

Comparison of Clinical Characteristics of Children Infected With Coronavirus Disease 2019 Between Omicron Variant BA.5 and BA.1/BA.2 in Japan.
Ikuse T, Aizawa Y, Yamanaka T, Hasegawa S, Hayashi T, Kon M, Tamura T, Saitoh A. Pediatr Infect Dis J. 2023 Jun 1;42(6):503-509. doi: 10.1097/INF.0000000000003894. Epub 2023 Mar 2. PMID: 36916865

High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity.
Nuñez NG, Schmid J, Power L, Alberti C, Krishnarajah S, Kreutmair S, Unger S, Blanco S, Konigheim B, Marín C, Onofrio L, Kienzler JC, Costa-Pereira S, Ingelfinger F; InmunoCovidCba; InViV working group; Pasinovich ME, Castelli JM, Vizzotti C, Schaefer M, Villar-Vesga J, Mundt S, Merten CH, Sethi A, Wertheimer T, Lutz M, Vanoaica D, Sotomayor C, Gruppi A, Münz C, Cardozo D, Barbás G, Lopez L, Carreño P, Castro G, Raboy E, Gallego S, Morón G, Cervi L, Acosta Rodriguez EV, Maletto BA, Maccioni M, Becher B. Nat Immunol. 2023 Jun;24(6):941-954. doi: 10.1038/s41590-023-01499-w. Epub 2023 Apr 24. PMID: 37095378

Pathways to Immunity: Patterns of Excess Death Across the United States and Within Closed Religious Communities.
Stein RE, Colyer CJ, Corcoran KE, Mackay AM. J Relig Health. 2023 Jun 1:1-16. doi: 10.1007/s10943-023-01838-z. Online ahead of print. PMID: 37261578

On a collision course: SARS-CoV-2 variants and CAR T cells.
Auletta JJ. Blood Adv. 2023 Jun 13;7(11):2643-2644. doi: 10.1182/bloodadvances.2023010371. PMID: 37310762

Risk of breakthrough SARS-CoV-2 infection and clinical outcomes among vaccinated patients with type 2 diabetes.
Bea S, Choi A, Kim JH, Cho YM, Choi WS, Jung J, Shin JY. Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15163. Online ahead of print. PMID: 37312652

Best practice implementation on reporting of coronavirus disease 2019 vaccine adverse events following immunization in Uasin Gishu County, Kenya.
Amdany H, Koech B. JBI Evid Implement. 2023 Jun 1;21(2):146-155. doi: 10.1097/XEB.0000000000000362. PMID: 36545897

RNase2 is a possible trigger of acute-on-chronic inflammation leading to mRNA vaccine-associated cardiac complication.
Ong EZ, Koh CWT, Tng DJH, Ooi JSG, Yee JX, Chew VSY, Leong YS, Gunasegaran K, Yeo CP, Oon LLE, Sim JXY, Chan KR, Low JG, Ooi EE. Med. 2023 Jun 9;4(6):353-360.e2. doi: 10.1016/j.medj.2023.04.001. Epub 2023 Apr 26. PMID: 37105176

Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease.
Nakahara H, Cheedarla N, Verkerke HP, Cheedarla S, Wu SC, Hendrickson JE, Chang A, McLemore ML, El Rassi F, Roback JD, Neish AS, Fasano RM, Stowell SR. Br J Haematol. 2023 Jun 7. doi: 10.1111/bjh.18899. Online ahead of print. PMID: 37287128

Editorial response to Cosentino and Marino RE: detection of SARS-CoV-2 IgA and IgG in human milk and breastfeeding infant stool 6 months after maternal COVID-19 vaccination.
Stafford LS, Valcarce V, Henry M, Neu J, Parker L, Mueller M, Vicuna V, Gowen T, Cato E, Kosik I, Yewdell JW, Atkinson M, Cacho N, Li N, Larkin J 3rd. J Perinatol. 2023 Jun;43(6):828-829. doi: 10.1038/s41372-023-01660-1. Epub 2023 Apr 6. PMID: 37024528

Comparison of a rapid fluorescence immunochromatographic test with an enzyme-linked immunosorbent assay for measurement of SARS-CoV-2 spike protein antibody neutralizing activity.
Filippatos F, Tatsi EB, Papagiannopoulos C, Syriopoulou V, Michos A. J Virol Methods. 2023 Jun;316:114728. doi: 10.1016/j.jviromet.2023.114728. Epub 2023 Apr 5. PMID:

Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID).
Navarro R, Paredes JL, Tucto L, Medina C, Angles-Yanqui E, Nario JC, Ruiz-Cabrejos J, Quintana JL, Turpo-Espinoza K, Mejia-Cordero F, Aphang-Lam M, Florez J, Carrasco-Escobar G, Ochoa TJ. Biometals. 2023 Jun;36(3):463-472. doi: 10.1007/s10534-022-00477-3. Epub 2022 Dec 7. PMID: 36474100

Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status - United States, April 2021-September 2022.
Jones JM, Manrique IM, Stone MS, Grebe E, Saa P, Germanio CD, Spencer BR, Notari E, Bravo M, Lanteri MC, Green V, Briggs-Hagen M, Coughlin MM, Stramer SL, Opsomer J, Busch MP. MMWR Morb Mortal Wkly Rep. 2023 Jun 2;72(22):601-605. doi: 10.15585/mmwr.mm7222a3. PMID: 37262007

Safety of COVID-19 vaccines: A comparison between adverse drug reactions among vaccines marketed in Europe.
Pardo-Cabello AJ, Manzano-Gamero V, Luna JD. Eur J Intern Med. 2023 Jun;112:122-125. doi: 10.1016/j.ejim.2023.02.014. Epub 2023 Feb 13. PMID: 36792428

Status of HBV birth dose vaccination in Africa: the impact of COVID-19 and Gavi support on policy development.
Njuguna HN, Hiebert L, Gupta N, Ward JW. Lancet Gastroenterol Hepatol. 2023 Jun;8(6):502-503. doi: 10.1016/S2468-1253(23)00071-7. Epub 2023 Mar 27. PMID: 36996854

An equity-focused approach to improving access to COVID-19 vaccination using mobile health clinics.
Mayfield CA, Priem JS, Inman M, Legare T, Snow J, Wallace E. Healthc (Amst). 2023 Jun;11(2):100690. doi: 10.1016/j.hjdsi.2023.100690. Epub 2023 Mar 23. PMID: 36996736

Association of SARS-CoV-2 Vaccination or Infection With Bell Palsy: A Systematic Review and Meta-analysis.
Rafati A, Pasebani Y, Jameie M, Yang Y, Jameie M, Ilkhani S, Amanollahi M, Sakhaei D, Rahimlou M, Kheradmand A. JAMA Otolaryngol Head Neck Surg. 2023 Jun 1;149(6):493-504. doi: 10.1001/jamaoto.2023.0160. PMID: 37103913

VITT two years later: should it still be in the scientific agenda?
Petito E, Gresele P. Thromb Haemost. 2023 Jun 7. doi: 10.1055/a-2107-0891. Online ahead of print. PMID: 37285904

A bioengineered pseudovirus nanoparticle displaying SARS-CoV 2 RBD fully protects mice from mortality and weight loss caused by SARS-CoV 2 challenge.
Xia M, López K, Vago FS, Huang P, Auguste DI, Jiang W, Auguste AJ, Tan M. Biotechnol J. 2023 Jun 10:e2300130. doi: 10.1002/biot.202300130. Online ahead of print. PMID: 37300425

Preferences and values for government policies on infectious disease outbreaks and epidemics for the Japanese population: a conjoint analysis.
Morita I, Kurazono K, Yoshida M, Hiroi S, Iwasaki K, Takeshima T, Ha C, Igarashi A. J Med Econ. 2023 Jun 14:1-33. doi: 10.1080/13696998.2023.2224167. Online ahead of print. PMID: 37313724

Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors.
Moon P, Zammit CM, Shao Q, Dovala D, Boike L, Henning NJ, Knapp M, Spradlin JN, Ward CC, Wolleb H, Fuller D, Blake G, Murphy JP, Wang F, Lu Y, Moquin SA, Tandeske L, Hesse MJ, McKenna JM, Tallarico JA, Schirle M, Toste FD, Nomura DK. Chembiochem. 2023 Jun 1;24(11):e202300116. doi: 10.1002/cbic.202300116. Epub 2023 May 3. PMID: 37069799

Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination.
Gumber L, Gomez N, Hopkins G, Tucis D, Bartlett L, Ayling K, Vedhara K, Steers G, Chakravorty M, Rutter M, Jackson H, Tighe P, Ferraro A, Power S, Pradère MJ, Onion D, Lanyon PC, Pearce FA, Fairclough L. Rheumatology (Oxford). 2023 Jun 1;62(6):2294-2303. doi: 10.1093/rheumatology/keac574. PMID: 36250898

Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) outbreaks in nursing homes involving residents who had completed a primary coronavirus disease 2019 (COVID-19) vaccine series-13 US jurisdictions, July-November 2021.
Wyatt Wilson W, Keaton AA, Ochoa LG, Hatfield KM, Gable P, Walblay KA, Teran RA, Shea M, Khan U, Stringer G, Colletti JG, Grogan EM, Calabrese C, Hennenfent A, Perlmutter R, Janiszewski KA, Kamal-Ahmed I, Strand K, Berns E, MacFarquhar J, Linder M, Tran DJ, Kopp P, Walker RM, Ess R, Read JS, Yingst C, Baggs J, Jernigan JA, Kallen A, Hunter JC; MOVIN Surveillance Team. Infect Control Hosp Epidemiol. 2023 Jun;44(6):1005-1009. doi: 10.1017/ice.2022.123. Epub 2023 Jan 16. PMID: 36645205

Four cases of audio-vestibular disorders related to immunisation with SARS-CoV-2 mRNA vaccines.
Ekobena P, Rothuizen LE, Bedussi F, Guilcher P, Meylan S, Ceschi A, Girardin F, Dao K. Int J Audiol. 2023 Jun;62(6):587-591. doi: 10.1080/14992027.2022.2056721. Epub 2022 May 5. PMID: 35510657

Reporting dinaciclib and theodrenaline as a multitargeted inhibitor against SARS-CoV-2: an *in-silico* study.
Ahmad S, Pasha Km M, Raza K, Rafeeq MM, Habib AH, Eswaran M, Yadav MK. J Biomol Struct Dyn. 2023 Jun;41(9):4013-4023. doi: 10.1080/07391102.2022.2060308. Epub 2022 Apr 22. PMID: 35451934

Antibody acquisition after second and third SARS-CoV-2 vaccinations in Japanese kidney transplant patients: a prospective study.

Deguchi H, Sakamoto A, Nakamura N, Okabe Y, Miura Y, Iida T, Yoshimura M, Haga N, Nabeshima S, Masutani K. Clin Exp Nephrol. 2023 Jun;27(6):574-582. doi: 10.1007/s10157-023-02334-0. Epub 2023 Mar 13. PMID: 36914824

Subacute monomelic radiculoplexus neuropathy following Comirnaty© (Pfizer-BioNTech COVID-19) vaccination: A case report.
Coly M, Balcerac A, Brasseur N, Sallansonnet-Froment M, Tafani C, Taifas I, Bréchemier ML, Drouard E, Foissaud V, Vest P, Vandendries C, Bompaire F, Bihan K, Ricard D. Rev Neurol (Paris). 2023 Jun;179(6):636-639. doi: 10.1016/j.neurol.2023.02.063. Epub 2023 Mar 14. PMID: 36925320

The WHO pandemic treaty: where are we on our scepticism?
Evaborhene NA, Oga JO, Nneli OV, Mburu S. BMJ Glob Health. 2023 Jun;8(6):e012636. doi: 10.1136/bmjgh-2023-012636. PMID: 37316254

Postoperative mortality and complications in patients with and without pre-operative SARS-CoV-2 infection: a service evaluation of 24 million linked records using OpenSAFELY.
McInerney CD, Kotzé A, Bacon S, Cutting JE, Fisher L, Goldacre B, Johnson OA, Kua J, McGuckin D, Mehrkar A; OpenSAFELY Collaborative; Moonesinghe SR. Anaesthesia. 2023 Jun;78(6):692-700. doi: 10.1111/anae.16001. Epub 2023 Mar 23. PMID: 36958018

A novel mathematical model for prioritization of individuals to receive vaccine considering governmental health protocols.
Shamsi Gamchi N, Esmaeili M. Eur J Health Econ. 2023 Jun;24(4):633-646. doi: 10.1007/s10198-022-01491-5. Epub 2022 Jul 28. PMID: 35900675

High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey.
Grignaschi S, Kim M, Zanframundo G, Ravichandran N, Lilleker JB, Sen P, Joshi M, Agarwal V, Kardes S, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Chatterjee T, Tan AL, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Nune A, Distler O, Chinoy H, Cavagna L, Agarwal V, Aggarwal R, Gupta L; COVAD study group. Rheumatol Int. 2023 Jun 14. doi: 10.1007/s00296-023-05344-z. Online ahead of print. PMID: 37314497

Brief Report: Declining Rates of SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies.
Meador CB, Naranbhai V, Hambelton G, Rivera J, Nabel CS, Lewinsohn R, Sakhi M, Balazs AB, Iafrate AJ, Gainor JF. Clin Lung Cancer. 2023 Jun;24(4):353-359. doi: 10.1016/j.cllc.2023.01.007. Epub 2023 Jan 25. PMID: 36792425

SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination.
Monin MB, Baier L, Berger M, Gorny JG, Zhou T, Mahn R, Sadeghlar F, Möhring C, van Bremen K, Boesecke C, Rockstroh J, Strassburg C, Eis-Hübinger AM, Gonzalez-Carmona MA. Gut. 2023 Jun;72(6):1227-1229. doi: 10.1136/gutjnl-2022-328169. Epub 2022 Jul 26. PMID: 35882561

Invasive meningococcal disease in Norway in the two decades before the COVID-19 pandemic.
Brynildsrud OB, Watle SV, Alfsnes K, Caugant DA. Int J Infect Dis. 2023 Jun;131:130-139. doi: 10.1016/j.ijid.2023.04.005. Epub 2023 Apr 7. PMID: 37030654

Myocarditis in Australian children following SARS-CoV-2 infection or COVID-19 vaccination: a retrospective case series.
Walker P, Lai TC, Schrader S, Crawford N, Cheng DR. Med J Aust. 2023 Jun 5;218(10):482-483. doi: 10.5694/mja2.51922. Epub 2023 Apr 15. PMID: 37061225

Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP, Chen C, Zhao S, Sun Y, Yiu K, Chan TO, Lai HL, Lai KC, Lau KM, Ling KC, Chan KKP, Ng SS, Ko FW, Peiris M, Hui DS. Lancet Microbe. 2023 Jun;4(6):e418-e430. doi: 10.1016/S2666-5247(23)00006-X. Epub 2023 Apr 20. PMID: 37086735

A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma.
Suzuki T, Kusumoto S, Kamezaki Y, Hashimoto H, Nishitarumizu N, Nakanishi Y, Kato Y, Kawai A, Matsunaga N, Ebina T, Nakamura T, Marumo Y, Oiwa K, Kinoshita S, Narita T, Ito A, Inagaki A, Ri M, Komatsu H, Aritsu T, Iida S. Int J Hematol. 2023 Jun;117(6):900-909. doi: 10.1007/s12185-023-03550-w. Epub 2023 Feb 15. PMID: 36790667

Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans.
Arunachalam PS, Scott MKD, Hagan T, Li C, Feng Y, Wimmers F, Grigoryan L, Trisal M, Edara VV, Lai L, Chang SE, Feng A, Dhingra S, Shah M, Lee AS, Chinthrajah S, Sindher SB, Mallajosyula V, Gao F, Sigal N, Kowli S, Gupta S, Pellegrini K, Tharp G, Maysel-Auslender S, Hamilton S, Aoued H, Hrusovsky K, Roskey M, Bosinger SE, Maecker HT, Boyd SD, Davis MM, Utz PJ, Suthar MS, Khatri P, Nadeau KC, Pulendran B. Nature. 2023 Jun;618(7964):E18. doi: 10.1038/s41586-023-05977-x. PMID: 37225997

Intranasal administration of sodium nitroprusside augments antigen-specific mucosal and systemic antibody production in mice.
Tada R, Yamazaki H, Nagai Y, Takeda Y, Ohshima A, Kunisawa J, Negishi Y. Int Immunopharmacol. 2023 Jun;119:110262. doi: 10.1016/j.intimp.2023.110262. Epub 2023 May 5. PMID: 37150015

Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination.
Pezzati L, Milazzo L, Carrozzo G, Kullmann C, Oreni L, Beltrami M, Caronni S, Lai A, Caberlotto L, Ottomano C, Antinori S, Ridolfo AL. J Infect Chemother. 2023 Jun;29(6):624-627. doi: 10.1016/j.jiac.2023.03.002. Epub 2023 Mar 11. PMID: 36914095

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients.
Aleissa MM, Little JS, Davey S, Saucier A, Zhou G, Gonzalez-Bocco IH, Crombie JL, Looka A, Baden LR, Issa NC, Hammond SP, Jacobson CA, Sherman AC. Transplant Cell Ther. 2023 Jun;29(6):398.e1-398.e5. doi: 10.1016/j.jtct.2023.03.005. Epub 2023 Mar 9. PMID: 36906276

The association of neonatal SARS-CoV-2 anti-spike protein receptor-binding domain antibodies at delivery with infant SARS-CoV-2 infection under the age of 6 months: a prospective cohort study.
Oz-Alcalay L, Elron E, Davidovich R, Chodick G, Osovsky M, Chen R, Ashkenazi-Hoffnung L. Clin Microbiol Infect. 2023 Jun;29(6):789-794. doi: 10.1016/j.cmi.2023.01.023. Epub 2023 Feb 4. PMID: 36739973

Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab.
Bacova B, Kohutova Z, Zubata I, Gaherova L, Kucera P, Heizer T, Mikesova M, Karel T, Novak J. Clin Exp Med. 2023 Jun;23(2):371-379. doi: 10.1007/s10238-022-00809-0. Epub 2022 Mar 29. PMID: 35352210

Immune Thrombocytopenia Relapse in Patients Who Received mRNA COVID-19 Vaccines [Letter].
Ali A, Zafar SA, Zehra SS. J Blood Med. 2023 Jun 2;14:377-378. doi: 10.2147/JBM.S419849. eCollection 2023. PMID: 37288287

Inactivated SARS-CoV-2 vaccine does not increase the risk of relapse in patients with clinically inactive adult-onset Still's disease.
Hong X, Pan H, Su Y, Hu Q, Sun Y, Liu H, Cheng X, Ye J, Shi H, Meng J, Zhou Z, Jia J, Liu T, Wang M, Chen X, Ma Y, Tang Z, Wang F, Zhang H, You Y, Zhu D, Chen L, Yang C, Teng J, Chi H. Rheumatology (Oxford). 2023 Jun 1;62(6):2262-2266. doi: 10.1093/rheumatology/keac620. PMID: 36282541

Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD.
Li D, Debbas P, Mujukian A, Cheng S, Braun J, McGovern DPB, Melmed GY; CORALE-IBD Study Group. Inflamm Bowel Dis. 2023 Jun 1;29(6):883-887. doi: 10.1093/ibd/izac174. PMID: 35998072

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated with AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
Tuffy KM, Ahani B, Aksyuk AA, Avila M, Brady T, Kijak GH, Koh G, Levin MJ, Roe TL, Schuko N, Thissen J, Ustianowski A, Zhang T, Kelly EJ, Streicher K. J Infect Dis. 2023 Jun 6:jiad210. doi: 10.1093/infdis/jiad210. Online ahead of print. PMID: 37280116

SARS-CoV-2 incubation period across variants of concern, individual factors, and circumstances of infection in France: a case series analysis from the ComCor study.
Galmiche S, Cortier T, Charmet T, Schaeffer L, Chény O, von Platen C, Lévy A, Martin S, Omar F, David C, Mailles A, Carrat F, Cauchemez S, Fontanet A. Lancet Microbe. 2023 Jun;4(6):e409-e417. doi: 10.1016/S2666-5247(23)00005-8. Epub 2023 Apr 18. PMID: 37084751

Lower frequency of SARS-CoV-2-associated severe respiratory infections among adults vaccinated against the 2021/22 season influenza.
Domnich A, Milano G, Capitani E, Camarri A, Bova G, Capecchi PL, Montomoli E, Manini I. Respir Med Res. 2023 Jun;83:100979. doi: 10.1016/j.resmer.2022.100979. Epub 2022 Nov 25. PMID: 36565562

The imprinting effect of covid-19 vaccines: an expected selection bias in observational studies.
Monge S, Pastor-Barriuso R, Hernán MA. BMJ. 2023 Jun 7;381:e074404. doi: 10.1136/bmj-2022-074404. PMID: 37286211

Diagnosing SARS-CoV-2 vaccination-related rhabdomyolysis requires the exclusion of all differential causes.
Finsterer J, Scorza FA. Pediatr Nephrol. 2023 Jun;38(6):1991-1992. doi: 10.1007/s00467-023-05890-5. Epub 2023 Jan 27. PMID: 36705756

Sex-specific differences in immune response to SARS-CoV-2 vaccination vanish with age.

Brigger D, Guntern P, Jonsdottir HR, Pennington LF, Weber B, Taddeo A, Zimmer G, Leborgne NGF, Benarafa C, Jardetzky TS, Eggel A. Allergy. 2023 Jun;78(6):1683-1686. doi: 10.1111/all.15652. Epub 2023 Jan 31. PMID: 36680391

Real-world practice of the Egyptian Kelleni's protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH.1.1 subvariants: a multi-purpose protocol.
Kelleni MT. Inflammopharmacology. 2023 Jun;31(3):1559-1560. doi: 10.1007/s10787-023-01180-6. Epub 2023 Mar 16. PMID: 36928633

Promoting and Building Long-Term Care Health Research Networks: GeroCovid Observational and Gerocovid Vax Initiatives.
GeroCovid Observational and GeroCovid Vax group. J Am Med Dir Assoc. 2023 Jun;24(6):926-927.e2. doi: 10.1016/j.jamda.2023.01.026. Epub 2023 Mar 3. PMID: 36878261

Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination.
Yoshida M, Kobashi Y, Kawamura T, Shimazu Y, Nishikawa Y, Omata F, Saito H, Yamamoto C, Zhao T, Takita M, Ito N, Tatsuno K, Kaneko Y, Nakayama A, Kodama T, Wakui M, Takahashi K, Tsubokura M. Sci Rep. 2023 Jun 7;13(1):9264. doi: 10.1038/s41598-023-36429-1. PMID: 37286720

Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination.
Kim H, Ahn HS, Hwang N, Huh Y, Bu S, Seo KJ, Kwon SH, Lee HK, Kim JW, Yoon BK, Fang S. Sci Rep. 2023 Jun 1;13(1):8926. doi: 10.1038/s41598-023-36070-y. PMID: 37264110

704/DNA vaccines leverage cytoplasmic DNA stimulation to promote anti-HIV neutralizing antibody production in mice and strong immune response against alpha-fetoprotein in non-human primates.
Colombani T, Haudebourg T, Pitard B. Mol Ther Nucleic Acids. 2023 May 4;32:743-757. doi: 10.1016/j.omtn.2023.04.029. eCollection 2023 Jun 13. PMID: 37251693

Transient plasma viral rebound after SARS-CoV-2 vaccination in an exceptional HIV-1 elite controller woman.
Di Girolamo L, Ferrara M, Trevisan G, Longo BM, Allice T, Burdino E, Alladio F, Fantino S, Di Perri G, Calcagno A, Bonora S. Virol J. 2023 Jun 13;20(1):123. doi: 10.1186/s12985-023-02086-z. PMID: 37312093

Immunization with messenger RNA vaccines against COVID-19 in adolescents with a history of multisystem inflammatory syndrome: a case series.
Curtti T, Agrimbau Vázquez J, Yori S, Kantarovsky A, Torolla J, Di Santo M, Hammermüller E, Urrutia L, Parra A. Arch Argent Pediatr. 2023 Jun 1;121(3):e202202757. doi: 10.5546/aap.2022-02757.eng. Epub 2022 Oct 6. PMID: 36194695

Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine dose.
Werbel WA, Karaba AH, Chiang TP, Massie AB, Brown DM, Watson N, Chahoud M, Thompson EA, Johnson AC, Avery RK, Cochran WV, Warren D, Liang T, Fribourg M, Huerta C, Samaha H, Klein SL, Bettinotti MP, Clarke WA, Sitaras I, Rouphael N, Cox AL, Bailey JR, Pekosz A, Tobian AAR, Durand CM,

Bridges ND, Larsen CP, Heeger PS, Segev DL; CPAT investigators. Am J Transplant. 2023 Jun;23(6):744-758. doi: 10.1016/j.ajt.2023.03.014. Epub 2023 Mar 24. PMID: 36966905

GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults.
Palmer CD, Scallan CD, Kraemer Tardif LD, Kachura MA, Rappaport AR, Koralek DO, Uriel A, Gitlin L, Klein J, Davis MJ, Venkatraman H, Hart MG, Jaroslavsky JR, Kounlavouth S, Marrali M, Nganje CN, Bae K, Yan T, Leodones K, Egorova M, Hong SJ, Kuan J, Grappi S, Garbes P, Jooss K, Ustianowski A. Nat Commun. 2023 Jun 6;14(1):3274. doi: 10.1038/s41467-023-39053-9. PMID: 37280238

Inactivated whole-virion SARS-CoV-2 vaccines and long-term clinical outcomes in patients with coronary atherosclerosis disease in China: a prospective cohort study.
Xu H, Zheng J, Zhao X, Zhou Q, Fan B, Wu H, Zhang S, Ge J. Cardiovasc Res. 2023 Jun 13;119(6):1352-1360. doi: 10.1093/cvr/cvad031. PMID: 36756815

Serological response after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy: a monocentric case-control study.
Montori M, Martini F, DE Blasio F, Buono T, Quatraccioni C, Guardati P, Calzolari M, Rossi C, Bendia E, Menzo S, Valenza C, Pellicano R, Maroni L, Benedetti A. Minerva Gastroenterol (Torino). 2023 Jun;69(2):268-276. doi: 10.23736/S2724-5985.22.03134-5. Epub 2022 Oct 18. PMID: 36255283

Response to Letter to the Editor: Post-Vaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease.
Bronsky J. J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):e90. doi: 10.1097/MPG.0000000000003760. Epub 2023 Mar 12. PMID: 36913707

Determination of mRNA copy number in degradable lipid nanoparticles via density contrast analytical ultracentrifugation.
Bepperling A, Richter G. Eur Biophys J. 2023 Jun 8:1-8. doi: 10.1007/s00249-023-01663-y. Online ahead of print. PMID: 37289289

Syndrome of inappropriate antidiuretic hormone and status epilepticus associated with mRNA-based SARS-CoV-2 vaccination.
Yang JW, Kim YR, Hong YA. Int Urol Nephrol. 2023 Jun;55(6):1645-1646. doi: 10.1007/s11255-022-03451-7. Epub 2022 Dec 30. PMID: 36581709

Ocular motility disorders after SARS-CoV-2 vaccination require the exclusion of all differential causes.
Finsterer J, Scorza FA. Graefes Arch Clin Exp Ophthalmol. 2023 Jun;261(6):1765-1766. doi: 10.1007/s00417-023-05991-9. Epub 2023 Feb 4. PMID: 36738346

Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.
Fallet B, Foglierini M, Porret R, Alcaraz A, Sauvage C, Jenelten R, Caplanusi T, Gilliet M, Perez L, Fenwick C, Genolet R, Harari A, Bobisse S, Gotardo R, Pantaleo G, Muller YD. J Infect. 2023 Jun 13:S0163-4453(23)00329-8. doi: 10.1016/j.jinf.2023.06.005. Online ahead of print. PMID: 37321353

More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants.
Monach PA, Branch-Elliman W. Lancet Infect Dis. 2023 Jun;23(6):654-655. doi: 10.1016/S1473-3099(23)00274-8. Epub 2023 Apr 26. PMID: 37119830

An isotope dilution mass spectrometry assay to track Norovirus-like particles in vaccine process intermediates by quantifying capsid protein VP1.
Jhingree JR, Boisvert J, Mercier G. Anal Methods. 2023 Jun 8;15(22):2729-2735. doi: 10.1039/d3ay00411b. PMID: 37199095

Oligonucleotide mapping via mass spectrometry to enable comprehensive primary structure characterization of an mRNA vaccine against SARS-CoV-2.
Gau BC, Dawdy AW, Wang HL, Bare B, Castaneda CH, Friese OV, Thompson MS, Lerch TF, Cirelli DJ, Rouse JC. Sci Rep. 2023 Jun 3;13(1):9038. doi: 10.1038/s41598-023-36193-2. PMID: 37270636

Commentary to Ocular dysmotility after SARS-CoV-2 vaccination requires the exclusion of all differential causes.
Park KA, Jeon H, Choi DG, Jung JH. Graefes Arch Clin Exp Ophthalmol. 2023 Jun;261(6):1767-1768. doi: 10.1007/s00417-023-05992-8. Epub 2023 Feb 15. PMID: 36790679

Waning cellular immune responses and predictive factors in maintaining cellular immunity against SARS-CoV-2 six months after BNT162b2 mRNA vaccination.
Ishii T, Hamada K, Jubishi D, Hashimoto H, Okamoto K, Hisasue N, Sunohara M, Saito M, Shinohara T, Yamashita M, Wakimoto Y, Otani A, Ikeda M, Harada S, Okugawa S, Moriya K, Yanagimoto S. Sci Rep. 2023 Jun 13;13(1):9607. doi: 10.1038/s41598-023-36397-6. PMID: 37311763

Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis.
Dai C, Dong ZY, Wang YN, Huang YH, Jiang M. Rev Esp Enferm Dig. 2023 Jun;115(6):306-314. doi: 10.17235/reed.2022.9264/2022. PMID: 36353949

Construction of Gene Expression Patterns to Identify Critical Genes under SARS-CoV-2 Infection Conditions.
Yu X, Li W, Wang J, Wu X, Sheng B. IEEE/ACM Trans Comput Biol Bioinform. 2023 Jun 7;PP. doi: 10.1109/TCBB.2023.3283534. Online ahead of print. PMID: 37285245

China's rolling COVID waves could hit every six months - infecting millions.
Ye Y. Nature. 2023 Jun;618(7965):442-443. doi: 10.1038/d41586-023-01872-7. PMID: 37286677

Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid.
Solimani F, Mesas-Fernández A, Bodner E, Carevic-Neri M, Hasheminasab M, Jakovljevicova T, Philipp A, Nast A, Worm M, Hilke FJ, Meier K, Ghoreschi K. J Eur Acad Dermatol Venereol. 2023 Jun;37(6):e695-e697. doi: 10.1111/jdv.18967. Epub 2023 Feb 27. PMID: 36786360

Empyema with an extensive retroperitoneal abscess after the first dose of the COVID-19 vaccine, a case report.

Yazdi SAM, Eshraghi N, Mirzaei S, Nazar E. Int J Surg Case Rep. 2023 Jun;107:108323. doi: 10.1016/j.ijscr.2023.108323. Epub 2023 May 13. PMID: 37201360

RNA editing: Expanding the potential of RNA therapeutics.
Booth BJ, Nourreddine S, Katrekar D, Savva Y, Bose D, Long TJ, Huss DJ, Mali P. Mol Ther. 2023 Jun 7;31(6):1533-1549. doi: 10.1016/j.ymthe.2023.01.005. Epub 2023 Jan 7. PMID: 36620962

Continuous surveillance and viral discovery in animals and humans are a core component of a one-health approach to address recent viral reverse zoonoses.
Kibenge FSB. J Am Vet Med Assoc. 2023 Apr 18;261(6):789-797. doi: 10.2460/javma.23.03.0148. Print 2023 Jun 1. PMID: 37072119

Investigating the association between the COVID-19 vaccination and incident gastrointestinal symptomology: A comprehensive dataset.
Houston KD, Hartnett J, Rose SJ. Data Brief. 2023 Jun;48:109287. doi: 10.1016/j.dib.2023.109287. Epub 2023 Jun 1. PMID: 37287691

Myocarditis and autoimmunity.
Matsumori A. Expert Rev Cardiovasc Ther. 2023 Jun;21(6):437-451. doi: 10.1080/14779072.2023.2219895. Epub 2023 Jun 2. PMID: 37243585

Highly attenuated poxvirus-based vaccines against emerging viral diseases.
Perdiguero B, Pérez P, Marcos-Villar L, Albericio G, Astorgano D, Álvarez E, Sin L, Elena Gómez C, García-Arriaza J, Esteban M. J Mol Biol. 2023 Jun 8:168173. doi: 10.1016/j.jmb.2023.168173. Online ahead of print. PMID: 37301278

Acute angle closure glaucoma following COVID-19 vaccination.
Salem Mahjoubi Y, Dahmani I, Souilem I, Aouinti I, Kastalli S, Daghfous R, El Aidli S. Therapie. 2023 Jun 7:S0040-5957(23)00082-3. doi: 10.1016/j.therap.2023.06.002. Online ahead of print. PMID: 37321945

Development of Nanopackaging for Storage and Transport of Loaded Lipid Nanoparticles.
Kaur A, Darvill D, Xiang S, Heng JYY, Petrov PK, Hoye RLZ, Chen R. Nano Lett. 2023 Jun 6. doi: 10.1021/acs.nanolett.3c01271. Online ahead of print. PMID: 37279451

Symmetrical Drug-Related Intertriginous Flexural Exanthema Induced by the Pfizer/BioNTech Comirnaty COVID-19 Vaccine.
Román Mendoza NM, Luna Bastante L, Sánchez Gilo A, Vicente Martin FJ. Actas Dermosifiliogr. 2023 Jun 5:S0001-7310(23)00420-9. doi: 10.1016/j.ad.2023.05.019. Online ahead of print. PMID: 37286077

Role of non-coding RNAs in tuberculosis and their potential for clinical applications.
Jumat MI, Sarmiento ME, Acosta A, Chin KL. J Appl Microbiol. 2023 Jun 1;134(6):lxad104. doi: 10.1093/jambio/lxad104. PMID: 37197901

Respiratory syncytial virus surge in 2022 caused by lineages already present before the COVID-19 pandemic.
Redlberger-Fritz M, Springer DN, Aberle SW, Camp JV, Aberle JH. J Med Virol. 2023 Jun;95(6):e28830. doi: 10.1002/jmv.28830. PMID: 37282809

Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies.
Bodner K, Irvine MA, Kwong JC, Mishra S. Int J Infect Dis. 2023 Jun;131:111-114. doi: 10.1016/j.ijid.2023.03.022. Epub 2023 Mar 27. PMID: 36990200

Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility.
Hale BG. Eur J Immunol. 2023 Jun;53(6):e2250164. doi: 10.1002/eji.202250164. PMID: 37027328

A Mobile-Based Preventive Intervention for Young, Arabic-Speaking Asylum Seekers During the COVID-19 Pandemic in Germany: Design and Implementation.
Frick U, Sipar D, Bücheler L, Haug F, Haug J, Almeqbaali KM, Pryss R, Rosner R, Comtesse H. JMIR Form Res. 2023 Jun 5;7:e44551. doi: 10.2196/44551. PMID: 37134019

Design and characterization of chimeric Rabies-SARS-CoV-2 virus-like particles for vaccine purposes.
Garay E, Fontana D, Villarraza J, Fuselli A, Gugliotta A, Antuña S, Tardivo B, Rodríguez MC, Gastaldi V, Battagliotti JM, Alvarez D, Castro E, Cassataro J, Ceaglio N, Prieto C. Appl Microbiol Biotechnol. 2023 Jun;107(11):3495-3508. doi: 10.1007/s00253-023-12545-w. Epub 2023 May 1. PMID: 37126083

[A national overview of the topics covered by young people in epidemiology: a comparison before and after the Covid-19.].
Ottone M, Petri D, Listorti E, Macciotta A, Moirano G, Murtas R, Renzi M, Asta F. Recenti Prog Med. 2023 Jun;114(6):309-315. doi: 10.1701/4042.40217. PMID: 37229671

Analysis of individual characteristics influencing user polarization in COVID-19 vaccine hesitancy.
Xie L, Wang D, Ma F. Comput Human Behav. 2023 Jun;143:107649. doi: 10.1016/j.chb.2022.107649. Epub 2023 Jan 17. PMID: 36683861

How to debunk misinformation? An experimental online study investigating text structures and headline formats.
Kotz J, Giese H, König LM. Br J Health Psychol. 2023 Jun 1. doi: 10.1111/bjhp.12670. Online ahead of print. PMID: 37263771

Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
Zheng Y, Pan J, Jin M, Wang J, Tung TH, Chen S, Bi X, Zhou K, Chen M, Wang D, Li J, Shen B, Ying L. Int Immunopharmacol. 2023 Jun;119:110151. doi: 10.1016/j.intimp.2023.110151. Epub 2023 Apr 5. PMID: 37044040

Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness.
Cassetti MC, Pierson TC, Patterson LJ, Bok K, DeRocco AJ, Deschamps AM, Graham BS, Erbelding EJ, Fauci AS. J Infect Dis. 2023 Jun 15;227(12):1433-1441. doi: 10.1093/infdis/jiac296. PMID: 35876700

The "humanized" N-glycosylation pathway in CRISPR/Cas9-edited Nicotiana benthamiana significantly enhances the immunogenicity of a S/preS1 Hepatitis B Virus antigen and the virus-neutralizing antibody response in vaccinated mice.

Pantazica AM, van Eerde A, Dobrica MO, Caras I, Ionescu I, Costache A, Tucureanu C, Steen H, Lazar C, Heldal I, Haugslien S, Onu A, Stavaru C, Branza-Nichita N, Liu Clarke J. Plant Biotechnol J. 2023 Jun;21(6):1176-1190. doi: 10.1111/pbi.14028. Epub 2023 Mar 10. PMID: 36779605

Reasons for COVID-19 vaccine hesitancy in ethnic minority groups: A systematic review and thematic synthesis of initial attitudes in qualitative research.
Shearn C, Krockow EM. SSM Qual Res Health. 2023 Jun;3:100210. doi: 10.1016/j.ssmqr.2022.100210. Epub 2022 Dec 22. PMID: 36573229

History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications.
Rodriguez Martin RR, Gonzalez Gonzalez O, Rodriguez Gonzalez C, Rodriguez Gonzalez RR. Int Immunopharmacol. 2023 Jun;119:110167. doi: 10.1016/j.intimp.2023.110167. Epub 2023 Apr 20. PMID: 37086680

An unusual occurrence of autoimmune pancreatitis after Gam-Covid-Vac (Sputnik V): A case report and literature review.
Chahed F, Ben Fadhel N, Maamri K, Abdelali M, Ben Romdhane H, Chadli Z, Ben Fredj N, Zrig A, Aouam K, Chaabane A. Br J Clin Pharmacol. 2023 Jun 13. doi: 10.1111/bcp.15817. Online ahead of print. PMID: 37311707

Reinfection by SARS-CoV-2 by divergent Omicron sublineages, 16 days apart.
Girardi V, Gularte JS, Demoliner M, da Silva MS, Filippi M, de Abreu Góes Pereira VM, Hansen AW, Rosa RB, Fleck JD, Spilki FR. Braz J Microbiol. 2023 Jun 3:1-5. doi: 10.1007/s42770-023-01018-x. Online ahead of print. PMID: 37269428

Potential differentiation of successive SARS-CoV-2 mutations by RNA: DNA hybrid analyses.
He L, Xie Z, Long X, Zhang C, Ma K, She L. Biophys Chem. 2023 Jun;297:107013. doi: 10.1016/j.bpc.2023.107013. Epub 2023 Mar 31. PMID: 37030215

Demographic, social, and behavioral correlates of SARS-CoV-2 seropositivity in a representative, population-based study of Minnesota residents.
Abhold J, Wozniak A, Mulcahy J, Walsh S, Zepeda E, Demmer R, Yendell S, Hedberg C, Ulrich A, Wurtz R, Beebe T. PLoS One. 2023 Jun 15;18(6):e0279660. doi: 10.1371/journal.pone.0279660. eCollection 2023. PMID: 37319239

Genotype Diversity of Enteric Viruses in Wastewater Amid the COVID-19 Pandemic.
Hoque SA, Kotaki T, Pham NTK, Onda Y, Okitsu S, Sato S, Yuki Y, Kobayashi T, Maneekarn N, Kiyono H, Hayakawa S, Ushijima H. Food Environ Virol. 2023 Jun;15(2):176-191. doi: 10.1007/s12560-023-09553-4. Epub 2023 Apr 14. PMID: 37058225

Racial Discrimination, Social Disadvantage, and Racial-Ethnic Disparities in COVID-19 Vaccine Uptake.
Haro-Ramos AY, Bacong AM, Rodriguez HP. AJPM Focus. 2023 Jun;2(2):100072. doi: 10.1016/j.focus.2023.100072. Epub 2023 Feb 1. PMID: 36744154

Fear of fertility side effects is a major cause for COVID-19 vaccine hesitance in infertile patients.

Kern J, Schippert C, Fard D, Bielfeld AP, von Versen-Höynck F. Front Med (Lausanne). 2023 Jun 1;10:1178872. doi: 10.3389/fmed.2023.1178872. eCollection 2023. PMID: 37324157

Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity.
Williams JA, Biancucci M, Lessen L, Tian S, Balsaraf A, Chen L, Chesterman C, Maruggi G, Vandepaer S, Huang Y, Mallett CP, Steff AM, Bottomley MJ, Malito E, Wahome N, Harshbarger WD. Sci Adv. 2023 Jun 9;9(23):eadg0330. doi: 10.1126/sciadv.adg0330. Epub 2023 Jun 7. PMID: 37285422

Analyzing immune responses to varied mRNA and protein vaccine sequences.
Park HJ, Bang YJ, Kwon SP, Kwak W, Park SI, Roh G, Bae SH, Kim JY, Kwak HW, Kim Y, Yoo S, Kim D, Keum G, Bang EK, Hong SH, Nam JH. NPJ Vaccines. 2023 Jun 5;8(1):84. doi: 10.1038/s41541-023-00684-0. PMID: 37271785

Serodominant SARS-CoV-2 Nucleocapsid Peptides Map to Unstructured Protein Regions.
Vandervaart JP, Inniss NL, Ling-Hu T, Minasov G, Wiersum G, Rosas-Lemus M, Shuvalova L, Achenbach CJ, Hultquist JF, Satchell KJF, Bachta KER. Microbiol Spectr. 2023 Jun 15;11(3):e0032423. doi: 10.1128/spectrum.00324-23. Epub 2023 May 16. PMID: 37191546

Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, Smith KJ. Vaccine. 2023 Jun 12:S0264-410X(23)00669-2. doi: 10.1016/j.vaccine.2023.06.007. Online ahead of print. PMID: 37316409

Identification of nurse shark V_{NAR} single-domain antibodies targeting the spike S2 subunit of SARS-CoV-2.
Buffington J, Duan Z, Kwon HJ, Hong J, Li D, Feng M, Xie H, Ho M. FASEB J. 2023 Jun;37(6):e22973. doi: 10.1096/fj.202202099RR. PMID: 37191949

A Rare Case of COVID-19 Vaccination-Induced Cholangiopathic Liver Injury.
Taj S, Sanekommu H, Johal A, Ravilla J, Imburgio S, Dandu S, Vedire A, Miller B, Hossain M. ACG Case Rep J. 2023 Jun 14;10(6):e01079. doi: 10.14309/crj.0000000000001079. eCollection 2023 Jun. PMID: 37324828

Racial and Ethnic Disparities in Excess Deaths after COVID-19 Vaccine Deployment among Persons with Kidney Failure.
Kim D, Swaminathan S, Lee Y, Wang V, Mehrotra R, Trivedi AN. Clin J Am Soc Nephrol. 2023 Jun 14. doi: 10.2215/CJN.0000000000000226. Online ahead of print. PMID: 37314763

Immunogenicity Evaluation of Thermostable Microparticles Entrapping Receptor Binding Domain of SARS-CoV-2 by Single Point Administration.
Ahuja R, Srichandan S, Meena J, Biswal BK, Panda AK. J Pharm Sci. 2023 Jun;112(6):1664-1670. doi: 10.1016/j.xphs.2023.01.024. Epub 2023 Feb 2. PMID: 36736778

Novel SARS-CoV-2 entry inhibitors, 2-anilinoquinazolin-4(3H)-one derivatives, show potency as SARS-CoV-2 antivirals in a human ACE2 transgenic mouse model.
Ko M, Lee JY, Shin YS, Jeon S, Myung S, Cho JE, Jang MS, Song JH, Kim HR, Park HG, Park CM, Kim S. J Med Virol. 2023 Jun;95(6):e28863. doi: 10.1002/jmv.28863. PMID: 37310127

COVID-19 vaccination uptake in people with multiple sclerosis compared to the general population.
Mayer D, Barun B, Lazibat K, Lasić S, Adamec I, Gabelić T, Krbot Skorić M, Habek M. Acta Neurol Belg. 2023 Jun 1:1-7. doi: 10.1007/s13760-023-02296-w. Online ahead of print. PMID: 37261658

Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea.
Noh H, Yoon S, Kim SH, Kim J, Seo JS, Kim JJ, Park IH, Oh J, Bae JY, Lee GE, Woo SJ, Seo SM, Kim NW, Lee YW, Jang HJ, Hong SM, An SH, Lyoo KS, Yeom M, Lee H, Jung B, Yoon SW, Kang JA, Seok SH, Lee YJ, Kim SY, Kim YB, Hwang JY, On D, Lim SY, Kim SP, Jang JY, Lee H, Kim K, Lee HJ, Kim HB, Kim SB, Park JW, Jeong DG, Song D, Choi KS, Lee HY, Choi YK, Choi JA, Song M, Park MS, Seo JY, Shin JS, Yun JW, Nam KT, Seong JK. Pulm Pharmacol Ther. 2023 Jun;80:102189. doi: 10.1016/j.pupt.2023.102189. Epub 2023 Jan 10. PMID: 36634813

Assay Harmonization Study To Measure Immune Response to SARS-CoV-2 Infection and Vaccines: a Serology Methods Study.
Kemp TJ, Hempel HA, Pan Y, Roy D, Cherry J, Lowy DR, Pinto LA. Microbiol Spectr. 2023 Jun 15;11(3):e0535322. doi: 10.1128/spectrum.05353-22. Epub 2023 May 16. PMID: 37191544

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).
Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F, van de Donk NWCJ, Ntanasis-Stathopoulos I, Vangsted AJ, Driessen C, Schjesvold F, Cerchione C, Zweegman S, Hajek R, Moreau P, Einsele H, San-Miguel J, Boccadoro M, Dimopoulos MA, Sonneveld P, Ludwig H. Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4. PMID: 37142661

Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2.
Chu X, Ding X, Yang Y, Lu Y, Li T, Gao Y, Zheng L, Xiao H, Yang T, Cheng H, Huang H, Liu Y, Lou Y, Wu C, Chen Y, Yang H, Ji X, Guo H. Biochem Biophys Res Commun. 2023 Jun 11;660:43-49. doi: 10.1016/j.bbrc.2023.04.002. Epub 2023 Apr 5. PMID: 37062240

Predicting the antigenic evolution of SARS-COV-2 with deep learning.
Han W, Chen N, Xu X, Sahil A, Zhou J, Li Z, Zhong H, Gao E, Zhang R, Wang Y, Sun S, Cheung PP, Gao X. Nat Commun. 2023 Jun 13;14(1):3478. doi: 10.1038/s41467-023-39199-6. PMID: 37311849

Aptamer-based nanointerferometer enables amplification-free ultrasensitive detection and differentiation of SARS-CoV-2 variants.
Chen C, Song X, Yu Y, Wang X, Xu H, Ji W, Ma J, Zhao C, Feng S, Wang Y, Su XD, Wang W. Anal Chim Acta. 2023 Jun 15;1260:341207. doi: 10.1016/j.aca.2023.341207. Epub 2023 Apr 11. PMID: 37121656

The Nucleocapsid Proteins of SARS-CoV-2 and Its Close Relative Bat Coronavirus RaTG13 Are Capable of Inhibiting PKR- and RNase L-Mediated Antiviral Pathways.
LeBlanc K, Lynch J, Layne C, Vendramelli R, Sloan A, Tailor N, Deschambault Y, Zhang F, Kobasa D, Safronetz D, Xiang Y, Cao J. Microbiol Spectr. 2023 Jun 15;11(3):e0099423. doi: 10.1128/spectrum.00994-23. Epub 2023 May 8. PMID: 37154717

CoronaVac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities.
Wang L, Li C, Li W, Zhao L, Zhao T, Chen L, Li M, Fan J, Li J, Wu C, Chen Y. Emerg Microbes Infect. 2023 Jun 13:2225640. doi: 10.1080/22221751.2023.2225640. Online ahead of print. PMID: 37309826

Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
Dampalla CS, Miller MJ, Kim Y, Zabiegala A, Nguyen HN, Madden TK, Thurman HA, Machen AJ, Cooper A, Liu L, Battaile KP, Lovell S, Chang KO, Groutas WC. Eur J Med Chem. 2023 Jun 5;254:115376. doi: 10.1016/j.ejmech.2023.115376. Epub 2023 Apr 15. PMID: 37080108

Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients.
Overheu O, Lendowski S, Quast DR, Kühn D, Vidal Blanco E, Kraeft AL, Steinmann E, Kourti E, Lugnier C, Steinmann J, Reinacher-Schick A, Pfaender S. J Cancer Res Clin Oncol. 2023 Jun 10:1-12. doi: 10.1007/s00432-023-04961-2. Online ahead of print. PMID: 37300723

Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants.
Stauft CB, Selvaraj P, D'Agnillo F, Meseda CA, Liu S, Pedro CL, Sangare K, Lien CZ, Weir JP, Starost MF, Wang TT. Nat Commun. 2023 Jun 9;14(1):3393. doi: 10.1038/s41467-023-39090-4. PMID: 37296125

Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
Kim WJ, Roberts CC, Song JY, Yoon JG, Seong H, Hyun HJ, Lee H, Gil A, Oh Y, Park JE, Lee JE, Jeon B, Kane D, Spruill S, Kudchodkar SB, Muthumani K, Park YK, Kwon I, Maslow JN. Vaccine. 2023 Jun 6:S0264-410X(23)00683-7. doi: 10.1016/j.vaccine.2023.06.013. Online ahead of print. PMID: 37296017

Pediatric Myocarditis.
Williams JL, Jacobs HM, Lee S. Cardiol Ther. 2023 Jun;12(2):243-260. doi: 10.1007/s40119-023-00309-6. Epub 2023 Mar 11. PMID: 36906691

Optimization and Deoptimization of Codons in SARS-CoV-2 and Related Implications for Vaccine Development.
Wu X, Shan KJ, Zan F, Tang X, Qian Z, Lu J. Adv Sci (Weinh). 2023 Jun 2:e2205445. doi: 10.1002/advs.202205445. Online ahead of print. PMID: 37267926

A novel consensus-based computational pipeline for screening of antibody therapeutics for efficacy against SARS-CoV-2 variants of concern including Omicron variant.
Kumar N, Kaushik R, Zhang KYJ, Uversky VN, Sahu U, Sood R, Bhatia S. Proteins. 2023 Jun;91(6):798-806. doi: 10.1002/prot.26467. Epub 2023 Jan 16. PMID: 36629264

A comparison of five Illumina, Ion Torrent, and nanopore sequencing technology-based approaches for whole genome sequencing of SARS-CoV-2.
Carbo EC, Mourik K, Boers SA, Munnink BO, Nieuwenhuijse D, Jonges M, Welkers MRA, Matamoros S, van Harinxma Thoe Slooten J, Kraakman MEM, Karelioti E, van der Meer D, Veldkamp KE, Kroes ACM, Sidorov I, de Vries JJC. Eur J Clin Microbiol Infect Dis. 2023 Jun;42(6):701-713. doi: 10.1007/s10096-023-04590-0. Epub 2023 Apr 5. PMID: 37017810

The Efficacy of SARS-CoV-2 Vaccination in the Elderly: A Systemic Review and Meta-analysis.
Yang XH, Bao WJ, Zhang H, Fu SK, Jin HM. J Gen Intern Med. 2023 Jun 2:1-9. doi: 10.1007/s11606-023-08254-9. Online ahead of print. PMID: 37266884

Treatment of COVID-19 patients with a SARS-CoV-2-specific siRNA-peptide dendrimer formulation.
Khaitov M, Nikonova A, Kofiadi I, Shilovskiy I, Smirnov V, Elisytina O, Maerle A, Shatilov A, Shatilova A, Andreev S, Sergeev I, Trofimov D, Latysheva T, Ilyna N, Martynov A, Rabdano S, Ruzanova E, Savelev N, Pletiukhina I, Safi A, Ratnikov V, Gorelov V, Kaschenko V, Kucherenko N, Umarova I, Moskaleva S, Fabrichnikov S, Zuev O, Pavlov N, Kruchko D, Berzin I, Goryachev D, Merkulov V, Shipulin G, Udin S, Trukhin V, Valenta R, Skvortsova V. Allergy. 2023 Jun;78(6):1639-1653. doi: 10.1111/all.15663. Epub 2023 Feb 14. PMID: 36721963

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.
Ragonnet-Cronin M, Nutalai R, Huo J, Dijokaite-Guraliuc A, Das R, Tuekprakhon A, Supasa P, Liu C, Selvaraj M, Groves N, Hartman H, Ellaby N, Mark Sutton J, Bahar MW, Zhou D, Fry E, Ren J, Brown C, Klenerman P, Dunachie SJ, Mongkolsapaya J, Hopkins S, Chand M, Stuart DI, Screaton GR, Rokadiya S. Nat Commun. 2023 Jun 7;14(1):3334. doi: 10.1038/s41467-023-37826-w. PMID: 37286554

Use of the Improvement Index to Evaluate Equitable COVID-19 Vaccine Allocation in the San Francisco Bay Area.
Jumamil RB, Rutherford G. AJPM Focus. 2023 Jun;2(2):100075. doi: 10.1016/j.focus.2023.100075. Epub 2023 Feb 4. PMID: 36776788

Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
Guenthoer J, Lilly M, Starr TN, Dadonaite B, Lovendahl KN, Croft JT, Stoddard CI, Chohan V, Ding S, Ruiz F, Kopp MS, Finzi A, Bloom JD, Chu HY, Lee KK, Overbaugh J. Proc Natl Acad Sci U S A. 2023 Jun 6;120(23):e2220948120. doi: 10.1073/pnas.2220948120. Epub 2023 May 30. PMID: 37253011

The Cost We Bear: Financial Implications for Hip Fracture Care Amidst the COVID-19 Pandemic.
Konda SR, Esper GW, Meltzer-Bruhn AT, Ganta A, Egol KA. J Am Acad Orthop Surg. 2023 Jun 5. doi: 10.5435/JAAOS-D-22-00611. Online ahead of print. PMID: 37279163

Variation in antibody titers determined by Abbott and Roche Elecsys SARS-CoV-2 assays in vaccinated healthcare workers.
Nakai M, Yokoyama D, Sato T, Sato R, Kojima C, Shimosawa T. Heliyon. 2023 Jun;9(6):e16547. doi: 10.1016/j.heliyon.2023.e16547. Epub 2023 May 22. PMID: 37235203

Seasonality, mass vaccination and critical policy evaluation on global exit strategy of COVID-19 crisis.
Roy I, Chapungu L, Nyambiya I. Phys Chem Earth (2002). 2023 Jun;130:103388. doi: 10.1016/j.pce.2023.103388. Epub 2023 Mar 5. PMID: 36923070

COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study.
Wesselink AK, Lovett SM, Weinberg J, Geller RJ, Wang TR, Regan AK, Willis MD, Perkins RB, Yland JJ, Koenig MR, Rothman KJ, Hatch EE, Wise LA. Vaccine. 2023 Jun 5:S0264-410X(23)00681-3. doi: 10.1016/j.vaccine.2023.06.012. Online ahead of print. PMID: 37301706

Longitudinal Assessment of Left Ventricular Function in Patients with Myopericarditis After mRNA COVID-19 Vaccination.
Nv B, McCollum S, Faherty E, Steele JM, Karnik R. Pediatr Cardiol. 2023 Jun 9:1-9. doi: 10.1007/s00246-023-03200-2. Online ahead of print. PMID: 37294336

The global challenges of the long COVID-19 in adults and children.
Rodriguez-Morales AJ, Lopez-Echeverri MC, Perez-Raga MF, Quintero-Romero V, Valencia-Gallego V, Galindo-Herrera N, López-Alzate S, Sánchez-Vinasco JD, Gutiérrez-Vargas JJ, Mayta-Tristan P, Husni R, Moghnieh R, Stephan J, Faour W, Tawil S, Barakat H, Chaaban T, Megarbane A, Rizk Y, Sakr R, Escalera-Antezana JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Camacho-Moreno G, Mendoza H, Rodriguez-Sabogal IA, Millán-Oñate J, Lopardo G, Barbosa AN, Cimerman S, Chaves TDSS, Orduna T, Lloveras S, Rodriguez-Morales AG, Thormann M, Zambrano PG, Perez C, Sandoval N, Zambrano L, Alvarez-Moreno CA, Chacon-Cruz E, Villamil-Gomez WE, Benites-Zapata V, Savio-Larriera E, Cardona-Ospina JA, Risquez A, Forero-Peña DA, Henao-Martínez AF, Sah R, Barboza JJ, León-Figueroa DA, Acosta-España JD, Carrero-Gonzalez CM, Al-Tawfiq JA, Rabaan AA, Leblebicioglu H, Gonzales-Zamora JA, Ulloa-Gutiérrez R. Travel Med Infect Dis. 2023 Jun 7:102606. doi: 10.1016/j.tmaid.2023.102606. Online ahead of print. PMID: 37295581

SARS-CoV-2 Omicron (B.1.1.529) infection in rhesus macaques, hamsters, and BALB/c mice with severe lung histopathological damage.
Yu W, Wang J, Yang Y, Tang C, Yang C, Li B, Wang H, Zhou Y, Huang Q, Yang H, Wu D, Luo Z, Gao J, Kuang D, Long H, Peng X, Xie Z, Lu S. J Med Virol. 2023 Jun;95(6):e28846. doi: 10.1002/jmv.28846. PMID: 37282766

Time-to-survival from COVID-19 disease and its associated factors in Osun State, Nigeria.
Olugbenga O, O A, Peter O, Rita O, O O, Od E, At O, James A. Infect Disord Drug Targets. 2023 Jun 13. doi: 10.2174/1871526523666230613122108. Online ahead of print. PMID: 37312448

COVID-19 induced anorexia nervosa: A case series and brief review of literature.
Esmaeeli ST, Rahimi Z, Saeed F, Shoib S. Clin Case Rep. 2023 Jun 13;11(6):e7534. doi: 10.1002/ccr3.7534. eCollection 2023 Jun. PMID: 37323292

Three to four mRNA COVID-19 vaccine in multiple sclerosis patients on immunosuppressive drugs: seroconversion and variants neutralization.
Louapre C, Belin L, Marot S, Hippolyte A, Januel E, Ibrahim M, Jeantin L, Zafilaza K, Malet I, Charbonnier-Beaupel F, Rosenzwajg M, Soulié C, Marcelin AG, Pourcher V. Eur J Neurol. 2023 Jun 13. doi: 10.1111/ene.15925. Online ahead of print. PMID: 37310391

Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA-1273: A Danish Population-Based Cohort Study.
Damkier P, Cleary B, Hallas J, Schmidt JH, Ladebo L, Jensen PB, Lund LC. Otolaryngol Head Neck Surg. 2023 Jun 8. doi: 10.1002/ohn.394. Online ahead of print. PMID: 37288514

Lessons From the Wrong Isolation Policy Violating Human Rights for Leprosy in Japan.
Horikoshi Y, Toizumi M. Pediatr Infect Dis J. 2023 Jun 1;42(6):e212-e216. doi: 10.1097/INF.0000000000003897. Epub 2023 Mar 2. PMID: 36916867

Risk factors for long coronavirus disease 2019 (long COVID) among healthcare personnel, Brazil, 2020-2022.
Marra AR, Sampaio VS, Ozahata MC, Lopes R, Brito AF, Bragatte M, Kalil J, Miraglia JL, Malheiro DT, Guozhang Y, Teich VD, Victor EDS, Pinho JRR, Cypriano A, Vieira LW, Polonio M, de Oliveira SM, Ricardo VCV, Maezato AM, Callado GY, Schettino GPP, de Oliveira KG, Santana RAF, Malta FM, Amgarten D, Boechat AL, Kobayashi T, Perencevich E, Edmond MB, Rizzo LV. Infect Control Hosp Epidemiol. 2023 Jun 5:1-7. doi: 10.1017/ice.2023.95. Online ahead of print. PMID: 37272468

The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies.
Xu J, Lan X, Zhang L, Zhang X, Zhang J, Song M, Liu J. Front Public Health. 2023 Jun 1;11:1165611. doi: 10.3389/fpubh.2023.1165611. eCollection 2023. PMID: 37325336

The Role of Interleukin-21 in COVID-19 Vaccine-Induced B Cell-Mediated Immune Responses in Kidney Disease Patients and Kidney Transplant Recipients.
Malahe SRK, den Hartog Y, Rietdijk WJR, van Baarle D, de Kuiper R, Reijerkerk D, Ras AM, Geers D, Diavatopoulos DA, Messchendorp AL, van der Molen RG, Remmerswaal EBM, Bemelman FJ, Gansevoort RT, Hilbrands LB, Sanders JS, GeurtsvanKessel CH, Kho MML, de Vries RD, Reinders MEJ, Baan CC; RECOVAC Consortium. Am J Transplant. 2023 Jun 1:S1600-6135(23)00492-6. doi: 10.1016/j.ajt.2023.05.025. Online ahead of print. PMID: 37270109

Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants.
Gonzalez-Reiche AS, Alshammary H, Schaefer S, Patel G, Polanco J, Carreño JM, Amoako AA, Rooker A, Cognigni C, Floda D, van de Guchte A, Khalil Z, Farrugia K, Assad N, Zhang J, Alburquerque B; PARIS/PSP study group; Sominsky LA, Gleason C, Srivastava K, Sebra R, Ramirez JD, Banu R, Shrestha P, Krammer F, Paniz-Mondolfi A, Sordillo EM, Simon V, van Bakel H. Nat Commun. 2023 Jun 3;14(1):3235. doi: 10.1038/s41467-023-38867-x. PMID: 37270625

The effect of early childhood respiratory infections and pneumonia on lifelong lung function: a systematic review.
Collaro AJ, McElrea MS, Marchant JM, Chatfield MD, Sondergeld P, Perret JL, Vicendese D, Anuntaseree W, Dharmage SC, Chang AB. Lancet Child Adolesc Health. 2023 Jun;7(6):429-440. doi: 10.1016/S2352-4642(23)00030-5. Epub 2023 Apr 7. PMID: 37037210

Burden of disease attributable to unsafe drinking water, sanitation, and hygiene in domestic settings: a global analysis for selected adverse health outcomes.
Wolf J, Johnston RB, Ambelu A, Arnold BF, Bain R, Brauer M, Brown J, Caruso BA, Clasen T, Colford JM Jr, Mills JE, Evans B, Freeman MC, Gordon B, Kang G, Lanata CF, Medlicott KO, Prüss-Ustün A, Troeger C, Boisson S, Cumming O. Lancet. 2023 Jun 5:S0140-6736(23)00458-0. doi: 10.1016/S0140-6736(23)00458-0. Online ahead of print. PMID: 37290458

Paediatric inflammatory multisystem syndrome in Canada: population-based surveillance and role of SARS-CoV-2 linkage.
El Tal T, Morin MP, Morris SK, Farrar DS, Berard RA, Kakkar F, Moore Hepburn C, Baerg K, Beaufils C, Bennett TL, Benseler SM, Beaudoin-Bussières G, Chan K, Cyr C, Dahdah N, Donner EJ, Drouin O, Edjoc R, Eljaouhari M, Embree JE, Farrell C, Finzi A, Forgie S, Giroux R, Kang KT, King M, Laffin Thibodeau M, Lang B, Laxer RM, Luu TM, McCrindle BW, Orkin J, Papenburg J, Pound CM, Price VE, Proulx-Gauthier

JP, Purewal R, Sadarangani M, Salvadori MI, Thibeault R, Top KA, Viel-Thériault I, Haddad E, Scuccimarri R, Yeung RSM. Pediatr Res. 2023 Jun 5:1-10. doi: 10.1038/s41390-023-02668-1. Online ahead of print. PMID: 37277605 Free PMC article.
Patients with positive versus negative SARS-CoV-2 linkages were compared, with positive linkage defined as any positive molecular or serologic test or close contact with confirmed COVID-19. ICU risk factors were identified with multivariable modified Poisson regress …

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20230601:20230615 as the publication date 76 records*

1.20230173058SARS-COV-2 VACCINE
US - 08.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17922328 Solicitante CANSINO BIOLOGICS INC. Inventor/a Junqiang LI
Disclosed is a SARS-CoV-2 vaccine, wherein the S protein of SARS-CoV-2 serves as the antigen, and the vaccine comprises an adenoviral vector, and the vaccine induces an improved protective immune response through mucosal immunity, thus preventing SARS-CoV-2 infection. Specifically, when atomized by an appropriate apparatus, the vaccine generates particles of improved uniformity, which can reach the lungs after being inhaled via the nasal cavity or the oral cavity, thus producing a protective immune response with respect to the entire respiratory tract and the lungs, enhancing the effective utilization rate of the vaccine, and increasing the effect of the vaccine.

2.WO/2023/098711VACCINE QUALITY CONTROL METHOD, VACCINE QUALITY CONTROL REAGENT, AND USE THEREOF
WO - 08.06.2023
Clasificación Internacional G01N 33/68 Nº de solicitud PCT/CN2022/135343 Solicitante TSINGHUA UNIVERSITY Inventor/a ZHANG, Jingren
A vaccine quality control method, a vaccine quality control reagent, and the use thereof. The vaccine quality control method comprises: detecting a vaccine to be detected and determining detection results. The detection comprises antibody titer detection, detection of the clearance half-time of pathogenic bacteria in the blood, detection of the capture rate of pathogenic bacteria in the liver, detection of the capture number of pathogenic bacteria in hepatic sinusoidal cells, and detection of animal survival rate; and when the preliminary detection results of all the detection modes show that the quality of said vaccine reaches the standard, indicating that the final quality of said vaccine reaches the standard.

3.20230173044RECOMBINANT PROTEIN FOR REMOVING BOAR TAINT AND VACCINE COMPOSITION COMPRISING THE SAME
US - 08.06.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 16964632 Solicitante BIOAPPLICATIONS INC. Inventor/a Eun-Ju SOHN
The present invention relates to a vaccine composition for removing boar taint, the vaccine composition including a recombinant protein in which a cholera toxin B subunit (CTB) and n gonadotropin-releasing hormones (GnRH) are fused, and more specifically, provides a recombinant protein for removing boar taint to induce antibodies against GnRH, a recombinant vector for producing the same, a vaccine composition for removing boar taint, the vaccine composition including the recombinant protein, and a method for removing boar taint using the same. The vaccine composition according to the present

invention induces antibodies against GnRH in an individual and has the effect of atrophying the testes through the induction of antibodies. Therefore, the present invention can be usefully used to remove boar taint by immunologically castrating a boar at low cost and with high safety and minimal side effects.

4.4190902REKOMBINANTES VACCINIAVIRUS
EP - 07.06.2023
Clasificación Internacional C12N 15/50 Nº de solicitud 21848897 Solicitante TOKYO METROPOLITAN INST MEDICAL SCIENCE Inventor/a KOHARA MICHINORI
The present invention provides a recombinant vaccinia virus serving as a clinically usable preventive vaccine for COVID-19 (vaccine for SARS-CoV-2), etc.The recombinant vaccinia virus of the present invention is characterized by comprising the whole or part of cDNA encoding nonstructural proteins or structural protein derived from SARS-CoV-2, and an expression promoter.

5.WO/2023/092863RECOMBINANT VIRUS COMBINATION BASED ON AFRICAN SWINE FEVER VIRUS (ASFV) GENES, AND VACCINE PREPARED THEREFROM
WO - 01.06.2023
Clasificación Internacional C07K 14/01 Nº de solicitud PCT/CN2022/074457 Solicitante ACADEMY OF MILITARY MEDICAL SCIENCES, ACADEMY OF MILITARY SCIENCES, PEOPLE'S LIBERATION ARMY OF CHINA Inventor/a HU, Rongliang
Disclosed in the present invention are a recombinant virus combination based on African swine fever virus (ASFV) genes, and a vaccine prepared therefrom. Provided in the present invention is an African swine fever virus protein combination, which comprises the following three proteins: MGF 110-5L-6L protein, B119L protein and DP96R protein. The above-mentioned ASFV protein combination also comprises at least one of the following 13 proteins: MGF 110-9L, I329L, MGF 505-5R, B438L, O61R, E199L, M448R, MGF 505-7R, A137R, I177L, I226R, DP71L and K196R. Provided in the present invention are a recombinant virus combination based on ASFV genes, and a vaccine prepared therefrom. After pigs are immunized with the vaccine, susceptible pigs can be protected from natural infection or artificial attack of ASFV. The vaccine is used for the prevention of African swine fever.

6.WO/2023/101381VACCINE PLATFORM FOR PRODUCING FOOT AND MOUTH DISEASE VIRUS-LIKE PARTICLES
WO - 08.06.2023
Clasificación Internacional C07K 14/005 Nº de solicitud PCT/KR2022/019148 Solicitante WATSON RND, INC. Inventor/a KIM, Bong Yoon
The present invention relates to a polynucleotide in which the 3C, 3D cleavage site, VP4, VP2, VP3, and VP1 base sequences of foot and mouse disease virus (FMDV) are sequentially connected, a recombinant vector carrying same, a transformant transformed with the recombinant vector, a method for producing foot and mouth disease virus-like particles using the transformant, and a vaccine composition using a food and mouth disease virus-like particle protein that assembles by itself using the polynucleotide. When a vaccine is prepared using the FMDV VLP of the present invention as an antigen, the period of antibody production in mice is short, the survival rate against foot and mouth disease virus challenge is high, and the neutralizing antibody titer is high. In addition, it was observed that antibody production started within about 2 weeks in pigs as well as mice and the PI value was more than 50% even after 6 weeks, so that the vaccine can be applied as a vaccine platform for producing foot and mouth disease virus-like particles.

7.WO/2023/098456VACCINE ADJUVANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 08.06.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/CN2022/131616 Solicitante CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY , CHINESE ACADEMY OF SCIENCE Inventor/a XU, Weiguo

An immunologic adjuvant, which is a terminal group-modified polylactic acid, and the terminal group of the terminal group-modified polylactic acid is a group containing NH_2 and/or a tertiary amine. Compared with the prior art, the amino-modified polylactic acid is used as a vaccine adjuvant, and a vaccine obtained by means of compounding the vaccine adjuvant with a vaccine antigen complex is more easily phagocytized by dendritic cells and initiates an immune response, and has a good immune effect and a high biocompatibility.

8.WO/2023/094967ORAL THERAPEUTIC VACCINE COMPOSITIONS, METHODS AND TREATMENT OF COVID
WO - 01.06.2023
Clasificación Internacional C12N 15/113 Nº de solicitud PCT/IB2022/061224 Solicitante IMMUNITOR (THAILAND) CO. LTD. Inventor/a JIRANTHITIKAL, Vichai
Described herein are oral vaccine compositions for preventing and treating COVID and COVID related complications (e.g., cytokine storm related complications). These oral vaccine compositions comprise hydrolyzed and heat inactivated anti-viral antisense and other nucleic acid components that target the expression of SARS-CoV-2 viral proteins. Such oral vaccine compositions are room temperature stable and stimulate humoral (antibody), cellular and mucosal immunity.

9.WO/2023/106839RECOMBINANT VACCINIA VIRUS EXPRESSING IL-12 AND USE THEREOF
WO - 15.06.2023
Clasificación Internacional C12N 7/00 Nº de solicitud PCT/KR2022/019840 Solicitante THE ASAN FOUNDATION Inventor/a SON, Woo-Chan
The present invention relates to a recombinant Vaccinia virus expressing IL-12 and a use thereof. The recombinant vaccinia virus having a B8R gene deleted therefrom and an IL-12 gene inserted into the site of the deleted B8R increases in IFN-γ activity and IL-12 activity to exhibits an immunologically synergistic effect, resulting in an improvement in anti-tumor immunity and thus is expected to be advantageously used for preventing, alleviating, or treating cancer.

10.20230173043KEXIN-DERIVED VACCINES TO PREVENT OR TREAT FUNGAL INFECTIONS
US - 08.06.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 17865080 Solicitante UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor/a Jay K. Kolls
A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as *Pneumocystis* spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.

11.WO/2023/094713CORONAVIRUS VACCINE
WO - 01.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2022/083740 Solicitante BIONTECH SE Inventor/a MUIK, Alexander
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

12.WO/2023/098679NOVEL CORONAVIRUS MRNA VACCINE AGAINST MUTANT STRAINS
WO - 08.06.2023

Clasificación Internacional C12N 15/50 Nº de solicitud PCT/CN2022/135107 Solicitante CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD. Inventor/a WEI, Lifan
Provided is a novel coronavirus mRNA vaccine against mutant strains, main components thereof comprising mRNA having mutation sites and lipid nanoparticles. The mRNA vaccine has a good immune effect against various mutant strains of the new coronavirus.

13.WO/2023/102375NANT COVID VACCINE CROSS REACTIVITY
WO - 08.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/US2022/080561 Solicitante IMMUNITYBIO, INC. Inventor/a SOON-SHIONG, Patrick
Recombinant SARS-CoV2 vaccine compositions and methods are presented that have unexpected cross-reactivity against a variety of other coronaviruses, and particularly against SARS-CoVl, MERS-CoV, OC43-CoV, and HKUl-CoV in addition to significant reactivity against SARS-CoV2A. Moreover, the vaccine compositions presented herein also produced cross-reactive memory B cells as well as cross-reactive memory T cells with cross-reactivity spanning a relatively wide range of different coronaviruses.

14.WO/2023/1015085'-UTR WITH IMPROVED TRANSLATION EFFICIENCY, A SYNTHETIC NUCLEIC ACID MOLECULE INCLUDING THE SAME, AND A VACCINE OR THERAPEUTIC COMPOSITION INCLUDING THE SAME
WO - 08.06.2023
Clasificación Internacional C12N 15/113 Nº de solicitud PCT/KR2022/019491 Solicitante MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH Inventor/a SHIN, Min-Kyung
Disclosed are a synthetic nucleic acid molecule including 5'-UTR with improved translation efficiency and a vaccine/therapeutic composition including the same, and more particularly, a 5'-UTR polynucleotide that is imparted with improved translation efficiency based on the specific motif thereof, a synthetic nucleic acid molecule including the same and a vaccine/therapeutic composition including the synthetic nucleic acid molecule. The 5'-UTR polynucleotide effectively induces expression of target proteins due to improved translation efficiency thereof and thus is useful for various RNA-based applications, for example, vaccines, in vivo/ex vivo gene therapy, etc.

15.20230173057METHOD FOR IMPROVING ANTIGEN IMMUNOGENICITY, CORONAVIRUS ANTIGEN, USE THEREOF, RECOMBINANT VECTOR, EXPRESSION KIT, TRANSGENIC CELL LINE, RECOMBINANT BACTERIUM, CORONAVIRUS VACCINE, PREPARATION METHOD OF ANTIGEN AND NUCLEOTIDE SEQUENCE
US - 08.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17912525 Solicitante GUANGZHOU QIANYANG BIO-TECHNOLOGY PHARMACEUTICAL CO., LTD. Inventor/a Hui ZHANG
Provided is a Helicobacter pylori ferritin-based novel coronavirus S protein single-region subunit nano-vaccine. According to the present invention, a receptor binding domain (RBD) of a virus is used as an antigen and is connected with a Helicobacter pylori multimeric protein (HP_Ferritin) to form a fusion protein RBD-HP_Ferritin, such that antigen multimerization is realized; and an eukaryotic cell expression system is then utilized for expression, so as to form a 24-mer nano-antigen by means of the self-assembly action of the HP_Ferritin. According to the solution, the defect that RBD monomers are insufficient in immunogenicity can be overcome; the obtained vaccine can remarkably improve the level of neutralizing antibodies of a host to viruses; and the generated antibodies have the capacity to strongly prevent the viruses from invading target cells.

16.20230173048ANTI-CANCER VACCINES AND RELATED THERAPY
US - 08.06.2023

Clasificación Internacional A61K 39/00 Nº de solicitud 17921837 Solicitante The Institute of Cancer Research: Royal Cancer Hospital Inventor/a Stephen Pettitt
The present invention provides an anti-cancer vaccine comprising: (i) at least one peptide comprising the amino acid sequence of a neoantigen encoded by a mutant homologous recombination (HR) DNA repair gene selected from the group: BRCA1, BRCA2, PALB2, CDK12, RAD51B, RAD51C and RAD51D, wherein the mutant gene comprises a reversion mutation; and/or (ii) at least one polynucleotide encoding the at least one peptide of (i). Also provided are engineered T cells that recognise said neoantigen. Related methods and medical uses of the vaccine and/or engineered T cell are provided, including for the treatment of cancers, such as homologous recombination (HR) deficient cancers that acquire PARP inhibitor resistance or platinum resistance by development of reversion mutations in an HR DNA repair gene selected from the group: BRCA1, BRCA2, PALB2, CDK12, RAD51B, RAD51C and RAD51D.

17.WO/2023/100984NASAL VACCINE-SPRAYING FORMULATION FOR SIMULTANEOUSLY TARGETING NASAL MUCOSA AND NASOPHARYNX
WO - 08.06.2023
Clasificación Internacional A61K 47/32 Nº de solicitud PCT/JP2022/044399 Solicitante TOKO YAKUHIN KOGYO CO., LTD. Inventor/a KAMISHITA, Taizou
The present invention pertains to a formulation that for spraying a nasal vaccine, that contains an antigen and a base agent obtained by adding polyethylene glycol to a crosslinkable polyacrylic acid, and that has an optimized spray pattern for simultaneously targeting the nasal mucosa and the nasopharynx.

18.20230178174METHOD AND SYSTEM FOR IDENTIFYING ONE OR MORE CANDIDATE REGIONS OF ONE OR MORE SOURCE PROTEINS THAT ARE PREDICTED TO INSTIGATE AN IMMUNOGENIC RESPONSE, AND METHOD FOR CREATING A VACCINE
US - 08.06.2023
Clasificación Internacional G16B 15/30 Nº de solicitud 17996615 Solicitante NEC ONCOIMMUNITY AS Inventor/a Boris Simovski
A computer-implemented method of identifying one or more candidate regions of one or more source proteins that are predicted to instigate an adaptive immunogenic response across a plurality of human leukocyte antigen, HLA, types, wherein the one or more source proteins has an amino acid sequence is disclosed. The method comprises (a) accessing the amino acid sequence of the one or more source proteins; (b) accessing a set of HLA types; (c) predicting an immunogenic potential of a plurality of candidate epitopes within the amino acid sequence, for each of the set of HLA types; (d) dividing the amino acid sequence into a plurality of amino acid sub-sequences; (e) for each of the plurality of amino acid sub-sequences, generating a region metric that is indicative of a predicted ability of the amino acid sub-sequence to instigate an immunogenic response across the set of HLA types, wherein the region epitopes, for each of the set of HLA types; and (f) applying a statistical model to identify whether any of the generated region metrics are statistically significant, whereby an amino acid sub-sequence identified as having a statistically significant region metric corresponds to a candidate region of the amino acid sequence that is predicted to instigate an immunogenic response across at least a subset of the set of HLA types. A corresponding system is also disclosed, as well as a method for creating a vaccine.

19.20230165951Engineering, production and characterization of plant produced Nucleocapsid and Spike structural proteins of SARS CoV 2 as vaccine candidates against COVID19
US - 01.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17457138 Solicitante Tarlan Mamedov Inventor/a Tarlan Mamedov

This document relates to materials and methods for engineering and production of highly soluble, functional active recombinant Nucleocapsid (N) and Spike (S) based vaccine candidates against highly pandemic SARC-CoV-2 infection, in *Nicotiana benthamiana* plant using a transient expression system.

20.20230172852Neoepitope Vaccine Delivery Vehicle and Methods of Making the Same
US - 08.06.2023
Clasificación Internacional A61K 9/06 Nº de solicitud 18062416 Solicitante ImmunityBio, Inc. Inventor/a Philip T. Liu
Disclosed herein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.

21.20230174588A VACCINE AGAINST SARS-COV-2 AND PREPARATION THEREOF
US - 08.06.2023
Clasificación Internacional C07K 14/005 Nº de solicitud 17920158 Solicitante ZYDUS LIFESCIENCES LIMITED Inventor/a Pankaj PATEL
The current invention provides a DNA construct comprising S gene or S1 gene region of 2019-nCoV spike-S protein. The DNA construct of the present invention comprises DNA plasmid vector carrying S gene or S1 gene region of 2019-nCoV spike-S protein. The vector may further comprise a gene encoding IgE signal peptide or a gene encoding t-PA signal peptide. The DNA construct according to the present invention is further used in the preparation of an immunogenic composition or a vaccine for treating or preventing corona virus or its related diseases.

22.WO/2023/102388HUMAN METAPNEUMOVIRUS VIRAL VECTOR-BASED VACCINES
WO - 08.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/US2022/080588 Solicitante SANOFI PASTEUR INC. Inventor/a CHAN, Yvonne
The present disclosure provides a human metapneumovirus (hMPV) vaccine comprising an hMPV F protein antigen, and methods of eliciting an immune response by administering said vaccine.

23.WO/2023/104114RNA FORMULATIONS AND LIPIDS
WO - 15.06.2023
Clasificación Internacional A61K 9/51 Nº de solicitud PCT/CN2022/137326 Solicitante IMMORNA (HANGZHOU) BIOTECHNOLOGY CO., LTD. Inventor/a WANG, Zihao
The disclosure relates to the method of lyophilizing RNA and mixing with a liquid LNP solution, e. g., to make an RNA vaccine or therapeutic. Included are methods for preparing and administering the vaccine or therapeutic.

24.WO/2023/094839PEPTIDE VACCINE
WO - 01.06.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/GB2022/053012 Solicitante ARGONAUT THERAPEUTICS LIMITED Inventor/a LA THANGUE, Nicholas
The present invention provides one or more immunogenic peptides derived from a PRMT5-E2F1 axis regulated long non-coding RNA gene or a derivative thereof; a pharmaceutical composition comprising one or more of said peptides; a vaccine comprising one or more of said peptides and their use in therapy, including a method for eliciting an immune response in a mammalian subject by administration of an agent capable of presenting the peptides to the host. The invention also relates to the use of a PRMT5 inhibitor for use in treating cancer by stimulating host immunity.

25.WO/2023/106319VACCINE COMPOSITION FOR INDUCING ANTI-IL-23 ANTIBODY
WO - 15.06.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/JP2022/045045 Solicitante OSAKA UNIVERSITY Inventor/a NAKAGAMI, Hironori

The present invention provides a vaccine composition which contains a complex of a T-cell receptor antigen peptide and a B-cell receptor antigen peptide and which can induce the production of an antibody against IL-23, wherein the B-cell receptor antigen peptide is represented by formula (I): X1-X2-X3-X4-X5-X6-X7-X8 (in the formula: X1 is S, A, G, T, K or R; X2 is P, A, G, S, T, K or R; X3 is S, A, G, T, K or R; X4 is Q, A, G, T or N; X5 is P, A, G, S, T, Q or N; X6 is W, A, Y or F; X7 is Q, A, G, T or N; and X8 is R, A, G or K).

26.WO/2023/098755RECOMBINANT HEGF-CRM197 TUMOR THERAPEUTIC VACCINE FORMULATION
WO - 08.06.2023
Clasificación Internacional A61K 39/05 Nº de solicitud PCT/CN2022/135608 Solicitante SHANGHAI HUIMMUTECH BIOTECHNOLOGY CO., LTD Inventor/a ZHANG, Wenyao
Provided in the present invention is a recombinant hEGF-CRM197 tumor therapeutic vaccine formulation. Specifically, the formulation of the present invention contains a therapeutically effective amount of a conjugate of a recombinant human epidermal growth factor (hEGF) and a diphtheria toxin mutant (CRM197), a phosphate base buffer solution with the pH in a range of 7.5-8.5, a polysorbate 20 surfactant and optionally a monosaccharide or disaccharide. The protein conjugate molecule in the formulation of the present invention can break immune tolerance and induce the production of an anti-human epidermal growth factor antibody in the human body; In addition, the protein conjugate molecule produces a lower proportion of polymers, and has a more uniform molecular weight distribution in the buffer, and better stability. Therefore, the formulation of the present invention can achieve large-scale production and can be stably stored for a long time.

27.WO/2023/097265MODIFIED GENE VACCINES AGAINST AVIAN CORONAVIRUSES AND METHODS OF USING THE SAME
WO - 01.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/US2022/080415 Solicitante WISCONSIN ALUMNI RESEARCH FOUNDATION Inventor/a TALAAT, Adel
The present invention provides both QuilA-loaded chitosan (QAC)-encapsulated NA vaccine compositions and viral vaccine compositions that encode an Infectious Bronchitis Virus (IB V) spike (S) protein, an IBV nucleocapsid (N) protein, or both the S protein and the N protein. Additionally, the present invention provides methods in which the disclosed vaccines are administered to a subject to induce an immune response against IBV or to vaccinate the subject against IBV.

28.WO/2023/107951NEOEPITOPE VACCINE DELIVERY VEHICLE AND METHODS OF MAKING THE SAME
WO - 15.06.2023
Clasificación Internacional A61K 39/385 Nº de solicitud PCT/US2022/081025 Solicitante IMMUNITYBIO, INC. Inventor/a LIU, Philip T.
Disclosed herein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.

29.20230172175RECOMBINANT PROTEIN PRODUCTION IN INSECTS
US - 08.06.2023
Clasificación Internacional A01K 67/033 Nº de solicitud 17911930 Solicitante Proteinea, Inc. Inventor/a Mahmoud Eljendy
The present disclosure relates to the field of commercial scale production and processing of pharmaceutical liquid or solid compositions derived from insects, wherein the compositions include a purified recombinant protein, vaccine, antibody, peptide, or chemical. Systems and methods to produce

the insects and a purified insect-derived recombinant protein, vaccine, antibody, peptide, insecticide, fungicide, or chemical within a bioreactor are also described.

30.WO/2023/094885ANTIGENIC DETERMINANTS, PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-COV-2
WO - 01.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/IB2022/000699 Solicitante ARABIAN GULF UNIVERSITY Inventor/a FATHALLAH, Mohamed-dahmani
Immunogenic peptides, polypeptides, protein subunits, nucleic acids encoding the same, compositions and vaccines containing the immunogenic peptides or nucleic acids, and methods of vaccination and/or treatment of SARS-CoV-2 infection. A serological diagnostic assay as well as a use of the serological assay with peptide P3 (SEQ ID NO: 3) to reveal whether a human suspected to be infected or to have been infected by a SARS-CoV-2 virus has generated an anti SARS-CoV-2 protective immunity.

31.20230165952BETACORONAVIRUS PROPHYLAXIS AND THERAPY
US - 01.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17997407 Solicitante Nykode Therapeutics ASA Inventor/a Agnete Brunsvik Fredriksen
Disclosed is a vaccine comprising an immunologically effective amount of a polynucleotide comprising a nucleotide sequence encoding a targeting unit, a dimerization unit and an antigenic unit, wherein the antigenic unit comprises at least one betacoronavirus epitope. The vaccine is ideal for pandemic and epidemics as it can induce rapid, strong immune response with lower/fewer doses because the antigen is targeted to antigen presenting cells and the antigen is produced in the body.

32.WO/2023/108083NANOPARTICLE IMMUNOGENIC COMPOSITIONS AND VACCINATION METHODS
WO - 15.06.2023
Clasificación Internacional A61K 47/60 Nº de solicitud PCT/US2022/081199 Solicitante YALE UNIVERSITY Inventor/a IWASAKI, Akiko
Compositions and methods for inducing a protective mucosal immunity against an antigen in a subject include the step of administering to a mucosal tissue an effective amount of a vaccine composition including the antigen or polynucleotide encoding an antigen associated or encapsulated within carriers such as poly(amine-co-ester) polymers in the form of particles (e.g., solid nanoparticles formed of PACE) or PACE copolymers and/or blends. Typically, the subject has previously been exposed to the antigen, for example, by administering to the same subject via a systemic or mucosal route of administration a priming antigen. In some embodiments, the polynucleotides-based vaccines are messenger RNAs encoding a viral antigen such as a coronavirus spike protein sequence, or a portion thereof. In preferred embodiments, the vaccine composition is administered intranasally.

33.20230173045RANKING NEOANTIGENS FOR PERSONALIZED CANCER VACCINE
US - 08.06.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 17764074 Solicitante Amazon Technologies, Inc. Inventor/a Layne Christopher PRICE
Disclosed herein are methods for ranking tumor-specific neoantigens from a tumor of a subject that are suitable for subject-specific immunogenic compositions. Suitable tumor-specific neoantigens are tumor-specific neoantigens that are likely presented on the cell surface of the tumor, are likely to be immunogenic, are predicted to be expressed in sufficient amounts to elicit an immune response in the subject, optionally represent sufficient diversity across the tumor, and have relatively high manufacture feasibility. The present methods take a set of neoantigens (peptide vaccine candidates) and ranks the neoantigens in a way such that a group of top-ranked neoantigens simultaneously promotes cell-surface

presentation of important neoantigens for Class I and Class II MHC molecules. The top-ranked neoantigens can then be further narrowed according manufacturability and/or other criteria.

34.20230173062SMALLPOX VACCINE FOR CANCER TREATMENT
US - 08.06.2023
Clasificación Internacional A61K 39/285 Nº de solicitud 18103214 Solicitante CALIDI BIOTHERAPEUTICS, INC. Inventor/a Aladar SZALAY
Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.

35.20230173049FUSION PROTEINS AND METHODS OF USE THEREOF
US - 08.06.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 17789858 Solicitante The Johns Hopkins University Inventor/a Mark Yarchoan
The invention features compositions and methods for treating and preventing cancer. In one aspect, isolated fusion proteins are provided that comprise a DNAJBI portion and a PRKACA portion. In a further aspect, compositions are provided, including immunogenic compositions that comprise an isolated fusion protein comprising a DNAJBI portion and a PRKACA portion. In a yet further aspect, a cancer vaccine is provided that comprises an isolated fusion protein comprising a DNAJBI portion and a PRKACA portion.

36.20230165950IMMUNOGENIC COMPOSITION COMPRISING CYAA-DERIVED POLYPEPTIDE PROMOTING A TH1/TH17-ORIENTED IMMUNE RESPONSE
US - 01.06.2023
Clasificación Internacional A61K 39/02 Nº de solicitud 17814988 Solicitante GENKYOTEX Inventor/a Rémi PALMANTIER
The invention relates to the use of a polypeptide derived from the adenylate cyclase of a *Bordetella* sp. (CyaA-derived polypeptide) by deletion of a segment of at least 93 amino acid residues, in particular a polypeptide derived from CyaA of *Bordetella pertussis*, as an immunomodifying antigen of the TH1/TH17-oriented immune response in an immunogenic composition. The invention relates to a vaccine candidate comprising such CyaA-derived polypeptide, either in an acellular immunogenic composition for active immunization against a condition causally related to the infection of a host by *Bordetella* sp. or in a combination composition encompassing said acellular immunogenic composition.

37.WO/2023/100159MULTICISTRON EXPRESSION VECTOR FOR COVID-19 VACCINE
WO - 08.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/IB2022/061742 Solicitante KASHIV BIOSCIENCES, LLC Inventor/a GUPTA, Sudharti
The present invention provides an expression vector comprises gene of interest encode more than one structural protein to enhance immune responses against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants. Further, the present invention the expression vector comprises spike protein of SARS-CoV-2 and one or more structural protein selected from membrane protein, envelope protein and nucleocapsid protein of SARS-CoV-2. The expression vector expressed mRNA capable to encode more than one structural protein to provide immune response against SARS-CoV-2 virus.

38.20230174996REASSORTED ISA VIRUS
US - 08.06.2023
Clasificación Internacional C12N 15/63 Nº de solicitud 17785223 Solicitante Intervet Inc. Inventor/a Stephane Villoing

The present invention is directed to a reassorted ISA virus comprising Genome segments 1-8 wherein at least one genome segment is from Genotype I and at least one genome segment is from genotype II, wherein genome segment 6 is of Genotype II. The reassorted ISA virus was found to grow well in suspension culture. The present invention is also directed to method to make the reassorted virus as well as vaccination methods using the reassorted ISA virus and to vaccine compositions comprising the reassorted ISA virus.

39.4190894VERFAHREN ZUR IN-VITRO-HERSTELLUNG VON REIFEN DENDRITISCHEN ZELLEN UNTER VERWENDUNG EINES BAKTERIELLEN LYSATS
EP - 07.06.2023
Clasificación Internacional C12N 5/0784 Nº de solicitud 21212360 Solicitante CIMAAS B V Inventor/a GERMERAAD WILFRED THOMAS VINCENT
The invention is in the field of cell biology and immunology. The invention provides methods for the production of a vaccine for cancer and infectious diseases. More in particular it provides a method for the improved production of mature dendritic cells. This improved production includes the use of a bacterial lysate produced by a new method.

40.WO/2023/094980ANTIBODIES TO CORONAVIRUS
WO - 01.06.2023
Clasificación Internacional C07K 16/10 Nº de solicitud PCT/IB2022/061257 Solicitante FONDAZIONE TOSCANA LIFE SCIENCES Inventor/a ANDREANO, Emanuele
The present disclosure provides human monoclonal antibodies that have potent neutralizing activity against SARS-CoV-2. The present disclosure also provides prevention methods, treatment methods, compositions, pharmaceutical compositions, and vaccine compositions that comprise or utilize the human monoclonal antibodies provided herein.

41.20230167157ANTIGENIC DETERMINANTS PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-CoV-2
US - 01.06.2023
Clasificación Internacional C07K 14/005 Nº de solicitud 18058403 Solicitante ARABIAN GULF UNIVERSITY Inventor/a Mohamed-Dahmani FATHALLAH
Immunogenic peptides, polypeptides, protein subunits, nucleic acids encoding the same, compositions and vaccines containing the immunogenic peptides or nucleic acids, and methods of vaccination and/or treatment of SARS-CoV-2 infection. A serological diagnostic assay as well as a use of the serological assay with peptide P3 (SEQ ID NO: 3) to reveal whether a human suspected to be infected or to have been infected by a SARS-CoV-2 virus has generated an anti SARS-CoV-2 protective immunity,

42.WO/2023/102359A MAPS VACCINE TARGETING SALMONELLA ENTERICA SEROVARS
WO - 08.06.2023
Clasificación Internacional A61K 39/112 Nº de solicitud PCT/US2022/080531 Solicitante THE CHILDREN'S MEDICAL CENTER CORPORATION Inventor/a MALLEY, Richard
Technologies for the prevention and/or treatment of *Salmonella* infections.

43.20230167159SARS-CORONAVIRUS 2 (SARS-COV-2) SUBUNIT VACCINE CANDIDATES
US - 01.06.2023
Clasificación Internacional C07K 14/165 Nº de solicitud 17906825 Solicitante Kansas State University Research Foundation Inventor/a Waithaka Mwangi
A new species of coronavirus, SARS-CoV-2, is the cause of a worldwide pandemic and has resulted in hundreds of thousands of deaths. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions to reduce the severity of, incidence of and transmissibility of SARS-CoV-2.

44.20230174937METHOD FOR THE PRODUCTION OF MATURE DENDRITIC CELLS IN VITRO USING A BACTERIAL LYSATE
US - 08.06.2023
Clasificación Internacional C12N 5/0784 Nº de solicitud 18073914 Solicitante CiMaas B.V. Inventor/a Wilfred Thomas Vincent GERMERAAD
The invention is in the field of cell biology and immunology. The invention provides methods for the production of a vaccine for cancer and infectious diseases. More in particular it provides a method for the improved production of mature dendritic cells. This improved production includes the use of a bacterial lysate produced by a new method.

45.4189686VERFAHREN ZUR HERSTELLUNG VON NEOPENEPITOP-HALTIGEN IMPFSTOFFEN
EP - 07.06.2023
Clasificación Internacional G16B 20/20 Nº de solicitud 21755404 Solicitante EVAXION BIOTECH AS Inventor/a TROLLE THOMAS
The present invention presents an improved method for identification of neoepitopes useful in active immunotherapy targeting malignant neoplasms. The method integrates identification of somatic variants of expression product with a balanced evaluation of such variants' 1) ability to bind MHC, 2) ability to induce immune responses, 3) clonal coverage in the tumour tissue, and 4) ability to evade immune responses. Also, the method is complemented by a method for purposive deselection of neoepitopes that could induced undesired immune response against normal cells. Also disclosed is a method for preparing immunogenic compositions, a method for treatment of cancer, and a computer system for identifying neoepitopes and neopeptides.

46.4190348VERWENDUNG VON EPIDERMALEN WACHSTUMSFAKTOR-DEPLETIONSMITTELN BEI DER BEHANDLUNG DER CHRONISCH OBSTRUKTIVEN LUNGENERKRANKUNG
EP - 07.06.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 21759232 Solicitante CT INMUNOLOGIA MOLECULAR Inventor/a MACÍAS ABRAHAM AMPARO EMILIA
The present invention is related to the fields of Biotechnology and Medicine. Particularly, it describes the use of epidermal growth factor (EGF) deprivation agents that contribute to lowering and/or depleting serum epidermal growth factor levels, which has implications in the treatment of the chronic obstructive pulmonary disease. These agents can be vaccine compositions comprising as active principle the conjugate between recombinant human EGF and a carrier protein.

47.WO/2023/101007ANTIGEN-PROTEIN EXPRESSION VECTOR AND UTILIZATION THEREOF
WO - 08.06.2023
Clasificación Internacional C12N 15/63 Nº de solicitud PCT/JP2022/044526 Solicitante I'ROM GROUP CO., LTD. Inventor/a SUZUKI, Shinnosuke
The present invention provides: a vector that expresses a fusion protein containing a secretion signal, an antigen-protein fragment, and a trimer forming domain; and usages thereof. Said vector has an excellent ability to secrete and release an antigen-protein fragment to the cell exterior. The present invention is capable of: maximizing the expression by minimizing a vaccine antigen and adding a trimer forming domain thereto; and maximizing secreted and released amounts of expression products by additionally adding a secretion signal. The present technology is assumed to be useful as a vector technology that can be programmed so as to induce both humoral immunity and cell-mediated immunity.

48.4188436SARS-COV-2-REZEPTORBINDUNGSDOMÄNE IN NATIVEN AUSSENMEMBRANVESIKELN
EP - 07.06.2023

Clasificación Internacional A61K 39/215 Nº de solicitud 21849046 Solicitante OMVAX INC Inventor/a MOE GREGORY
The disclosure provides native outer membrane vesicle (NOMV) vaccines containing a coronavirus receptor binding domain (RBD) modified to be a lipoprotein. Also provided are compositions comprising a meningococcal strain having a plasmid-borne gene encoding the SARS-CoV-2 RBD modified to be a lipoprotein. Also provided are a meningococcal strain and a NOMV vaccine containing a plasmid coding for the SARS-CoV-2 RBD with a promoter/enhancer and polyA sequence that provide for expression of the RBD in mammalian cells.

49.WO/2023/097102SARS COV-2 VACCINE, ASSOCIATED POLYNUCLEOTIDES, AND METHODS OF USE
WO - 01.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/US2022/051178 Solicitante AEGIS LIFE, INC. Inventor/a JIANG, Hong
The present disclosure relates to a vaccines and related polynucleotides useful in eliciting an immune response to the SARS-CoV-2 virus and related methods of use.

50.WO/2023/107672PHYSIOLOGICAL METRICS AS CANDIDATE PREDICTORS OF ANTIBODY RESPONSE FOLLOWING VACCINATION AGAINST COVID-19
WO - 15.06.2023
Clasificación Internacional C12N 7/00 Nº de solicitud PCT/US2022/052356 Solicitante THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor/a MASON, Ashley E.
Methods, systems, and devices are provided for predicting the robustness of an antibody response of a subject to the SARS-CoV-2 spike protein receptor binding domain based on measurement of physiological metrics following vaccination. In particular, one or more physiological metrics of the subject selected from dermal temperature deviation, heart rate, respiratory rate, heart rate variability, and deep sleep duration are measured with a wearable device before and after vaccinating the subject, wherein increases in dermal temperature deviation, heart rate, and respiratory rate, and decreases in heart rate variability on the first night after administration of the vaccine to the subject are correlated with greater antibody responses to the SARS-CoV-2 spike protein.

51.WO/2023/105247METHODS AND COMPOSITIONS TO POTENTIATE THE IMMUNE RESPONSE WITH LYSINE DEACETYLASE INHIBITORS
WO - 15.06.2023
Clasificación Internacional A61K 31/167 Nº de solicitud PCT/GB2022/053173 Solicitante CAMBRIDGE ENTERPRISE LIMITED Inventor/a MCKINNEY, Eoin F.
The invention relates to methods and compositions to boost immune responses to both infection and vaccination against and infection. In particular, the present invention is aimed at providing a method to boost immune responses to both infection with an infectious agent and vaccination against an infection with an infectious agent. It is also aimed at providing a treatment of infectious disease and vaccine adjuvant for the prevention of infection with an infectious agent.

52.WO/2023/102448CORONAVIRUS VACCINE FORMULATIONS
WO - 08.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/US2022/080700 Solicitante NOVAVAX, INC. Inventor/a SMITH, Gale
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

53.20230173054TARGET SEQUENCE OF RNA VIRUS AND USE THEREOF
US - 08.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 17453574 Solicitante SHANGHAI PUBLIC HEALTH CLINICAL CENTER Inventor/a Wenqiang Yu
The present invention provides a target sequence of an RNA virus. The target sequence is a nucleic acid sequence fragment in the gene sequence in the RNA virus containing 20-40 bases and having not less than 95% similarity to genome sequence of human or related species such as livestock and poultry. The above-mentioned target sequence of the RNA virus is selected from SEQ ID NO. 1 - SEQ ID NO. 615. The present invention also relates to a primer composition for constructing the above-mentioned target sequence, biomaterials such as antisense RNA related to the above-mentioned target sequence, and related uses such as design of a vaccine lacking the target sequence. The virus fragment with the above-mentioned sequence constructed in the present invention has the function of interacting with human genomic DNA and is similar to viral miRNA. Moreover, the effect of overexpression of the target sequence of the RNA virus on the expression level of surrounding genes is verified, and a new concept that the above-mentioned target fragment is an important pathogenic substance of the RNA virus is proposed. The above-mentioned target sequence has important application value for the detection and diagnosis of RNA viruses, drug screening, as well as the treatment of diseases caused by RNA viruses and the design/optimization of vaccines and methods.

54.20230173060LARGE SEQUENCE PAN-CORONAVIRUS VACCINE COMPOSITIONS
US - 08.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18046875 Solicitante THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor/a Lbachir BenMohamed
Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CD8 T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and/or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and/or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).

55.WO/2023/108117ENGINEERED FC DOMAINS AND ENGINEERED HCMV VIRAL FC RECEPTORS
WO - 15.06.2023
Clasificación Internacional C07K 16/10 Nº de solicitud PCT/US2022/081258 Solicitante BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor/a MAYNARD, Jennifer
Recombinant antibodies are provided that comprise engineered human IgG1 Fc domains that have reduced affinity for viral FcγRs, such as HCMV gp34 and gp68, as compared to a wild-type human IgG1 Fc domain. The engineered human IgG1 Fc domains have equivalent affinity for CD16A and FcRn as compared to a wild-type human IgG1 Fc domain. Also provided are engineered forms of HCMV gp34 and their use in a vaccine.

56.4188426KONSENSUSSEQUENZ DER ANTIGEN-TELOMERASE UND IHRE VERWENDUNG ZUR PRÄVENTIVEN UND THERAPEUTISCHEN IMPFUNG
EP - 07.06.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 21762530 Solicitante EVVIVAX S R L Inventor/a AURISICCHIO LUIGI
The present invention relates to the generation of a consensus sequence of the antigen telomerase (ConTRt) and the use thereof in preventive and therapeutic vaccination, wherein the consensus sequence of telomerase was generated by the fusion of two sequences, one belonging to human telomerase

(hTERT) and the other to dog telomerase (dTERT), with the aim of developing an effective vaccine for the treatment of tumours expressing both human and dog telomerase, hence in both the human and veterinary sectors.

57.20230172902METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19
US - 08.06.2023
Clasificación Internacional A61K 31/357 Nº de solicitud 18047432 Solicitante Lloyd Hung Loi Tran Inventor/a Lloyd Hung Loi Tran
The present invention recognizes that there is a need for the prophylaxis or treatment of COVID and COVID-19. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using various pharmaceutical compositions. A second aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of antimalarial drugs and antiviral drugs. A third aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using nanoparticle formulations that include pharmaceutical compositions. A fourth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of various pharmaceutical compositions. A fifth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using a polio vaccine and pharmaceutical compositions.

58.20230173051COMPOSITIONS COMPRISING THREE OSPA FUSION PROTEINS FOR MEDICAL USE
US - 08.06.2023
Clasificación Internacional A61K 39/02 Nº de solicitud 17917624 Solicitante Valneva Austria GmbH Inventor/a Nicole Bézay
The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipSID1-S2D1), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1-SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.

59.2613460Methods for the prophylaxis and treatment of Covid and Covid-19
GB - 07.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 202217355 Solicitante LLOYD HUNG LOI TRAN Inventor/a LLOYD HUNG-LOI TRAN
The present invention recognizes that there is a need for the prophylaxis or treatment of COVID and COVID-19. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using various pharmaceutical compositions. A second aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of antimalarial drugs and antiviral drugs. A third aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using nanoparticle formulations that include pharmaceutical compositions. A fourth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID- 19 using combinations of various pharmaceutical compositions. A fifth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using a polio vaccine and pharmaceutical compositions.

60.20230173053Lyophilized Live Bordetella Vaccines
US - 08.06.2023
Clasificación Internacional A61K 39/02 Nº de solicitud 18159550 Solicitante ILiAD Biotechnologies, LLC Inventor/a Marcel Thalen
Formulations of lyophilized *Bordetella* bacteria which are stable for at least two years when stored at temperatures between -20° and 22.5° C., and which exhibit sufficient homogeneity (no bacterial

clumping) bacterial viability and potency to be used as a live vaccine are made by harvesting *Bordetella* bacteria from a culture at an OD600 between 0.4 and 1.6; mixing the harvested *Bordetella* bacteria with a lyophilization buffer comprising 5-65% by weight a cryoprotectant sugar and having a temperature between 2-3 5° C., wherein the ratio of harvested *Bordetella* bacteria to lyophilization buffer is between 5:1 and 1:5 by volume; lyophilizing the mixture of the *Bordetella* bacteria and the lyophilization buffer; wherein the hold time between the harvesting and lyophilization steps is less than 48 hours; and collecting the lyophilized *Bordetella* bacteria.

61.20230174589STRUCTURALLY MODIFIED CHIMERIC POLYPEPTIDE OF HUMAN PAPILLOMAVIRUS, RECOMBINANT PROTEIN COMPRISING SAME POLYPEPTIDE, AND USE OF SAME PROTEIN
US - 08.06.2023
Clasificación Internacional C07K 14/005 Nº de solicitud 17924177 Solicitante GENEMATRIX, INC. Inventor/a Soo Ok KIM
The present invention relates to a chimeric recombinant protein having a therapeutic effect on cervical cancer by fusing genetic modified E6 and E7, which are carcinogenesis-inducing proteins of human papillomavirus high-risk group type 16, with a fusion protein for increasing immunogenicity, the HPV type 16 E6, E7 chimeric recombinant protein fused with the flagellin fusion protein of the present invention showed the lowest tumor cell volume, and the immune response of specific T cells according to the recombinant antigen was significantly confirmed, and when the prophylactic effect was measured, it was confirmed that the volume of tumor cells was low and the antibody titer was increased, therefore human papillomavirus recombinant antigen of the present invention shows tumor treatment and prophylaxis and can be applied as a therapeutic/prophylactic vaccine composition.

62.4188405PHARMAZEUTISCHE FORMULIERUNG MIT EINER KOMBINATION AUS REKOMBINANTEN NEWCASTLE-KRANKHEITSVIREN ZUR BEHANDLUNG VON KREBS
EP - 07.06.2023
Clasificación Internacional A61K 35/768 Nº de solicitud 21742155 Solicitante THALLER TRISTAN WOLFRAM Inventor/a THALLER ARNO
The invention relates to a pharmaceutical formulation comprising at least three recombinant transgene expressing Newcastle Disease Virus (NDV) strains, which have been demonstrated to possess significant oncolytic activity against mammalian cancers and an improved safety profile, a non-recombinant NDV strain, a reovirus type-3 and optionally a vaccinia virus. At least one of the recombinant NDV strains comprises in its viral genome a nucleic acid sequence comprising at least one foreign gene, the at least one foreign gene encoding a checkpoint modulator, and at least one of the recombinant NDV strains comprises in its viral genome a nucleic acid sequence comprising at least one foreign gene, the at least one foreign gene encoding an angiogenesis inhibitor. The viral genome of each of the at least three recombinant NDV strains comprises a mutation in the HN gene, said mutation allowing replication of said rgNDV in a cancer cell to a higher level than replication of an otherwise identical NDV not having said mutation in the HN gene. The pharmaceutical formulation provides an improved treatment of cancer, because instead of a monotherapy, a mixture of oncolytic viruses is applied.

63.20230173061HUMAN CYTOMEGALOVIRUS POLYEPITOPE VACCINE COMPOSITION
US - 08.06.2023
Clasificación Internacional A61K 39/245 Nº de solicitud 17921945 Solicitante The Council of the Queensland Institute of Medical Research Inventor/a Rajiv Khana
Disclosed is a human herpesvirus immunotherapy. More particularly, disclosed is a composition that includes one or more recombinant proteins that include a plurality of epitopes derived from multiple human cytomegalovirus antigens, a CMV envelope5glycoprotein, and a TLR agonist.

64.WO/2023/102520PARENTERALLY ADMINISTRABLE INFLUENZA VACCINE AND USES THEREOF
WO - 08.06.2023
Clasificación Internacional A61K 39/145 Nº de solicitud PCT/US2022/080808 Solicitante CODAGENIX INC. Inventor/a COLEMAN, John Robert
The present invention provides for parenterally administrable live attenuated influenza immune compositions. Methods of using parenterally administrable live attenuated influenza immune compositions to elicit an immune response, and particularly, a protective immune response are also provided.

65.20230173046MULTICOMPONENT CHEMICAL COMPOSITION OF A PEPTIDE-BASED NEOANTIGEN VACCINE
US - 08.06.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 17788651 Solicitante AMAZON TECHNOLOGIES, INC. Inventor/a Frank Wilhelm SCHMITZ
Provided herein are immunogenic compositions comprising tumor-specific neoantigen long peptides, tumor-specific neoantigen short peptides, and adjuvant, optionally a helper peptide, and optionally a tumor-specific peptide. The disclosure also provides methods of using these immunogenic compositions for treating cancer.

66.4188437IMPFSTOFFZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON
EP - 07.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 21850622 Solicitante UNIV LELAND STANFORD JUNIOR Inventor/a MASSOUD TARIK F
Provided herein, *inter alia*, are complexes comprising nanoparticles attached to viral proteins or nucleic acids encoding said viral proteins. Methods for making and using said complexes are provided. Compositions including the complexes are contemplated to be useful for treating and/or preventing viral infections.

67.WO/2023/105221VACCINE BOOST METHODS AND COMPOSITIONS
WO - 15.06.2023
Clasificación Internacional A61K 39/395 Nº de solicitud PCT/GB2022/053122 Solicitante VACCITECH (UK) LIMITED Inventor/a EVANS, Thomas
The invention relates to combinations, compositions, methods and dosage regimes for use in medicine, optionally wherein the use may be the treatment of chronic hepatitis B virus (HBV) infection or cancer, including inducing an improved immune response and improvement in the performance of therapeutic vaccines.

68.20230174602NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
US - 08.06.2023
Clasificación Internacional C07K 14/47 Nº de solicitud 17820824 Solicitante Immatics Biotechnologies GmbH Inventor/a Colette SONG
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

69.WO/2023/094595CORONAVIRUS DERIVED RNA REPLICONS AND THEIR USE AS VACCINES
WO - 01.06.2023

Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2022/083289 Solicitante CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS Inventor/a ENJUANES SÁNCHEZ, Luis
A propagation-defective, replication-competent RNA replicon derived from the SARS-CoV-2 coronavirus that comprises a polynucleotide sequence SEQ_ID 2 or a variant of SEQ_ID 2 having at least 80 % identity, more preferably 85% identity, even more preferably at least 90 % identity, and even more preferably 91 % or 92 % or 93 % or 94 % or 95 % or 96 % or 97 % or 98 % or even up to 99 % identity with respect to the SEQ_ID 2 polynucleotide sequence, wherein the variant of SEQ_ID2 does not comprise sequences suitable for expressing an ORF8 protein, wherein the ORF8 protein is encoded by a gene having at least 80% identity to the sequence of SEQ_ID36, methods of preparation thereof and the use in vaccine compositions.

70.4188939REPLIKATIONSDEFIZIENTER ADENOVIRUS
EP - 07.06.2023
Clasificación Internacional C07K 14/005 Nº de solicitud 21755406 Solicitante LEIBNIZ INST FUER VIROLOGIE Inventor/a BODDIN JANA
The present invention generally relates to the field of adenoviruses and adenoviral vectors that can be used as vaccines and gene therapy vectors. More specifically, the present invention relates to an adenovirus or an adenoviral vector that comprises a mutated DNA-binding protein that inhibits adenoviral DNA replication in a cell infected with a virus expressing said protein. The invention further relates to a nucleotide sequence encoding the mutated DNA-binding protein. In another aspect, the invention provides pharmaceutical compositions, vaccines and cells that comprise the mutated protein, a nucleotide sequence encoding same, or a modified adenovirus or adenoviral vector comprising any of those. The invention also relates to the use of the mutated protein, a nucleotide sequence encoding the same, or an adenovirus or recombinant adenoviral vector comprising any of those for the preparation of a vaccine.

71.20230174586STRAIN DIS-DERIVED RECOMBINANT VACCINIA VIRUS HAVING NOVEL INFLUENZA VIRUS-DERIVED HEMAGGLUTININ PROTEIN GENE
US - 08.06.2023
Clasificación Internacional C07K 14/005 Nº de solicitud 17293378 Solicitante TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE Inventor/a Fumihiko YASUI
Provided are: a recombinant vaccinia virus which is effective for the prevention of the development of a disease by the infection by H7 avian influenza virus and has high safety; and a vaccine against H7 avian influenza virus, which comprises the recombinant vaccinia virus. The recombinant vaccinia virus according to the present invention is a recombinant vaccinia virus having such a structure that an expression promoter and the full length or a part of cDNA encoding hemagglutinin protein of H7 avian influenza virus are contained in the genome for vaccinia virus strain DIs.

72.WO/2023/096896DETECTION OF COVID-19 ASSOCIATED CARDIAC INJURY AND VACCINE-ASSOCIATED MYOCARDITIS
WO - 01.06.2023
Clasificación Internacional C12Q 1/70 Nº de solicitud PCT/US2022/050706 Solicitante NFERENCE, INC. Inventor/a SOUNDARARAJAN, Venkataramanan
This application relates to methods of treating and/or preventing a coronavirus infection in a subject in need thereof, and treating cardiac injury in said subjects.

73.20230167462RECOMBINANT ADENOVIRUS EXPRESSING AFRICAN SWINE FEVER VIRUS EP153R-EP402R PROTEIN AND CONSTRUCTION METHOD THEREOF
US - 01.06.2023
Clasificación Internacional C12N 15/86 Nº de solicitud 18057765 Solicitante Institute of Animal Sciences of Chinese Academy of Agricultural Sciences Inventor/a HONG JIA

The present disclosure provides a recombinant adenovirus for expressing African swine fever virus (ASFV) EP153R-EP402R protein and a construction method thereof, and belongs to the technical field of genetic engineering. In the present disclosure, a recombinant adenovirus vector pAD-CMV-EGFP-EP153R-EP402R is obtained through a series of intermediate processes using a recombinant adenovirus shuttle vector pENTRE-EGFP-TOPO; the recombinant adenovirus vector is linearized to transfect AD293 cells, a recombinant virus is screened according to cytopathy formed by adenovirus infection, an adenovirus packaging process is achieved, and the recombinant adenovirus for expressing ASFV EP153R-EP402R protein is obtained, laying a foundation for the construction of a recombinant adenovirus vaccine for expressing the ASFV EP153R-EP402R protein.

74.20230173050VACCINE IMMUNOGENS
US - 08.06.2023
Clasificación Internacional A61K 39/015 Nº de solicitud 17610380 Solicitante OXFORD UNIVERSITY INNOVATION LIMITED Inventor/a Adrian Vivian Sinton Hill
An immunogenic composition comprising: a) one or more *Plasmodium*-derived ribosomal or ribosomal associated protein or immunogenic fragment thereof which has a sequence which is at least about 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to a ribosomal or ribosomal associated protein or an immunogenic fragment of a ribosomal or ribosomal associated protein recited in FIG. 1; or a ribosomal or ribosomal associated protein or peptide or immunogenic fragment thereof as recited in FIG. 2 or FIG. 3; and/or b) a polynucleotide encoding one or more protein, peptide or immunogenic fragment of a); wherein the immunogenic composition is for use in eliciting an immune response in a subject to treat or prevent malaria. Also provided are *Plasmodium*-derived ETRAMPs and/or histones, or immunogenic fragments thereof, for use in eliciting an immune response in a subject, preferably to treat or prevent malaria.

75.WO/2023/096766METHODS OF BLOCKING ASFV INFECTION THROUGH INTERRUPTION OF CELLULAR AND VIRAL RECEPTOR INTERACTIONS
WO - 01.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/US2022/049832 Solicitante CHEN, Dalu Inventor/a CHEN, Dalu
A method of preventing and treating viral infections in animals (and preferably ASFV in porcine), by inhibiting viral ligand interactions with critical cellular receptors that are involved either directly (endocytosis and/or macropinocytosis) or indirectly (phagocytosis of RBCs that have been aggregated by viral interactions) with cellular entry in an animal, and preventing and treating the viral infection in the animal. A method of treating a viral infection in an individual with a virus that is both lysogenic and lytic. A composition for treating a viral infection in an individual with a virus that is both lysogenic and lytic. A vaccine for preventing viral infection, including whole and/or partial domains of proteins of both a lysogenic and lytic phase of a virus.

76.4188482SYSTEME UND VERFAHREN FÜR VORGEFÜLLTE MEDIZINISCHE ABGABEANORDNUNGEN
EP - 07.06.2023
Clasificación Internacional A61M 5/24 Nº de solicitud 21850313 Solicitante KOSKA FAMILY LTD Inventor/a CHA JAE-HYOK
A pre-filled medical delivery assembly assembled and configured to allow delivery of a single dose of a therapeutic agent (e.g., vaccine, drug, medicament, etc.) from a Blow-Fill-Seal (BFS) vial to a patient. The delivery assembly generally includes a modular design consisting of separately constructed components cooperatively arranged and coupled to one another.

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu

FINLAY EDICIONES